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3D Functionalized Multi-Supportive Structures (FMSS) – A Novel 
Route for Spinal Cord Injury Regeneration 
 
ABSTRACT 
 
A deregulation or injury in the nervous system usually leads to devastating 
consequences. In the particular case of spinal cord injury (SCI), patients have to deal 
with several neurological deficits and disabilities. Therefore, it is urgent to develop 
therapeutic strategies that can specifically target this problem. Different possible 
solutions have been experimented to solve these conditions, such as cell and molecular 
therapies, although the outcomes are still not satisfactory, imposing a need for 
alternative approaches. Tissue engineering has been proposed as a new method to 
address these problems. The tissue engineering strategy usually implies the use of a 3D 
structure that is able to support the cell growth and differentiation in an adequate 
environment towards the development of a functional tissue engineered system. With 
the concepts of tissue engineering in mind, the main goal of the work described in this 
thesis was to develop a structure that can be easily, efficiently, and successfully applied 
in the treatment of spinal cord lesions. 
In the work presented in this thesis, a natural blend of starch/poly-ε-caprolactone 
(SPCL) was processed by rapid prototyping in order to create a tubular porous scaffold. 
Then, these SPCL scaffolds were filled with the gellan gum hydrogel with the purpose 
of creating a novel hybrid structure. In this biphasic scaffold the SPCL phase aims to 
mimick the vertebra bone functions, while the gellan gum hydrogel is designed to be a 
cell encapsulation system to support axonal regeneration in the injured spinal cord. The 
developed scaffolds presented tunable outer layer thickness, mechanical modulus, 
fiber/filament orientation, and pore geometry. Moreover, the scaffolds disclosed a non-
x 
cytotoxic behavior and allowed the in vitro culturing of oligodendrocytes, olfactory 
ensheathing cells (OECs) and Schwann cells for periods up to three weeks. In order to 
overcome some of the drawbacks associated with the use of gellan gum, namely the 
absence of biological signals for cellular adhesion and proliferation, this hydrogel was 
chemically conjugated with the peptide sequence GRGDS, via Diels-Alder click 
chemistry. It was observed that the novel GRGDS-gellan gum had a profound effect on 
neural stem cell morphology and proliferation. These results demonstrated the 
importance of GRGDS for cell-gellan gum interaction. Subsequently, the in vivo 
experiments revealed that hybrid structures are biocompatible. However, more 
importantly, in vivo tests showed that SPCL are suitable structures to promote spine 
stabilization and that the stabilization of SCI rats was associated with functional motor 
recovery. Finally, in the scope of this thesis, it was also assessed the effects of OECs 
secretome on the growth of adult stem cells derived from adipose, bone marrow, 
umbilical cord and nervous tissue. Results revealed that OECs secretome increase the 
metabolic activity and/or proliferation of these adult stem cells. 
As a concluding remark, it can be stated that the work described in this thesis brings 
new knowledge to the cell biology, biomaterial and spinal cord injury fields. The results 
obtained in the in vivo experiments indicate that researchers currently testing treatments 
for SCI repair might have to take into account the use of spine stabilization in 
combination with their approaches. From the biomaterial point of view, the simplicity 
and broad applicability of the Diels-Alder click chemistry (used to functionalize the 
gellan gum) can be easily extended to other molecules to further improve this material. 
Finally, important understanding was herein created about biological/molecular 
interactions between OECs and adult stem cells from several origins. 
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Estruturas de Suporte Multifuncionais: Uma Nova Terapia para 
Regeneração de Lesões da Medula Espinal 
 
RESUMO 
 
Uma lesão do sistema nervoso acarreta normalmente consequências devastadoras. No 
caso particular de lesões da medula espinal (LME), os pacientes têm que lidar com 
múltiplas insuficiências biológicas. Por este motivo, é urgente desenvolver terapias que 
possam resolver eficazmente este problema. Diferentes estratégias têm sido propostas 
para tratar esta condição, tais como, terapias baseadas em transplantação celular e/ou 
terapias moleculares. No entanto, os resultados não têm sido satisfatórios, reforçando a 
ideia que são necessárias abordagens alternativas. A engenharia de tecidos tem sido 
proposta como um novo método para enfrentar estes problemas. Esta estratégia implica 
o uso de uma estrutura 3D que é capaz de suportar o crescimento e a diferenciação 
celular de forma a criar um ambiente adequado para o desenvolvimento de um tecido 
funcional. Tendo por base os conceitos da engenharia de tecidos, o principal objectivo 
do trabalho descrito nesta tese foi o desenvolvimento de um sistema que possa ser 
aplicado facilmente e eficazmente no tratamento de LME. 
Neste trabalho, o polímero natural de poli-caprolactona de amido (SPCL) foi 
processado por prototipagem rápida de forma a criar estruturas tubulares porosas. 
Seguidamente, o interior das estruturas de SPCL foram preenchidos com o hidrogel 
gellan gum de forma a criar uma estrutura híbrida. Neste sistema, o SPCL tem como 
objectivo mimetizar as funções do osso vertebral. Por sua vez, o hidrogel tem como 
objectivo servir como um sistema de encapsulamento celular de forma a suportar a 
regeneração nervosa. As estruturas desenvolvidas possuem espessura, orientação e 
geometria do poro e características mecânicas configuráveis. Adicionalmente, as 
xii 
estruturas apresentaram um comportamento não tóxico e permitiram o crescimento in 
vitro de oligodendrócitos, células do bolbo olfactivo (OECs) e células de Schwann. De 
forma a ultrapassar algumas das desvantagens do gellan gum, nomeadamente o facto de 
este material não possuir na sua estrutura sinais biológicos, este material foi modificado 
com o péptido GRGDS. Foi observado que o GRGDS-gellan gum tem um forte efeito 
na morfologia e proliferação de células estaminais neuronais. Estes resultados 
demonstraram a importância do péptido GRGDS na interacção célula-gellan gum. 
Seguidamente, as experiencias in vivo revelaram que estas estruturas são 
biocompatíveis, mas, mais importante, os testes em animais demostraram que as 
estruturas de SPCL permitem a eficaz estabilização da coluna vertebral e que esta 
estabilização promove a recuperação da função motora de ratos com LME. Finalmente, 
no âmbito do trabalho descrito nesta tese, foi também estudado o efeito que os factores 
secretados pelas OECs exercem sobre a proliferação e/ou actividade metabólica de 
células estaminais adultas derivadas do tecido adiposo, da medula óssea, do cordão 
umbilical e do tecido nervoso. Os resultados revelaram que as OECs produzem factores 
que promovem o aumento da actividade metabólica e/ou proliferação dessas células 
estaminais adultas. 
O trabalho descrito nesta tese originou novo conhecimento para as áreas de biologia, de 
biomateriais e de regeneração de LME. As experiências in vivo revelaram que os 
investigadores que estejam actualmente a testar terapias para LME devem ter em conta 
a estabilização vertebral. Do ponto de vista dos biomateriais, a modificação do gellan 
gum é simples e de ampla aplicabilidade. Neste sentido, o gellan gum pode agora ser 
facilmente modificado com diferentes moléculas consoante a aplicação desejada. 
Finalmente, o entendimento sobre o efeito dos factores produzidos pelas OECs em 
células estaminais, poderá revelar-se importante para futuras terapias celulares. 
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INTRODUCTION TO THESIS FORMAT 
 
This thesis is divided into four sections that include a total of eight chapters. The body 
of the thesis chapters is based on the series of related papers published or submitted for 
publication in peer-reviewed journals. Each thesis chapter is presented in the manuscript 
form, i.e. with the abstract, introduction, materials and methods, results, discussion and 
conclusions sections. A list of references is also provided as a subsection within each 
chapter. The contents of each chapter are summarized below. 
 
Section I (Chapter I) 
Chapter I presents a comprehensive and extensive overview on the spinal cord injury 
(SCI) condition. It starts covering areas from physiology and anatomy of the spinal 
cord, neuropathology of the SCI, current clinical options, neuronal plasticity after SCI, 
animal models and recovery assessment techniques, focusing the subsequent discussion 
on a variety of promising neuroprotective, cell-based and combinatorial therapeutic 
approaches that have recently moved, or are close to, clinical testing. New research 
directions are also proposed in the end of this chapter. 
 
Section II (Chapter II) 
Chapter II fully describes the experimental work and protocols related to the obtained 
results. Although each part of the work is accompanied by its specific materials and 
methods section, this chapter intends to condensate and assemble the relevant 
information on this matter. 
 
Section III (Chapter III to VII) 
These chapters describe the experimental work performed within the scope of this 
thesis. 
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Chapter III describes the development and characterization of a novel hybrid tubular 
scaffold aimed at SCI repair. This biphasic scaffold comprises two natural 
polysaccharide based biomaterials: starch/poly-ε-caprolactone (SPCL) and gellan gum. 
After the scaffold development, this chapter focuses on the physical (porosity and 
mechanical behavior) and biological (cytotoxicity, 3D culture and biocompatibility) 
characterization of the abovementioned structures. 
 
Chapter IV reports on the importance of spine stabilization in SCI rats. The vertebral 
column of SCI rats was stabilized using the SPCL scaffolds developed in the previous 
chapter. The locomotor behavior of the rats was then analyzed by three different tests 
(BBB, rotarod and open field) and neuronal regeneration was assessed by histological 
analysis (H&E). 
 
Chapter V presents the SPCL scaffolds as a 3D culture system. In this chapter, 
olfactory ensheathing cells (OECs) and Schwann cells were cultured on the SPCL 
fibbers. The metabolic activity, proliferation, morphology and migration were then 
analyzed. 
 
Chapter VI explains the synthesis of a biologically functional gellan gum hydrogel. It 
describes the use of Diels-Alder click-chemistry to immobilize a fibronectin derived 
peptide on the gellan gum structure. The bioactivity of the novel hydrogel was tested 
using neural stem cells (NSCs) and confocal microscopy. Moreover, this chapter 
describes the positive effect of the OECs secretome on the NSCs survival and 
proliferation. 
 
Chapter VII presents the final experimental study performed within the scope of this 
thesis. In this chapter, the secretome of OECs and adult stem cells derived from 
umbilical cord, adipose or bone marrow tissue was studied. The metabolic activity, 
 xlix 
proliferation and differentiation of adult stem cells were analyzed when they were 
culture under the influence of the OECs secretome. The stem cells secretome effects on 
OECs culture were also consider. 
 
Section IV (Chapter VIII) 
This chapter contains the general conclusions of the works carried out under the scope 
of this thesis. Some specific remarks and future prospects are also provided. 
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CHAPTER I 
From Basics to Clinical: A Comprehensive Review on Spinal Cord Injury* 
 
Abstract 
 
Spinal cord injury (SCI) is a devastating neurological disorder that affects thousands of 
individuals each year. Over the past decades enormous progress has been made in our 
understanding of the molecular and cellular events generated by SCI, providing insights 
into crucial mechanisms that contribute to tissue damage and regenerative failure of 
injured neurons. Current treatment options for SCI include the use of high dose 
methylprednisolone, surgical interventions to stabilize and decompress the spinal cord, 
and rehabilitative care. Nonetheless, SCI is still a harmful condition for which there is as 
yet no cure. However, it is no longer a matter of whether regeneration can occur. 
Cellular, molecular, rehabilitative training and combinatorial therapies have been shown 
promising results in animal models. Nevertheless, work remains to be done to ascertain 
whether any of these therapies can safely improve outcome after human SCI. This review 
provides an extensive overview of the SCI universe. It stats covering areas from 
physiology and anatomy of the spinal cord, neuropathology of the SCI, current clinical 
options, neuronal plasticity after SCI, animal models and recovery assessment 
techniques, focusing the subsequent discussion on a variety of promising neuroprotective, 
cell-based and combinatorial therapeutic approaches that have recently moved, or are 
close to, clinical testing. 
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*These chapter is based on the following publication: 
Silva NA, Sousa N, Salgado AJ and Reis RL, “From Basics to Clinical: A 
Comprehensive Review on Spinal Cord Injury”, Submitted 
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1. Introduction 
 
The Edwin Smith papyrus, an ancient Egyptian physician textbook, has described in 1700 
BC the Spinal Cord Injury (SCI) as a “ailment not to be treated” [1]. Now, almost 4000 
years later, the treatment of SCI remains mainly palliative: preventing injury progression; 
treating spasticity, dysautonomia, and deafferentation pain syndromes; implementing 
bowel and bladder regimens; managing complications of sensory loss; and teaching 
patients how to cope with their disabilities. Fortunately, ongoing advances in 
neurobiology research promise to change this paradigm from palliation to cure.  
The number of people in the United States who currently live with SCI is estimated to be 
around 253,000 with 11,000 new cases occurring each year. Causes include penetrating 
bullet wounds and other forms of violence (26%) and nonpenetrating lesions from 
vehicular accidents (38%), and sports accidents (7%), as well as falls (22%), especially in 
elderly persons [2]. This condition usually leads to devastating neurological deficits and 
disabilities that provoke not only the loss of sensory and motor capabilities (paraplegia or 
tetraplegia) but other common problems related with SCI as frequent infections in 
bladder, kidneys, bowel problems, and cardiac and respiratory dysfunctions. All of these 
problems have a strong impact on the physiologic, psychological and social behavior of 
SCI patients. For all of these reasons, is urgent to develop therapeutic strategies that can 
specifically target this problem. 
This review intends to provide an extensive overview of the SCI universe. It will expand 
from the basic biology to the current state of research and clinic areas and finish with the 
future trends for this field.  
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2. Central Nervous System  
 
Every thought, action or emotion reflects the activity of the nervous system, which is 
divided into the central nervous system (CNS) that includes the brain and spinal cord, 
and the peripheral nervous system (PNS), which includes the cranial nerves arising 
from the brain and the spinal nerves arising from the spinal cord. 
Although exceedingly complex, nervous tissue is made up of just two principal types of 
cells [3, 4]:  
(1) Neurons (Fig.1A) are the basic structural and functional units of the nervous system. 
Neurons vary in appearance, but all of them have just three parts: a cell body, dendrite(s), 
and an axon. The cell body contains the nucleus as well as other organelles. In motor 
neurons, the dendrites are the many short extensions that receive signals from sensory 
receptors or other neurons. At the dendrites, signals can result in nerve impulses that are 
then conducted by an axon. The axon is the portion of a neuron that conducts nerve 
impulses. Any long axon is also called a nerve fibber. Long axons are covered by a white 
myelin sheath formed from the membranes of tightly spiralled glia cells. Neurons are 
specialized to respond to physical and chemical stimuli, conduct impulses, and release 
specific chemical regulators. Through these activities, neurons perform such functions as 
storing memory, thinking, and regulating other organs and glands; 
 (2) Glia cells are supportive cells in the nervous system that aid the function of neurons. 
For example, types of glia cells found in the brain are microglia, astrocytes, and 
oligodendrocytes. Microglia (Fig.1B) cells are the immune mediators of the CNS, 
possessing a macrophage like behaviour, phagocyting death tissue and cells, as well 
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foreign agents. Astrocytes (Fig.1C) are the most abundant glial cell type. They are 
responsible for mediating the synaptic transmission, provide nutrients for the neurons and 
simultaneously they make part of the blood brain barrier (BBB), which can be look as a 
filter against foreign agents that intend to enter the CNS. Oligodendrocytes (Fig.1D) are 
the cells involved on the production of the myelin sheath, which encases the neurons. 
Therefore they are of the utmost importance within the CNS, as the loss of myelinazation 
leads to extensive damage within the latter, as it happens during SCI. With similar 
function, the Schwann cells are the type of glia that produces the myelin layer in the PNS. 
The areas of the nervous system that are rich in myelinated fibers are known as white 
matter while the areas containing the cell bodies and demyelinated neurons are known as 
grey matter [5, 6]. 
 
 
3. Physiology and Anatomy of the Spinal Cord 
 
The spinal cord provides a means of communication between the brain and the peripheral 
nerves that leave the cord. Besides that, it is also able to produce reflexes, called the 
 
Figure I.1. Immunocytochemistry images of CNS cells. (A) MAP-2 positive neuron. 
(B) CD11B positive microglia. (C) GFAP positive astrocytes. (D) O4 positive 
oligodendrocytes. 
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spinal reflex. Specific nerve pathways allow for reflexive movements rather than those 
initiated voluntarily by the brain, such as coughing, sneezing and vomiting. 
The spinal cord extends from the base of the brain (in medulla oblongata) through the 
foramen magnum of the skull to the firsts lumbar vertebras. The cord only extends to the 
L1 vertebra in human, or L3 in the case of rats, because the vertebral column grows faster 
than the spinal cord. For this reason, and below the cervical levels, the spinal nerves run 
increasingly obliquely downwards to their intervertebral foramina. The spinal cord is 
protected by the vertebral column, which is composed of individual vertebrae. It is also 
protected by three membranes of connective tissue called meninges. From the outside in, 
the meninges are the dura mater, arachnoid mater and pia mater. Finally and helping to 
protect the spinal cord too, as well with others function, there are the subarachnoid space 
(between arachnoid and pia) filled with cerebrospinal fluid and the epidural space 
(between dura and periosteum) filled with loose fibrous and adipose connective tissues 
[3, 5, 7]. 
 
Unlike the brain, in which the gray matter forms a cortex over white matter, the gray 
matter of the spinal cord is located centrally, surrounded by white matter. The central 
gray matter is arranged in the form of a butterfly. The projections of the gray matter 
within the spinal cord are called horns. The two dorsally projecting arms are called the 
dorsal horns, and the two ventrally projecting arms are called the ventral horns (also 
called posterior and anterior horns, respectively). The gray matter is made up of 
interneurons, the cell bodies and dendrites of efferent neurons, the entering fibers of 
afferent neurons, and glial cells. The surround white matter (except when the dorsal horns 
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touch the margins of the spinal cord) is composed mostly of groups of myelinated axons 
of interneurons. These groups of axons, called fibber tracts or pathways, run 
longitudinally through the cord, some descending to relay information from the brain to 
the periphery, others are ascending to transmit information to the brain (Fig.2). 
The names of the ascending tracts usually start with the prefix spino- and end with the 
name of the brain region where the spinal cord fibbers first synapse. The anterior 
spinothalamic tract, for instance, carries impulses conveying the sense of touch and 
pressure, and synapses in the thalamus. From there it is relayed to the cerebral cortex. 
The names of descending motor tracts, conversely, begin with a prefix denoting the 
brain region that gives rise to the fibbers and end with the suffix -spinal. The lateral 
corticospinal tracts, for instance, begin in the cerebral cortex and descend the spinal cord. 
More information about the most important tracts that run in the spinal cord can be found 
in the Watson, Paxinos and Kayalioglu book [8].  
 
Figure I.2. Ascending and descending spinal tracts. (A) Lateral 
spinothalamic tract carrying sensorial information from peripheral organs to 
the brain. (B) Pyramidal corticospinal tracts carrying motor information 
from cortex to peripheral organs. Adapted from reference 3. 
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The above mentioned fibber tracts are crucial in the communication between spinal cord 
and brain. Groups of afferent (sensory) fibbers that enter the spinal cord from the 
peripheral nerves enter on the dorsal side of the cord via the dorsal roots. Small bumps on 
the dorsal roots, the dorsal root ganglia, contain the cell bodies of the afferent neurons. 
The axons of efferent (motor) neurons leave the spinal cord on the ventral side via the 
ventral roots. Near the cord, the dorsal and ventral roots from the same level combine to 
form a spinal nerve, one on each side of the spinal cord. The spinal nerves are designated 
by the five vertebral levels: from which they exit: cervical, 
thoracic, lumbar, sacral and cocygeal. The human spinal 
cord comprises 31 spinal nerves (Fig. 3): 8 cervical 
nerves (C) – control the muscles and glands and receive 
sensory input from the neck, shoulder, arm and hand; 12 
thoracic nerves (T) - associated with the chest and 
abdominal walls; 5 lumbar nerves (L) - associated with 
the hip and leg; 5 sacral nerves (S) - associated with the 
genitals and lower digestive tract; and 1 coccygeal nerve 
(Coc) – supply the skin over the coccyx. Although the 
spinal cord of the rat comprises 34 spinal nerves - 8 
cervical, 13 thoracic, 6 lumbar, 4 sacral and 3 coccygeal – 
the general associated functions are similar. 
 
 
 
 
Figure I.3. Set of the 31 
spinal nerves. Adapted 
from reference 4. 
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4. Neuropathology of Spinal Cord Injury 
 
4.1. From acute to chronic injury 
 
When the spinal cord is lacerated or macerated by a sharp penetrating force, contused or 
compressed by a blunt force (most common [9]), or infarcted by a vascular insult, it 
begins a neurological damage in the spinal cord that is normally called “primary 
injury”. Based on imaging and histology of injured human spinal cords, traumatic SCI 
was classified by Bunge and colleagues as: contusion with cavity formation; massive 
compression; or laceration [10, 11]. The mechanical injure leads to a cascade of 
biological events, describe as “secondary injury”, which occurs over the time course of 
minutes to weeks and provokes further neurological damage. Finally, and occurring over 
a time course of days to years, there is the onset of chronic phase, that leads to 
neurological impairments in both orthograde and retrograde directions, including brain 
regions [12, 13].  
The understanding of the biochemical and cellular events that compose the secondary and 
chronic phase is of utmost importance, since it could provide significant information that 
might lead to promises therapies that minimize the extension of the lesion and improve 
the regeneration. In 1911, Alfred Allen [14] was the first suggesting that secondary 
events happen after spinal cord injury.  He reported neurological dependent functions 
improvements after the removal of inflammatory fluid in spinal cord injury of dogs. 
Therefore, Dr. Allen theorized that it was a noxious agent present in the hemorrhagic 
fluid that might cause further damage to the spinal cord [15]. Following him, several 
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authors postulate numerous biochemical mechanisms that elucidate the progressive pos-
traumatic damage of spinal cord tissue. These secondary events consist of: 
- Vascular changes - includes hemorraghe, vasospam, thrombosis, loss of 
autoregulation, breakdown of blood brain barrier and infiltration of inflammatory cells. 
This leads to edema, necrosis and ischemia [16-18]; 
- Free radical formation and lipid peroxidation - causes oxidative death in spinal cord 
neurons [19] and reduce the spinal cord blood flow leading again to edema and 
inflammatory response [20, 21]. Moreover, it has been show that lipid peroxidation 
affects the ATPase activity [22] as well cause cytoskeleton degradation [23]; 
- Disruption of ionic balance of K
+
, Na
+
, Ca
2+
 - leads to depolarization of cells 
membranes, ATPase failure and increase of intracellular  Ca
2+
 [24]. All of these events 
increase cell death; 
- Glutamate excitotoxicity - after the SCI there is an increased release of extracellular 
amino acids, namely glutamate, that induce excessive activation of glutamate receptors 
leading to further neuronal cell death [25-28]; 
- Apoptosis - the programmable mechanism of cell dead occurs after SCI and involves 
reactive gliosis that includes increased expression of glial fibrillary acidic protein 
(GFAP) and astrocyte proliferation. Moreover, demyelination of tracts away from the 
injury, appear to be due in part to apoptosis [29]. 
- Inflammatory response - following neural trauma the resident microglia become 
activated, while rapidly infiltrating leukocytes start to release an increased amount of 
cytokines and reactive oxygen species (ROS) [30], which will allow higher extravasation 
of leukocytes and further tissue damage [31-33]. Nevertheless, some studies 
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demonstrated that inflammation also plays an important role in neural tissue repair [34]. 
The challenge for researchers is to learn how to control the interactions between the 
nervous and immune systems to minimize delayed neurodegeneration while promoting 
axonal and regeneration. For example, the expression of the proinflammatory cytokine 
TNF-α is upregulated after a neural damage leading to oligodendrocytes dead and white 
matter injury [35, 36]. However, White and colleagues [37] demonstrated that TGF-α 
infusion preserve the supportive and survival effects that the astrocytes have under the 
neurons, and altered astrocytes activation. 
 
Finally, the chronic phase comprises events like white matter demyelination, gray matter 
dissolution, connective tissue 
deposition and reactive gliosis that 
lead to glial scar formation. The glial 
scar works like a physical barrier, do 
not allowing axons to grown across it. 
It is formed predominantly by reactive 
astrocytes, microglia/ macrophages, 
and extracellular matrix molecules, 
especially chondroitin sulfate 
proteoglycans [38-40]. Moreover, in 
approximately 25% of SCI patients 
the glial scar surrounds a cystic cavity 
that progressively expands leading to a condition called syringomyelia. Finally the input 
 
Figure I.4. Schematic representation of the 
SCI site. Adapted from reference 13.  
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changes in inhibitory and excitatory neurotransmitters and in many cases the permanent 
neuron hyperexcitability, results in chronic pain syndromes and consequently mood 
disorders such as depression [41, 42]. 
 
4.2. Molecules with growth-inhibitory effects in CNS 
 
The external environment greatly influences the intrinsic growth ability of an injured 
neuron. It is known that during the injury phases several molecules display inhibitory 
effects in neuron regeneration. The most studied group is the myelin-associated 
molecules. After the injury, the disruption myelinated axons as well as oligodendrocytes 
dead, leads to the release of myelin debris. Among these, the Nogo protein is the most 
“famous”. Nogo is a membrane protein expressed by oligodendrocytes and some 
neurons, and causes growth inhibition and growth cone collapse when binding to its 
receptor in neurons membrane [43, 44]. Other molecule of this group is the myelin-
associate glycoprotein (MAG). MAG is one of the inhibitors of white matter 
regeneration and there are several studies, both in vitro and in vivo, that show the 
inhibitory capability of MAG [45-47]. However the mechanism of neural growth 
inhibition is not fully understood. Finally, Tenascin R is an inhibitory molecule present 
in extracellular matrix of CNS, which is produced by oligodendrocytes and is upregulated 
after injury. Tenascin R interacts with the axonal receptor F3/11 inhibiting its growth. 
Tenascin R also interacts with several proteoglycans implicated in growth inhibition [48-
50]. 
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The proteoglycans are the second major group of molecules that present an inhibitory 
profile after a CNS injury. These molecules consist of a protein core linked by four sugar 
moieties to a sulphated glycosaminoglycan (GAG) chain that contains repeating 
disaccharide units [51]. Proteoglycans are mainly expressed by astrocytes, 
oligodendrocyte precursors and meningeal cells and are deeply involved in the glial scar 
formation [52]. There are four kwon classes of proteoglycans: (i) heparan sulphate 
proteoglycans (HSPGs), (ii) dermatan sulphate proteoglycans (DSPGs), (iii) keratan 
sulphate proteoglycans (KSPGs) and (iv) chondroitin sulphate proteoglycans (CSPGs) 
[51]. The last ones are the most important and studied. The CSPGs forms a relatively 
large family, which includes aggrecan, brevican, neurocan, NG2, phosphacan and 
versican. There are several evidences about the axon regeneration inhibition profile of 
CSPGs. It was demonstrated that CSPGs expression increase after and around the CNS 
injury site [53-55], and more importantly, Davids et al. [56] show that sensory neurons 
are capable to repair their axons through the white matter, but the regeneration stops 
when are CSPGs deposition. More information about CSPGs and glial scar can be found 
in Fawcett and Silver reviews [52, 57].  
 
It is important to note that the role of glial scar is very complex. Despite of all studies 
demonstrating its detrimental effects [58, 59] some others studies have shown a 
beneficial role of the glial scar during the acute phase (1–2 weeks) after spinal cord 
injury. Elimination of reactive astrocytes or preventing their migration and scar formation 
after injury resulted in a failure of blood-brain barrier repair accompanied by massive 
inflammatory cell infiltration and increased loss of neurons and oligodendrocytes with a 
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consequent worse functional outcome [60, 61]. Thus, an acute astrocytic response 
appears important to limit and restrain the inflammatory response, but this may be at the 
expense of reduced axonal regrowth. 
 
5. Neuronal Plasticity after Spinal Cord Injury 
Derived from the Greek word plassein, plasticity refers to the ability of being molded or 
altered. The CNS is highly malleable, experiencing plasticity over its lifetime. The 
process of learning, skill acquisition and specially the response to an injury provokes 
neuronal reorganization, synaptic rearrangements, changes in the neuronal activation 
pattern and intact or lesioned axon collateral sprouting. Reports in both animal models 
and human patients revealed that some regions from brain undergo plasticity after a 
central or peripheral injury. Kaas and colleagues, for instance, described that the cortical 
territories controlling intact body parts of monkeys with long-standing amputations tend 
to enlarge and invade those that have lost their peripheral targets [62]. Similar cortex 
reorganization was also observed in humans with a SCI [63-65]. Moreover, Jain et al. 
observed that complete cervical spinal cord lesions deactivated the forelimb, trunk and 
hindlimb representations in the somatosensory cortex [66]. Additionally, Cramer et al., 
using functional magnetic resonance imaging (fMRI), described that the sensorimotor 
cortex of chronic, complete SCI patients, presented a volume of activation much reduced 
than controls [12]. The cortex is not the only region affected by a SCI. Subcortical 
structures such as the red nucleus and the cuneate nuclei of the brain-stem also 
experience plasticity. For instance, Lawrence et al. previously described that a novel 
pathway is formed between the left and the right red nucleus in monkeys subjected to 
CHAPTER I. From Basics to Clinical: A Comprehensive Review on Spinal Cord Injury 
19 
unilateral corticospinal tract (CST) lesions. The axonal sprouting between both red 
nucleus was responsible of the partial recovery of the voluntary control of harm and foot 
[67, 68]. The axonal sprouting of sensory fibbers in the cuneate nuclei after SCI has also 
been described. For example, Kass and colleagues demonstrated that incomplete SCI 
lesions led to sprouting of spared forelimb primary afferents in the cuneate nuclei of the 
brain stem and this led to the reactivation of forelimb representations on the 
somatosensory cortex [66, 69]. 
Concerning the spinal cord tissue, several studies were able to confirm that plasticity 
takes place after injury. This was first suggested by the observation that paralysed cats 
with complete spinal cord transection could be trained to walk on a treadmill [70, 71]. In 
the first days after SCI, cats could not support their body and could not initiate 
spontaneous rhythmic movements. However, after one month, the injured cats were able 
to perform coordinated movements. These studies also pointed out the fact that plasticity 
is significantly influence by physical activity. Trained injured cats showed functional 
recovery three times greater than untrained animals [71]. The finding that the spinal cord 
had plastic properties led to novel rehabilitation strategies for SCI in humans. Patients 
with incomplete SCI achieved significant functional benefits by daily training on a 
moving treadmill [72]. Nowadays, locomotion training is becoming routine for 
incomplete SCI patients all over the word. 
Studies in animal models further elucidated us about the events that are behind the 
functional recovery after an incomplete SCI. The spinal cord is capable to adapt by 
mechanisms involving spared long-tract axon collateral sprouting [73], sprouting of 
CHAPTER I. From Basics to Clinical: A Comprehensive Review on Spinal Cord Injury 
20 
spinal interneurons [74], adaptations of the motorneurons caudal to the injury [75], and 
by functional redundancy [76]. 
The specific biological mechanisms behind the neuronal plasticity are still fairly known. 
The components of the secondary insult arising from the SCI may play an important role 
in the plasticity observed. The damaged BBB and the immune response after the SCI 
expose the nervous tissue to a high concentration of cytokines and growth factors that 
induce changes at the cellular level of the spinal cord. Moreover, the mechanism with 
strongest evidence in mediating changes in plasticity is the removal of GABAergic 
inhibition in excitatory synapses. GABA is the most important inhibitory 
neurotransmitter in the brain and GABAergic neurons constitute 25~30% of the neuronal 
population in the motor cortex [77]. Several studies have shown that modulation of 
GABAergic inhibition plays a significant role in cortical plasticity [78, 79]. Moreover, 
Roi et al. demonstrated that the GABAergic intracortical inhibitory circuit is reduced in 
SCI patients [80]. These findings may help to explain the cortical plasticity observed after 
a SCI. 
It is now clear and well accepted that plasticity occurs in the mammalian CNS in 
response to injury. However, it is also clear that not all the plasticity is beneficial. 
Patients with complete SCI exhibited several abnormal features of brain activation, which 
some studies suggest a partial loss of motor cortex function. In this sense, brain events 
that normally occur during voluntary actions are limited after SCI and may also 
contribute to the inability of patients to perform movements. For therapies that aim to 
restore motor function after SCI, alterations in the brain functions mean that the initiation 
of movements might not occur normally. Therefore, addressing these changes may be 
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important to implement a successful therapy in complete SCI chronic patients. A 
tremendous number of questions still need to be addressed in order to harness plasticity, 
such as whether harmful plasticity can be prevented at the same time when beneficial 
changes are encouraged. 
 
6. Highlights of Clinic State for Spinal Cord Injury  
 
To date, there are no efficient and trustworthy clinic treatments available for SCI patients. 
The usual surgical procedures made by physicians are the stabilization and 
decompression of spinal cord combined with a high dose methylprednisolone (MP) 
therapy [81]. However, surgery and MP approaches are deeply involved in controversial 
since there are no consensuses about the true beneficial effects in both topics. 
 
6.1. Surgical Interventions 
There are strong evidences from animal models that decompression of spinal cord 
improves recovery and minimize the secondary injury after SCI [82-85]. On the other 
hand the outcome from human trials is not so clear, as there are several reports that have 
argued against surgery, especially early intervention in critically ill patients [86-88]. The 
question about the optimal timing of surgical interventions (or even the intervention) has 
generated considerable debate and remains unanswered for the entire spine. However, the 
number of studies showing that early decompression have a neuroprotective effect in 
humans is much higher than the studies that show no effects or negative impact [89]. 
Nevertheless, the benefits of early intervention are yet to be fully demonstrated. It is 
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important to be aware about the complexity and the individuality of SCI. This can explain 
why there are no conclusive data about surgery as a valid practice option. In this sense, 
prospective, randomized and multicenter clinical trials are needed in the future in order to 
gain valuable data. 
 
6.2. Pharmacological Interventions 
The delivery of a pharmacological agent shortly after acute SCI that might improve 
neurological function and/or support neurological recovery has long been explored. A 
variety of promising drugs have been tested in animal models, but few have had potential 
application to human SCI patients. Methylprednisolone is the most prescribe agent in 
clinical practice, however, is also the most controversial. MP is a corticosteroid identified 
as being able of inhibit the lipid peroxidation, maintain the blood-spinal cord barrier, 
enhance spinal cord blow flow, inhibit endorphin release, limit the inflammatory 
response and scavenge damaging free radicals [90-92]. These pre-clinical findings led, in 
1979, to the initiation of a multicenter, randomized, double-blinded clinical trial named 
National Acute Spinal Cord Injury Study (NASCIS). The analysis of 330 patients 
revealed no differences in neurological recovery, motor and sensory function, between 
groups either at 6 weeks or 6 months after the injury [93]. Further animal studies suggest 
that the MP dose used in NASCIS I was not sufficient to elicit neuroprotection [94, 95]. 
Thus, a multicenter NASCIS II trial was initiated in 1985 using a much higher dose of 
MP. Five years later and after analysed 487 patients, Bracken and his team reported that 
the administration of high dose of MP within 8 hours after injury was associated with a 
significant improvement in motor and sensory function at the 6-month follow up 
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compared with patients receiving placebo, naloxone or MP at later times [96]. Despite of 
these results the NASCIS II trial has not been universally accepted. Several 
methodological, scientific and statistical issues were criticized [97-101]. For instance, 
only upon stratification of the data was possible to obtain statistical differences. These 
originate concerns about the small sample population size for the groups showing 
beneficial effects. Moreover, there were no functional outcome measures defined to 
assess whether the statistical improvements noted with MP were correlated with clinical 
significance. These critics led to the development of a third NASCIS. The study initiated 
in 1991 and published in 1997 involved 499 patients and additional functional outcome 
was measure. Namely, the Functional Independence Measure (FIM) was used to assess 
self-care, mobility, locomotion, sphincter control, communication and social cognition of 
acute SCI patients. The authors reported that no benefit was associated with extending 
MP administration beyond 24h if patients had received MP within 3h of injury. Although, 
patients that received MP between 3 and 8h after the injury demonstrated improvements 
in motor capabilities if drug administration was continued for 48h in comparison to 24h 
group [102]. These differences were observed only at the 6 weeks and 6 months follow-
up and no statistically significant differences were observed for FIM scale at 1 year 
[103]. After the NASCIS II and III the administration of MP to acute SCI patients was a 
common practice among physicians. However, the intense criticisms to both clinical trials 
associated with the fact that all NASCIS studies reported a statistically significant 
increase in wound infections, gastrointestinal hemorrahages, sepsis, pulmonary 
embolism, severe pneumonia and death culminated with the following opinion from the 
American Association of Neurological Surgeons/Congress of Neurological Surgeons 
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(AANS/CNS): “Methylprednisolone for either 24 or 48 hours is recommended as an 
option in the treatment of patients with acute spinal cord injuries that should be 
undertaken only with the knowledge that the evidence suggesting harmful side effects is 
more consistent than any suggestion of clinical benefit” [104]. Hulbert et al. reported that 
after the recommendations of AANS/CNS there has been a complete reversal in Canadian 
clinical practice patterns of MP administration for SCI. The authors showed that in just 
five years the number of surgeons that prescribed MP changed from 76% to just 24% 
[105]. 
In order to avoid adverse side effects derived by systemic high dose injections of MP, 
directed and sustained delivery of methylprednisolone by means of an adequate drug 
delivery system, for instance a nanoparticle-based system, is under evaluation [106, 107]. 
Although much more pre-clinical data are needed, these safer and more efficient routes of 
delivering MP to neuronal cells after a SCI might be extremely beneficial to protect and 
regenerate the nervous tissue.  
Other pharmacological agents, such as monosialotetrahexosylganglioside (GM-1), 
thyrotropin-releasing hormone (TRH), gacyclidine, naloxone and nimodipine, have been 
subjected to investigation in large multicenter prospective randomized controlled clinical 
trials [108]. However, none of them have demonstrated clinical beneficial outcomes in 
SCI patients. In this sense, the search for the pharmacological agent with the ability to 
improve neurological function is still open. Many promising therapies are currently under 
pre-clinical investigation with the potential of entering in clinical trials in the future (see 
section 9.2 of the present chapter). 
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7. Animal Models in SCI Research 
 
The use of animal models is critical for development of experimental therapies that are 
aimed to repair the injured spinal cord. Animals such as cats, dogs, swine, rats, mice and 
non-human primates are being used as SCI models [29, 109-112]. Rat models are by far 
the most commonly used, mainly due to their cost, accessibility, easy to care for, and 
because of the existence of well-established functional analysis techniques. Mice are also 
widely used, essentially because of our ability to manipulate their genome and in this way 
dissect complex molecular events [113]. Non-human primates experiments are very 
limited fundamentally due to high costs and ethical reasons. However, to prove safety 
and efficacy prior human experiments may be essential the use, in a small scale, of non-
human primates. 
In experimental animal models, three general classes of injury are frequently used: 
transection, contusion and compression [114]. Different types of injury address different 
questions, and therefore each type own advantages and disadvantages. 
 
The transection model requires the opening of the dura and the segmentation of some or 
all spinal cord with a sharp instrument [114]. The spinal cord can be transected and left in 
place or a small section can be removed, normally, for implantation of a specific device. 
Unilateral hemisection is sometimes preferred than full transection because the integrity 
and function of one side of the cord is preserved. This is usually sufficient to maintain 
bladder and bowel function which results in less post-operative care and less animal 
death. The transection model provides valuable information in strategies that target axon 
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regeneration and may be the most appropriate models for the implantation of specific 
devices. However, SCI such as produced by transection is rarely seen in human patients. 
In consequence, many researches use the compression and contusion injury models. 
 
The contusion model is induced by hitting the exposed spinal cord (without disruption of 
the dura) with a blunt contusion force. This model is often obtained using a computer-
controlled impactor. This equipment consists of an animal trap device that reproducibly 
delivers a weight (in the case of the New York University impactor [115]) or a solenoid 
(Ohio State University impactor [116]) to the spinal cord, with a computer monitoring the 
impact. These devices allow the regulation of biomechanics events such as impulse, 
velocity, power and energy, thus permitting a superior control of the injury degree. 
Moreover, the contusion type of injury better mimic the lesions seen in human than the 
transection models [117]. However, in this model it is difficult to distinguish between the 
spare and regenerated tissue. 
 
The compression model was introduced by Rivlin and Tator in 1978. The injury is 
induced by compressing the spinal cord with a modified aneurysm clip [118]. Similar 
injuries using forceps or a compression balloon have also been described [119, 120]. 
Similar to impactor models, the compression model can create different degrees of SCI 
by adjustment of the compression strength, the compression time, or both [121]. The 
compression model also mimics the neuropathology over time observed in humans. It 
begins with an early phase of spreading hemorrhagic necrosis and edema, progressing to 
a phase of partial repair and reorganization, and ending in a chronic phase with the 
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central cyst formation, atrophy and glial scar. Mainly used by Fehlings and Tator labs, 
the clip compression model has provided valuable knowledge about pahtophysiology of 
SCI [122], timing of decompression [123] and neuroprotective agents [124]. The 
difficulty in verify anatomical axonal regeneration is also the major disadvantage of this 
model. 
 
8. Recovery Assessment 
 
An accurate and reliable evaluation of functional recovery after SCI is an essential step 
for those attempting the repair of the spinal cord and/or to study the spontaneous 
functional improvements over time. Behavioral analysis (motor and sensory), histological 
staining and electrophysiology are the mainly used techniques to determine functional 
and anatomical recovery. The proper selection of anatomic, neurophysiologic and 
functional tests before beginning an animal study is crucial for its success. 
 
8.1. Behavior Evaluation 
The key element of any behavioral test is the ability to produce reliable, reproducible and 
worthwhile data [125]. Behavior evaluation in SCI animals are currently being used to: 
(i) correlate the degree of functional deficits with lesion severity, location and duration 
[76, 126, 127]; (ii) to document the extent of recovery after SCI with or without 
therapeutic interventions [46, 128]; and/or (iii) to identify the integrity of specific motor 
and sensory systems [129, 130]. The behavior tests used in SCI are commonly classified 
as motor or sensory tests; however, since some could fall in more than one category, 
CHAPTER I. From Basics to Clinical: A Comprehensive Review on Spinal Cord Injury 
28 
Muir el al. classified them according to the type of data collected. The categories 
included: (i) endpoint measures, in which behavior is scored according to some goal to be 
reached (e.g., horizontal ladder walking test); (ii) kinematic measures, which can range 
from qualitative description of movements to continuous quantitative measurements (e.g., 
BBB scale); and (iii) kinetic measures, which quantify, for instance, the force produced 
by the limbs (e.g., limb grip strength test). 
 
The most commonly test used to assess motor function after a SCI is the BBB locomotor 
scale. The BBB is a 21 point scale designed in 1995 by Basso, Beattie, and Bresnahan to 
assess recovery of himdlimb function after thoracic spinal injury [126]. Each point in the 
score represents a specific set of characteristics demonstrated by the animal during 
spontaneous open field locomotion. The scale range goes from 0 (no apparent 
movements) to 21 (normal movement, coordinated gait with parallel paw placement) 
being scores from 0 to 7 related with recovery of isolated movements in the hip, knee and 
ankle joints; from 8 to 13 associated with return of paw placement and coordinated 
movements with the forelimbs; and from 14 to 21 related with the recovery of toe 
clearance, trunk stability, and predominant paw and tail position. The BBB scale is 
widely used mainly because the test produce reliable, reproducible and worthwhile data. 
Moreover, the BBB scale owns more advantages: (i) it is easy to learn and perform; (ii) 
provides a meaningful measure of recovery of a clinically relevant behavior 
(locomotion); and (iii) animal training is not a requirement. The subjectivity of the test is 
the main limitation of the BBB [131, 132]. However, in order to decrease its subjectivity 
the test should be blind and performed by two independents researchers. Moreover, the 
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BBB scale cannot be used as a recovery assessment tool for all the therapeutic 
approaches used in SCI. Since the lower part of the scale concerns about gross aspects of 
locomotion, while the upper part of the scale includes discrete movement aspects, 
recovery assessment of a treatment that only improves toe clearance or trunk stability 
without having any impact on forelimb-hindlimb coordination cannot be done by using 
the BBB scale. In order to solve this problem and improve the sensitivity of the BBB 
scale a sub-scoring system was proposed [128, 133]. In the BBB sub-scoring scale each 
of the behavioral attributes is scored independently and then added them together to yield 
a single score. In this sense, using the sub-scoring system is possible to discriminate 
between gross and fine recovery. 
Another commonly used test to evaluate locomotion recovery after spinal cord injury is 
the horizontal ladder walking test [134]. In this test, animals walk along a horizontal 
ladder with variable rung spacing. Crossing the ladder requires an accurately placement 
of animals’ limbs on the bars. Moreover, to prevent the animals from learning the pattern 
and anticipating the position of the rungs, the distances between metal rungs are irregular 
and the pattern differs, depending on whether the animal is walking from the left or the 
right side. The missteps frequency is calculated as the number of foot slips by each limb 
divided by the total number of steps [135]. This test is simple, cheap and uncovers 
discrete changes in motor recovery; however, it cannot be used in complete paralyzed 
animals and requires training. 
An exciting method to evaluate locomotor behavior is the three dimensional analysis of 
musculoskeletal movement of animals. This biomechanical calculation usually involves 
the use of several video cameras (or one video camera and an specific arrangement of 
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mirrors [136]) oriented at 45 and 135° bilaterally with respect to the direction of 
locomotion and reflective markers attached to the animal skin at the spine, iliac crest, 
greater trochanter, lateral condyle, 
lateral malleolus, the distal end of the 
fifth metatarsal, and the lateral surface 
of the fifth metatarsal [136, 137]. With 
this method is possible to obtain 
precise geometric locomotor profiles of 
the animals (Fig.5) and, with it, detect 
fine motor improvements that otherwise would be impossible to distinguish. Moreover, it 
was previous demonstrated that is possible to obtain animal locomotor profiles during 
other behavioral tests. Zörner et al. acquired locomotor profiles of rats and mice while 
animals were walking in a horizontal ladder, swimming, wadding or just walking in a 
plain surface [136]. In this way it was possible to study four different types of locomotion 
in SCI animals in a precise manner. Despite all these advantages, the three dimension 
analyses are expensive, time consuming, lacks standardization and sometimes data 
obtained from these approaches can be difficult to interpret. Nevertheless, profiling 
locomotion is a powerful tool to assess recovery in SCI animals. 
 
The assessment of sensory function in SCI rats is usually done by using the hot plate and 
Von Frey filaments tests. The hot plate test measures the hind paw withdrawal latency 
from a radiant heat source. Animals are placed inside a plastic cage with a hot source 
below the hindlimbs and the test is finalized when rats lick their paw. Depending of the 
 
Figure I.5. Three dimensional analyses of 
musculoskeletal movements. Adapted from 
reference 136. 
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protocol, rats which show no reaction to the hot source are removed after 35-60s to avoid 
paw injury [138, 139]. Additionally to the hot plate measurements, the Von Frey 
filaments are often used to evaluate if animals experience mechanical allodynia. 
Allodynia is a type of neuropathic pain characterized by an increased sensitivity to 
innocuous stimuli. The filaments (1-300g) are sequentially applied to the plantar surface 
of the fore or hindlimbs, with a pressure that causes a slight bend of the filament, until the 
withdrawal response is obtained. A positive reaction occurs when the paw is quickly 
removed away from the filament. This response may be associated with vocalization, 
flinching and/or abnormal aggressive behavior [140]. It is important to note that sensory 
tests are usually difficult to interpret as they virtually all depend on a motor end point that 
could of course be compromised by the SCI. 
In this review we only focused on the tests most commonly found in literature. More 
information about behavioral testing in SCI animals can be obtained in Sedý review 
[141]. 
 
8.2. Anatomic analyses 
The landmark work of Falck and colleagues in the 1960s marked the beginning of a new 
era in neuroanatomy. The development of methods to identify biogenic amines in tissue 
sections made possible the identification of neuronal population according to the 
neurotransmitter(s) they utilized [142, 143]. Subsequent experiments demonstrated that 
was possible to identify not just the biogenic amines but a wide range of conventional 
neurotransmitters, peptides, enzymes, and others proteins [144]. These techniques are 
now known as immunohistochemistry and provided valuable knowledge about 
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anatomic changes, pathophysiology, neuronal regeneration, and plasticity of the spinal 
cord tissue after suffer a lesion. Examples of biomarkers usually employed in SCI-related 
experiments can be found in Table 1. The selection of appropriated markers depend of 
the hypothesis that is been tested. For example, approaches aimed at SCI repair normally 
utilize markers that allow the observation of axon regeneration such as growth associated 
protein 43 (GAP 43), neurofilament (NF) for axons cytoskeleton, or/and the calculus of 
the amount of serotonergic neurons (5-HT). Alternatively, the experimental work aiming 
on the understanding of the SCI pahtophysiology may use others markers such as the 
nogo receptor IN-1, the glial scar constituent CSPG or the GFAP for astrogliosis. The 
choice of appropriated biomarkers is therefore crucial for the successful anatomic 
evaluation of the spinal cord tissue. 
Another helpful technique for identifying axons that are injured or regenerating is the 
employment of axonal tracers. Neurons can specifically internalize macromolecules and 
transfer them to others neurons of the same pathway. By doing that is possible to identify 
entire neuronal tracts, from the motor cortex to the end of the spinal cord or vice versa. 
Upon internalization the tracers can be transported in either an anterograde or retrograde 
fashion. Antereograde tracers are transported from the cell bodies to the axons, while 
retrograde tracers are transported from axons to cell bodies. It is common practice to 
apply a tracer distally to the injury and then evaluated its presence in the cell bodies 
proximally. For instance, if the spinal cord is full transected at T5 and a retrograde tracer 
is injected at T11, the presence of the tracer above the T5 section implies that 
regeneration across the lesion occurred. Examples of retrograde tracers generally 
employed in SCI experiments are the Fluoro-Gold, Fast-Blue, leucoagglutinin (PHA-L) 
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and the fluoro-emerald [145, 146]. Alternatively, anterograde tracers normally employed 
are the cholera toxin B subunit (CTB), the enzyme horseradish peroxidase conjugated to 
wheat germ agglutinin (WGA-HRP) and, the most commonly found in literature, the 
biotinylated dextran amine (BDA) [145-149]. It is important to note that, this technique 
can be misleading if the track is incompletely cut and axons have been spared, or if 
excessive tracer is used proximally to lesion. 
 
 
Table I.1. Most popular biomarkers employed in SCI experiments. 
Marker Identifies: Information about: References 
    
GAP 43 Growing neurons Axonal regeneration [150] 
NF Neurofilament peptide Axonal organization [151] 
Β-tubulin III / TUJ-1 Neurons Neuronal organization [152] 
MAP-2 Neurons Neuronal organization [152] 
BLBP Neural progenitor Neurogenesis [153] 
CGRP C-Fibers axons Neuropathic pain [151] 
PV Parvalbumin neurons Sensory neurons [151] 
DexTR Sensory axons Ascending pathways [154] 
5-HT Serotonergic neurons Neuronal organization [151] 
DBH Dopamine neurons Neuronal organization [146] 
NK1-R Substance P Neuronal survival [155] 
c-Fos Neurons Activated neurons [149] 
OX42 Microglia Inflammation [156] 
PDGF-αR Progenitores oligodendrocytes Glial scar/repair [152] 
APC Mature oligodendrocytes Cell organization/myelin [152] 
MBP Myelin sheath Mature oligodendrocytes [157] 
GFAP Astrocytes Glial scar/ astrogliosis [148] 
p75 Schwann cells Invading Schwann cells [152] 
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Table I.1. Most popular biomarkers employed in SCI experiments. (continued) 
Marker Identifies: Information about: References 
    
P0 Schwann cells Invading Schwann cells [152] 
Active caspase 3 Apoptotic cells Cell death [158] 
TrK A, B or C Tyrosine kinases receptors NGF, BDNF or NT3/4 [159] 
IN-1 and NEP1-40 Nogo receptor Inhibitory molecule Nogo [147] 
anti-CSPGs CSPG Glia scar [152] 
Neurocan CSPG Glia scar [37] 
C4S Chondroitin CSPG GAG digestion [152] 
MMP-2 Matrix metalloproteinases Glial scar degradation [160] 
Laminin B2 Laminin Permissive ECM [37] 
 
8.3. Electrophysiology 
Electrophysiology techniques provide direct and precise measurements of muscle 
activation, reflex latency, reflex responses, and transmission of both somatosensory-
evoked potentials and motor-evoked potentials. By doing so, neurophysiologic testing has 
been useful for evaluating experimental therapies for spinal cord injuries [161-164]. The 
technique is based on the stimulation of a specific neuronal track on one point, 
transmission of the evoked potential through the injured area, and impulse recording on 
the other point of the track. In this way is possible to obtain valuable information about 
injured and regenerating neuronal pathways. Electrophysiology can be useful for in vivo 
and also in vitro experiments. For instance, Fehlings and coworkers have provided 
significant insights into how influxes of sodium, calcium, and potassium ions mediate 
secondary axonal damaged after a SCI just working in vitro [165, 166]. Moreover, 
Bradbury et al. demonstrated that chondroitinase ABC is able to restore post-synaptic 
activity below the lesion site after electrical stimulation of corticospinal neurons in vivo 
CHAPTER I. From Basics to Clinical: A Comprehensive Review on Spinal Cord Injury 
35 
[161]. Usually, electrophysiology testing is performed in anesthetized animals; however, 
it is also possible to execute neurophysiologic recordings while animals perform other 
behavioral tests (known as contact electrode recording) [167]. The main disadvantages of 
electrophysiology are the need of specialized devices and operators, its invasiveness, and 
the fact that the testing cannot be repeated daily or weekly (except for the contact 
electrode recording test). Nevertheless, these electrophysiologic techniques will most 
likely continue to play a role in the assessment of therapeutic approaches, especially in 
conjunction with other outcome tests. 
 
9. Novel Strategies for SCI Repair 
 
As described in section 4 of the present chapter a combination of factors is responsible 
for the lack of neural regeneration and minimal functional recovery usually observed 
after SCI. Given the multifaceted nature of SCI, many conceptually different paths to 
facilitate recovery have been investigated. In this section we discuss the diverse 
therapeutic approaches that are being tested for SCI. 
 
9.1. Cell Therapy 
Motivated by the physical consequences of the World War II, the era of cell 
transplantation began with the landmark work of Georges Mathé, which transplanted 
bone marrow to six persons exposed to high doses of radiation [168]. More than sixty 
years later cells derived from the bone marrow are still the ones frequently used in 
clinical transplantation. Nevertheless, cell transplantation approaches have, since then, 
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been extensively investigated for a wide range of diseases/injuries. In the particular case 
of SCI, cells such as neural stem cells (NSCs), mesenchymal stem cells (MSCs), 
embryonic stem (ES) cells, olfactory ensheathing cells (OECs), Schwann cells (SCs) and 
more recently, induced pluripotent stem (iPS) cells, already provided valuable pre-
clinical data about their regenerative potential in SCI animal models. The properties, 
advantages and disadvantages of each of these cells are further explored bellow. 
 
9.1.1. Neural Stem Cells 
Neural stem cells are multipotent cells with the ability to differentiate into neurons, 
oligodendrocytes, and astrocytes. These cells are present in the adult and developing CNS 
and can be isolated and expanded in vitro (self-renewing cells that are often cultured as 
neurospheres) [169]. The rationale behind the use of NSCs in SCI treatments focus on the 
replacement of lost tissue (mainly neurons and oligodendrocytes) by these cells, as well 
as by the provision of trophic support to the survival neuronal tissue. Indeed, it was 
demonstrated that NSCs are able to secrete several neurotrophic factors, including nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF) and glial-derived 
neurotrophic factor (GDNF), in vitro and in vivo [170]. However, when NSCs were 
transplanted to normal or injured adult rat spinal cord either remained undifferentiated or 
differentiated along the glial lineage [171, 172]. Neuronal differentiation is rarely 
observed in the spinal cord. The Gage lab demonstrated that in vivo differentiation of 
NSCs is extremely related with environments cues. They showed that adult spinal cord-
derived NSCs implanted into a neurogenic region (granular layer of the hippocampus) 
differentiated in neurons; however, the same kind of cells transplanted into the adult 
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spinal cord only give rise to glial cells [172]. Remaining undifferentiated or differentiated 
predominantly into glial cells is a potential problem for the direct transplantation of NSCs 
into the injured spinal cord. Nevertheless, functional improvements assessed by the BBB 
locomotor scale have been reported by several authors after the transplantation of NSCs 
in SCI animals [173-176]. Moreover, an interesting approach proposed by Fisher lab is 
the use of a mix population of neuronal-restricted precursors (NRPs) and glial-restricted 
precursors (GRPs). Restricted precursors cells are different from NSCs since they are 
committed to a specific lineage (give rise just to neurons or just to glial cells). The mixed 
population can be obtained either by directed isolation from fetal spinal cord or by pre-
differentiation of NSCs in vitro. This experimental design improved cell survival and 
migration, increased cell differentiation into neural and glial phenotypes and ultimately 
led to motor improvements of SCI animals [177, 178]. 
A plethora of different origins NSCs has been described, either isolated from embryonic 
or adult spinal cord and brain regions. Generally, these cells integrated well in the host 
spinal cord and usually led to an improved motor behavior. The translational studies to 
humans recently start with the recruiting of SCI patients for a phase I/II clinical trial to be 
held in Switzerland and sponsored by the biotechnology firm StemCells Inc. (source: 
clinicaltrials.gov; clinical trial identifier: NCT 01321333). Nevertheless, the absence of a 
full understanding about the mechanisms through which NSCs provide functional benefit 
conjugated with practical issues hindering their isolation and differentiation as well as 
some ethical concerns (namely when fetal NSCs are used) greatly contribute to the 
absence of more clinical trials using NSCs in SCI patients. A much more detailed 
characterization, especially of the adult NSCs and their application in different injury 
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models, severities, and treatment intervals will most likely increase the translation studies 
of these cells. 
 
9.1.2. Mesenchymal Stem Cells 
Adult tissues, such as bone marrow, adipose, umbilical cord and others represent 
plentiful, ethical, and easily accessible sources of MSCs for regenerative applications. 
These multipotent cells are particularly appealing for SCI repair because they are easy to 
isolate and expand without serious ethical and technical problems. Moreover, the MSCs 
are known to present low immunogenicity, have an anti-
inflammatory/immunosuppressant effect, do not form tumors, have a pathotropic action, 
and by the ability to be transplanted in an autologous way [179]. The MSCs derived from 
the bone marrow (bmMSCs) are perhaps the most widely applied stem cells in SCI 
experiments. Several laboratories qualify these cells as pluripotent since they 
demonstrated that bmMSCs had the ability to differentiate into neurons and glia cells 
[180-182]. However, these findings have not been confirmed and some authors argue that 
cell fusion and transdifferentiation is happening rather than cell differentiation [183-185]. 
Approximately 50% of the experimental studies employing bmMSCs in SCI animal 
models led to some motor improvements [186]. In the majority of the studies the cells 
were injected into or next to the spinal cord lesion site, however, some authors 
demonstrated that bmMSCs can be successful delivery intrathecally [187] and even 
intravenously [188]. In a work perform by Deng and colleagues an impressive BBB score 
of 13 is attribute to SCI rats injected with human bmMSCs versus a score of 6 in control 
animals [189]. In an interesting study, Zurita and Vaquero transplanted autologous 
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bmMSCs 3 months after the injury and evaluated the animals for up to 12 months. They 
reported an improvement to a BBB of around 17, whereas the control animals were 
completely paralyzed throughout the time of the experiment (BBB=0) [190]. Such result 
of the control animals is very unusual since typically controls score a few points in the 
BBB even in short time experiments. Pre-clinical experiments in large SCI animals such 
as pigs and nonhuman primates have been carried out and animals transplanted with 
bmMSCs improved their locomotor performance. The potential mechanism by which 
bmMSCs may me acting it remains fairly known; however neurotrophic factor and anti-
inflammatory cytokines secretion have been proposed [188, 191, 192]. 
From a translational perspective, clinical trials that reported the transplantation of 
bmMSCs into SCI patients did not reveal any major motor improvement up to one year 
after the surgery [193-195]. Unfortunately, these reports included small patient cohorts 
and were mostly not controlled. Thus, a systematic clinical validation is needed. 
Nevertheless, these first trials were extremely important in establishing the safety and 
feasibility of the clinical use of bmMSCs given that no serious complications were 
reported. Moreover, these translational studies have continue, for instance, at least two 
more clinical centers are recruiting SCI patients for this purpose (NCT01446640 and 
NCT 01328860) and another two clinical trials are currently active (NCT 01162915 and 
NCT 01325103). 
Another possible source of MSCs is the umbilical cord and the adipose tissue. These cells 
share many similarities with the bmMSCs and therefore their potential for SCI 
regeneration should be more explored. Umbilical cord derived cells are usually obtained 
from a gelationous matrix enclosed by the epithelial cells known as Wharton’s jelly (WJ-
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MSCs) [196]. Some authors demonstrated that WJ-MSCs are more highly proliferative 
and thus can be more rapidly and extensively propagated than adult bmMSCs [197, 198]. 
Moreover, Yang et al. demonstrated that the transplantation of human WJ-MSCs in full 
transected rats led to axonal regeneration across the injured area as well as to an increase 
of trophic factors. These findings were associated with functional motor improvements 
[199]. 
With respect to MSCs derived from the adipose tissue (ASCs), which can be easily 
obtained from subcutaneous areas through a lipoaspiration surgery, some authors also 
claim that these cells have a higher growth rate when compared to bmMSC [200]. 
Regarding the in vivo experiments, the transplantation of these cells in a contusion SCI 
rat model revealed to promote functional recovery both in the BBB and grid test and 
decrease cavitation of spinal cord tissue [201]. Surprisingly, and in spite of the limited 
understanding of efficacy, safety and feasibility of ASCs, one clinical trial was already 
conclude in Korea using this cells in SCI patients (NCT01274975). No data is available 
until now, however, clearly both adipose and umbilical cord derived MSCs needed much 
more pre-clinical data in order to be considered for clinical trials. 
 
9.1.3. Olfactory Ensheathing Cells 
Olfactory ensheathing cells are a glial cell type which plays an important role in the 
lifelong neural regeneration capacity of olfactory neurons. They support the constant 
regeneration of olfactory axons from the PNS (the olfactory mucosa) into the CNS (the 
olfactory bulb) [202]. In this sense, OECs hold great promising for SCI treatment since, it 
is possible that they can create a permissive microenvironment for axonal regeneration 
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across the lesion site. OECs can be obtained through nasal biopsies and, either implanted 
right way in conjugation with the cell matrix and/or other cells, or dissociated and 
cultured until sufficient cell numbers are obtained [203, 204]. 
After the implantation of OECs into a complete thoracic transection injury model, 
Ramon-Cueto and co-workers were able to demonstrate regeneration of corticospinal 
axons and improvements in animal motor behavior [205, 206]. Moreover, Raisman and 
Li demonstrated both in discrete and chronic SCI models that OECs were able to promote 
corticospinal regeneration and functional recovery [207, 208]. These studies gain 
considerable international attention and many others followed them. Improved function 
using xeno or allotransplanted OECs has been observed after incomplete and complete 
lesions, in chronic and acute SCI animals [209-213]. However, it is important to note that 
there are a significant number of experiments that fail to demonstrate any therapeutic 
action of OECs after transplantation in SCI models [214-217]. Yet, about two thirds of 
the experimental studies reported improvements in behavior outcome [186].  
The mechanisms underlying the improvements observed after OECs transplantation are 
still in debate. It was demonstrated that, after implantation, the OECs are able to migrate 
in the white and gray matter as well as through the glial scar [206, 218]. However, it is 
yet to be demonstrated if the OECs migration trails the axon regeneration preventing in 
this way the axons to respond to the inhibitory signals found in the injury site. 
Furthermore, Takami and colleagues demonstrated that the OECs led to a decrease in the 
astrocytic response and a decrease on the expression of the growth-inhibitory molecules 
CSPGs [217]. Others also demonstrated that OECs are able to secrete neurotrophic 
factors such as NGF and BDNF [219]. A controversial subject is related with the ability 
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or not of the OECs to remyelinate injured axons. Previous experiments showed enhanced 
myelination after OECs transplantation [220, 221], however, the possibility that the 
myelin formed by derived Schwann cells rather than OECs remains to be excluded [222]. 
The preclinical data in conjugation with the possibility of autologous transplantations 
make these cells attractive for translational studies. Indeed, it was already reported that 
more than 400 SCI patients were transplanted with OECs [203, 204, 223, 224]. Feron et 
al. reported the absence of complication following 3 years after transplantation; however, 
no improvements were detected [203]. Furthermore, Lima and colleagues, in an 
unblinded, non-randomized trial, reported improvements in 11 of the 20 chronic SCI 
patients being the condition of 1 patient deteriorate after the trial [204].  It must not be 
overlooked that this intervention was combined with a strong rehabilitation regimen and 
no controls patients were used. Additionally to these trials, physicians from Poland are 
now recruiting SCI patients for another clinical trial (NCT 01231893). These studies are 
important to help us disclosing about OECs safety and feasibility. However, it seems that 
more preclinical data is needed, especially in contusion/compression SCI models, in 
order to establish whether there are conditions under which transplantation of OECs 
promote plasticity, neuroptrotection, regeneration and/or functional recovery. 
 
9.1.4. Schwann Cells 
 Schwann cells (SCs) are known as the oligodendrocytes of the PNS, given that they 
produce the myelin sheaths that surround the PNS axons. Moreover, after an injury in the 
PNS, SCs play a key role in promoting axonal regeneration by three mechanisms: the 
secretion of a variety of growth factors, such as NGF, BDNF, NT3, CNTF, GDNF as 
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well as FGF; the expression on the membrane surface of adhesive molecules such as L1 
and N-CAM, which are known to support axon growth; and the production of 
extracellular matrix molecules that also support axon growth, such as laminin, fibronectin 
and collagen [225-227]. It was the discovery of these sui generis characteristics generated 
interest in SCs as a potential candidate for SCI repair. 
Of all cells types being used in SCI therapies, SCs have the longest history of 
transplantation, being the first experiment proposed by Bunge and colleagues in 1981 
[228]. Since then, the efficacy of Schwann cells in promoting axonal regeneration and 
myelination has been extensively studied in a variety of experimental models [226, 229]. 
For instance, Takami et al. demonstrated that after implantation of SCs into SCI animals 
the cavitation is reduced and sensory and spinal axons extend into grafts, and many are 
myelinated. Moreover, functional recovery was also reported [217]. Others demonstrated 
that implanted SCs cause extensive infiltration of endogenous SCs to the site of injury 
[230]. In fact, it was recognized that cell transplants, not just SCs but also skin-derived 
precursors and blockers of inhibitory molecules facilitate the invasion of host SCs into 
the injured spinal cord [151, 231]. This invasion of endogenous cells suggests that host 
SCs may contribute to the recovery observed in other therapies. 
Surprisingly, it has been shown that when SCs were used alone their migration into the 
CNS is stopped after contact with astrocytes [232]. Additionally, corticospinal tracts 
show a delayed and poor regeneration activity after SCs transplantation [233], and 
finally, SCs transplants do not allow axons that enter into grafts to exit and reenter on the 
host spinal cord [164]. As a result of these limitations, SCs have been used in 
combination with other co-treatments such as neuroprotective agents, blockers of 
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inhibitory molecules or neurotrophic factors [234-236]. These combination experiments 
led to superior therapeutic outcomes, which suggest that SCs “need a friend” that 
minimize the inhibitory nature of the lesion site (please see the combinatory therapeutic 
approaches section - 9.3.1). 
The translational studies are not abundant using SCs. In fact it was only possible to found 
one clinical trial employing these cells and there are no signals that more will come 
(clinicaltrials.gov). In the study of Saberi and coworkers, autologous transplantation of 
SCs in just four SCI patients did not reveal any serious complications up to 1 year after 
the surgery. However, not functional outcome was reported [237]. In a clinical trial using 
multiple sclerosis patients, SCs revealed to be safe and feasible, as well as promoted 
remyelination [238]. It is clear that additional clinically relevant experiments are required 
to scrutinize the therapeutic potential of SCs in SCI.  
 
9.1.5. Embryonic Stem Cells 
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the 
blastocyt. These cells have the indefinitely ability of self-renew and can differentiate into 
cells from all three germ layers [239]. These characteristics make them an attractive cell 
source for SCI regeneration. However, ES cells are not directly transplanted in animal 
models, usually an in vitro pre-differentiation protocol is performed in order to obtain a 
desirable cell population [240]. McDonald and coworkers pre-differentiated mouse ES 
cells in neurons or oligodendrocytes and demonstrated both remyelination and functional 
recovery in contusion SCI animals [241, 242]. The Keirstead lab has focused on the pre-
differentiation of human ES cells into oligodendrocytes progenitor cells (OPCs). The 
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implantation of OPCs in myelin-deficient shiverer mice demonstrated that these cells 
differentiated in mature oligodendrocytes and restored myelination [243]. Another study 
from the same lab but now using contusion injured animals demonstrated that OPCs 
transplantation lead to remyelination and locomotor functional recovery [244]. 
Nevertheless, there are several concerns regarding to the use of ES cells. First of all, 
ethical concerns were raised concerning to the destruction of human embryos in order to 
isolate ES cells. Furthermore, concerns about the safety of ES cells transplantation were 
raised due to the formation of teratomas [245]. Possible clinical applications of ES-
derived cells critically depend on the ability of labs to produce pure differentiated cell 
populations in vitro. The U.S. biotechnology company Geron was until recently 
recruiting SCI patients to test the safety of embryonic-derived OPCs (NCT01217008). 
This clinical trial was originally approved by the FDA, then put on hold due to concerns 
of cyst formation, and then in October of 2010 approved again but not without 
considerable objection and controversy [246, 247]. In October 2011, Geron presented the 
first results of the ES derived cells clinical trial. The cells were well tolerated by the 
patients, with no serious adverse events. However, no neurological recovery was 
observed [248]. Despite of these results, that bring to light the possible safety of ES 
derived cells therapies, one month later the Geron administration surprisingly decided to 
shut down all the experiments envolving ES cells claiming financial reasons [249]. Due 
to all the controversy around the use of ES cells, researchers tend to choose other sources 
of stem cells for regenerative therapies. 
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9.1.6. Induced Pluripotent Stem Cells 
In 2006, Takahashi and Yamanaka demonstrated that pluripotent cells could be obtained 
from fibroblast by the introduction of four genes into cells via retrovirus-mediated gene 
transfer [250]. Subsequently, others demonstrated that induction to pluripotency can also 
be performed without the need of potential hazardous viral vectors through the use of 
chemical and small molecules [251], proteins [252], non-integrating excisable virus 
[253], and drug selectable targeting [254]. The resulting cells, termed induced pluripotent 
stem (iPS) cells demonstrated to have many of the characteristics of ES cells, such as 
such as tri-lineage differentiation and generation of viable chimaeras [250]. However, the 
use of iPS cells owns several advantages over the ES cells. They circumvent the ethical 
concerns associated with ES cells and allow autologous transplantations of pluripotent 
cells. Nevertheless, iPS and ES cells also share similar disadvantages such as the ability 
to form teratomas [250, 255]. 
An increasing number of experiments are been conduct with iPS cells in SCI models. 
Recently, two experiments from Okano lab demonstrated that NSCs derived from iPS 
cells implanted in immunodeficient contusion mice result in trilineage neural 
differentiation, functional recovery and no tumor formation [256, 257]. Much more 
studies are required to confirm the safety and feasibility of iPS cells before clinical a can 
be initiated. 
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9.2 Molecular Therapy 
 
The remarkable advances in molecular biology in the past decades have led to a better 
understanding of the mechanisms implicated in the pathophysiology of SCI as well as 
mechanisms that control axonal growth and sprouting. This knowledge has raised the 
hope of developing new therapies that can attenuate secondary damage and maximize 
regeneration after a SCI. Molecular therapies usually focus on the modulation of 
inflammatory response, administration of growth-stimulating factors and/or blocking the 
inhibitory nature of the injured adult CNS tissue. In this section approaches that, by 
lowering the extrinsic inhibitory cues or increasing intrinsic growth promoting cues, 
accomplished various degrees of anatomical growth often correlated with improved 
behavioral outcomes, will be reviewed. 
 
9.2.1. Protecting the Spinal Cord 
As mention above (see section 4 of this chapter) the pathophysiology of a SCI is very 
severe and complex, playing a crucial role on the failure of axonal regeneration. While 
the use of the anti-inflammatory drug methylprednisolone is very controversial with no 
robust evidences of clinical benefits and several side effects, researches are now focusing 
on how to exploit the constructive effects of inflammation and at same time avoid the 
destructive effects. 
In this context, Bethea and colleagues proposed the use of interleukin-10 (IL-10), an 
anti-inflammatory cytokine capable of inhibiting the inflammatory reactions of 
monocytes and macrophages in the PNS, and capable of inhibiting the production of 
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TNF-α by astrocytes in CNS, in a SCI condition [258]. They demonstrated that the 
systemic administration of IL-10 significantly reduces the lesion volume by 
approximately 50% and this was correlated with enhanced functional recovery [258]. 
More recently experiments also demonstrated that IL-10 promotes direct neuronal 
survival, provide trophic support to neurons and limits the onset and progression of 
injury-induced pain behavior [259-261]. It is important to note that, in one study 
conducted by Takami and colleagues the administration of IL-10 led, indeed, to reduction 
a of gray matter damage but did not improve functional outcomes [262]. In this sense, 
further pre-clinical experiments are needed before the beginning of clinical trials using 
IL-10 in SCI patients. 
 
In the last decade, the broad-spectrum antibiotic minocycline has sparked significant 
interest in the neuroscience community for its potential role in pos-traumatic 
neuroinflammation. The ability of minocycline to inhibit microglial activation, inhibit the 
release of pro-inflammatory mediators and to have an anti-apoptotic action has made it an 
attractive agent to study in SCI models [263, 264]. Wells and colleagues in 2003 were the 
firsts describing the beneficial effects of minocycline in SCI rodents. Minocycline 
treatment increased rubrospinal tracts, reduce lesion area and improve functional 
outcome in BBB scale and inclined plane test [112]. After this initial study, it was 
demonstrated in different labs that minocycline treatment reduces cavitation, apoptotic 
cells, caspase-3 activity, cytochrome c release, necrosis and gliosis [265-267]. Moreover, 
the neuroanatomic improvements were correlated with functional beneficial outcomes. 
However, more recently, three studies failed to demonstrated beneficial effects of 
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minocycline in SCI models [268-270]. One study, in particular, was a NIH sponsored 
formal replication attempt that was unable to reproduce previous results [268]. Despite of 
this inconsistency a human clinical trial was initiated in 2007 in Calgary, Alberta 
(Identifier: NCT005594494). No published analysis of data is available; however, a large 
scale multicenter randomized study sponsored by Rick Hansen Institute is already 
planned in Canada [271]. 
 
Due to the known side effects of steroids agents, several non-steroidal anti-inflammatory 
drugs (NSAIDs) are been tested in SCI models. The most widely used are indomethacin 
and ibuprofen. Many of the indomethacin studies showed decreased edema, less tissue 
damage and less migrolia and astrocytes [272-274]. The majority of the studies do not 
assessed behavioral outcomes, and the results of the few that did are contradictory [275, 
276]. Additionally, the study of Guven and colleagues also show that indomethacin 
significantly increased lipid peroxidation, suggesting a harmful role for this drug [277]. 
Ibuprofen, however, has more recently been found to promote histological and behavioral 
improvements even when administrated 3 and 7 days post injury [278, 279]. Moreover, 
ibuprofen also reduced RhoA activation, which may indicate that this drug, in 
conjugation with attenuation of inflammation, can promote axonal sprouting [279]. A 
controversial issue of these pre-clinical experiments is the dose used. The conversion of 
the therapeutic dose used in rats to a human equivalent dose suggests that it was used a 
concentration 5 to 7 times higher than what is known to be clinically safe [280].   
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Recently, pre-clinical experiments using the FDA approved drug atorvastatin (Lipidor) 
revealed beneficial effects when administrated in SCI models. Atorvastatin is commonly 
used for the treatment of high cholesterol, triglyceride levels and prevention of heart 
attacks and stroke. It was found by Pannu and colleagues that atorvastatin reduces the 
expression of inflammatory cytokines, macrophage invasion, GFAP reactive astrocytes 
and apoptotic cells. Moreover, atorvastatin treatment also promoted tissue sparing and 
significant locomotor recovery [281, 282]. Déry et al. also demonstrated that atorvastatin 
prevented the elevation of caspase-3 activity and significantly improved locomotor 
outcome [283]. However, more pre-clinical experiments should be performed for this 
drug before any clinical trial, since, a recent attempt to replicate these results failed to 
demonstrated any beneficial outcome [284]. 
 
The hematopoietic growth factor erythropoietin (EPO) is produced in the kidney and 
stimulates proliferation and differentiation of erythroid precursor cells [285]. However, it 
is also known to exert non-hematopoietic effects in the CNS. For instance, EPO has a 
trophic effect on cholinergic neurons, influencing their differentiation, maintenance and 
regeneration [286]. After SCI, EPO administration has shown a neuroprotective effect, 
namely, by reducing apoptosis, inflammation, lipid peroxidation and by increasing white 
and gray matter sparing [287-289]. Many authors also reported improved locomotion 
scores and improved function on the swimming test. However, these beneficial effects 
were not always found [290, 291]. A NIH-sponsored attempt to reproduce the positive 
effects of EPO failed to demonstrate both histological and behavioral outcomes [291]. 
Nevertheless, a modified version of EPO (lacking hematopoietic effects) was being test 
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in SCI patients, although, the Italian medicine agency recently suspended the trial without 
public explanations (NCT00561067). 
 
It has been long understood that neuronal damage is mediated by disproportionate 
intracellular accumulation of sodium and calcium ions. This accumulation is mediated by 
overstimulation of NMDA receptors (due to high glutamate levels after injury) in a 
process known as “excitotoxicity” [165, 292]. In order to protect neural tissue several 
researchers explored the therapeutic potential of either sodium channel blockers, such as 
riluzole, or NMDA antagonists, such as magnesium. 
Riluzole is a FDA-approved drug for the treatment of amyotrophic lateral sclerosis that 
has been found to promote tissue sparing, decrease lipid peroxidation, reduce neuronal 
loss, enhance eletrophysiologic recordings and improve functional recovery [124, 293-
295]. Of note, in a study by Kitzman and colleagues, higher dose of riluzole was 
associated with undesired side effects, such as lethargy and locomotor ataxia [296]. 
Encouraged by preclinical results and facilitated by the fact that oral riluzole is FDA-
approved; a multicenter clinical trial for acute human SCI is ongoing in North American 
(NCT 00876889). 
Magnesium is a natural mineral that play an important role in several functions of the 
human body. It was demonstrated that magnesium levels decrease significantly within the 
injured spinal cord [297], and that the severity of injury was closely correlated with 
magnesium levels in plasma and cerebrospinal fluid [298]. Moreover, the fact that 
magnesium is able to block NMDA receptors encouraged its use in SCI models. Results 
revealed that magnesium can increase tissue sparing, reduce apoptosis, lipid peroxidation, 
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restore BBB integrity and improve functional outcome [299, 300]. It should be noted that 
the doses used so far exceed the tolerable by humans. In this sense, formulations of 
magnesium within polyethylene glycol (PEG) were been developed and revealed that 
PEG allows that a much lower dose of magnesium can be applied effectively [301]. This 
PEG formulation is commercialized by Medtronic and will be used in a Phase II 
multicenter clinical trial. 
 
In the fall of 2007, Kevin Everett, a NFL football player, suffered a cervical SCI and 
achieved significant neurologic recovery after systemic hypothermia treatment [302]. 
This well-publicized case triggered the resurgence of interest in a treatment that has 
fascinated scientist for many decades [303].  While technically not a “molecular therapy”, 
systemic hypothermia was included in this review due its effects on neuroinflammation 
and neuroprotection. Hypothermia provides protection to neural tissue by slowing basic 
enzymatic activity, thus reducing the energy requirements of the cells and maintaining 
intracellular ATP concentrations [304, 305]. Experiments in SCI models demonstrated 
that moderate hypothermia treatment (30-34ºC) attenuate neutrophil invasion, reduce 
oxidative stress, apoptosis, vasogenic edema, and tissue damage [306-309]. Although the 
majority of the studies do not report any behavioral outcome, functional improvements 
have been described by some authors [306, 308]. As far as we know, the only side effect 
of hypothermia treatment was published by Strain and colleagues, which observed that 
hypothermia significantly increased gastric ulcerogenesis [310]. The first clinical trial 
using hypothermia in human SCI (14 patients) was conducted by investigators from the 
Miami Project, which verified the safety of this treatment, seeing that, hypothermia do 
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not increased the incidence of secondary complications usually observed in these 
patients. Moreover, they observed that, although without statistically significance, 42.8% 
of the patients recovery from a complete stage to incomplete SCI stage [311, 312]. Due to 
these promising findings, a large-scale trial of systemic hypothermia is now being 
organized. 
 
9.2.2. Overcoming the inhibition 
As discussed above (see section 4 of this chapter) the pathophysiology of SCI goes well 
beyond of inflammation, edema and cell death. The axonal regeneration which would be 
necessary for re-establishing connectivity across the injury site is inhibited by a number 
of features within the injured CNS. Myelin, for instance, contains several inhibitory 
molecules that hold back axonal growth. Additionally, within days after injury, a glial 
scar is formed around the injury site, producing a physical barrier to axonal regeneration. 
In order to overcome these inhibitors to axonal growth a number of therapeutic strategies 
have been proposed. 
In 1988 Schwab and Caroni reported the first evidence of the presence of molecules in 
the myelin that inhibit axon growth [313]. Among them, one of the most potent inhibitor 
was a 250-kDa glycoprotein than was later named Nogo [314]. Subsequently, they 
generated and administrated in SCI models a blocking anti-Nogo antibody, which was 
associated with improved behavioral outcomes on a variety of tests, such as open field 
locomotion, rope climbing and food pellet reaching. Moreover, anti-Nogo treatment led 
to substantial axonal sprouting and long-distance corticospinal regeneration [315-317]. 
Nevertheless, a study from Oudega and colleagues demonstrated that blocking Nogo does 
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not promote the regeneration of sensory axons suggesting that future treatments will have 
to include the neutralization of other inhibitory molecules [318]. Moreover, an 
independent study sponsored by the NIH failed to replicate the beneficial outcomes 
observed after the administration of NEP1-40 (an anti-Nogo peptide generated in 
Strittmatter lab) [319], suggesting that the use of antibodies may be more valuable in this 
situation. The anti-Nogo antibody from the Schawb group, on the other hand, 
demonstrated to promote corticospinal tract axons regeneration also in marmoset 
monkeys [320]. The pre-clinical data generated by Schawb lab were undergoing 
translational human testing in a clinical trial sponsored by Novartis (Identifier: 
NCT00406016). At the time of writing, results of this study have yet to be published. 
 
After the discovery of the Nogo glycoprotein other myelin-associated inhibitory 
molecules were identified in CNS. Among them were the myelin-associated glycoprotein 
(MAG) and the oligodendrocyte myelin glycoprotein (OMgp) [321]. Surprisingly, it was 
demonstrated that both MAG and OMgp binds with high-affinity to the Nogo receptor 
(NgR) [45, 322], suggesting that the different inhibitory molecules within the myelin 
activated the same intracellular signaling pathway. Then, unlike the anti-Nogo antibody, 
which is specific to the Nogo protein, a single pharmacological intervention targeting this 
intracellular pathway might neutralize the effect of many myelin inhibitors.   
It was demonstrated that the point of convergence for a single therapeutic intervention 
might be on the Rho pathway [323]. Rho is a small guanosine triphosphatase (GTPase) 
that plays an important role in transducing extracellular signals to changes in cytoskeletal 
proteins [324]. Therefore, the activation of Rho leads to the depolymerization of actin 
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filaments and subsequently growth cone collapse. On the other hand, the inhibition of 
Rho leads to the polymerization of actin making possible the axonal growth [323]. 
The landmark work of Jalink and colleagues demonstrated that inhibition of Rho 
pathways using C3 transferase promotes neurite outgrowth [325]. Moreover, 
administration of C3 transferase also demonstrated to have a beneficial effect in vivo. 
Dergham and colleagues verified that animals treated with C3 presented long-distance 
regeneration of corticospinal axons, which was correlated with beneficial functional 
outcomes [326]. These results were confirmed by others labs [327] but not in all studies 
[328]. Nevertheless, experiments found in literature suggest that either the direct 
inhibition of Rho or selective Rho kinase or even non-selective protein kinase have a 
beneficial effect in axonal regeneration and locomotor behavior [328-330]. 
On the basis of these preclinical findings, a multicenter clinical trial, headed by Lisa 
McKerracher and sponsored by BioAxone Therapeutics Inc. (NCT00500812) initiated in 
2005, demonstrated that Cethrin (commercial name for a Rho antagonist) slightly 
improved the motor recovery without serious adverse events [331]. Such results have 
encouraged the planning of a subsequent large randomized clinical trial (NCT00610337) 
that was prematurely terminated because of insufficient funds. 
 
An important class of inhibitory ECM molecules is the chondroitin sulfate proteoglycan 
(CSPG). Activation of astrocytes in injured spinal cord is associated with changes in the 
ECM, being the CSPG an important component of this matrix and having a substantial 
inhibitory effect on the endogenous regeneration [332]. A number of pre-clinical 
experiments, mainly from Fawcett lab, demonstrated that degradation of CSPGs with the 
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chondroitinase ABC (ChABC) enzyme can render a more permissive environment for 
axon regeneration (both ascending sensory projection and descending motor projection), 
can restore post-synaptic activity below the injured site and can promote functional 
recovery of locomotor and proprioceptive behavior [161, 333, 334]. More recently, the 
work of Garcia-Alias and colleagues evidenced that ChABC treatment opens a window 
during which rehabilitative training supports functional improvements [335]. However, 
significant improvements with ChABC alone were not observed by others [336]. Some 
authors demonstrated, yet, that ChABC may play an important role as an adjunct therapy 
for cell transplants [336, 337]. The ChABC translational studies in SCI humans did not 
start yet. The Seikagaku Corporation decided not to publish the results of the safety and 
efficacy tests of ChABC in non-human primate models of SCI. The Japanese Corporation 
announced in November 2011 that due to the promising results of a phase II clinical trial 
using ChABC for the treatment of lumbar disc herniation, a phase III clinical trial will be 
initiated [338]. This seems to indicate that ChABC is safe for humans; nevertheless, tests 
in SCI patients are still required. 
 
There are other molecules that also display an inhibitory effect after SCI. However the 
amount of preclinical experiments employing these molecules is still reduced, and so, 
they will not be deeply discussed here. Nonetheless, many molecules from the 
semaphorins and ephrins family act as inhibitory or repulsive cues for axonal growth 
[339, 340]. The inhibition of such molecules in SCI models enhanced axonal 
regeneration, increased myelination (derived from higher invasion of peripheral Schawnn 
cells), reduced apoptosis, and was correlated with better functional recovery [151, 341, 
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342]. Nevertheless, more preclinical data is needed to verify the robustness of these 
therapeutic approaches. 
 
9.2.3. Stimulating axonal growth 
Trophic factors are tightly linked to cell growth, guidance, and survival during the 
development. In CNS, neurotrophic factors are regulated both spatially and temporally, 
usually decreasing as the development proceeds. However, their expression persists 
throughout adulthood in many CNS regions associated with functional plasticity 
(hippocampus, cortex and olfactory bulb) [343]. Conversely, the spinal cord deals with a 
huge reduction in neurotrophins levels from embryonic state to adult maturation [343]. 
Nevertheless, the clear evidence that several growth factors play a central role on the 
axonal regeneration after a PNS injury made them an attractive therapeutic tool for SCI 
repair [344-346]. 
Neurotrophins have been capable to promote axonal regeneration and sprouting of both 
ascending and descending fibers but with two major constrains: deficient repair of 
corticospinal tracks and lack of regeneration through degenerative white matter [347]. 
Even so, NGF has demonstrated that is able to promote the sprouting and regeneration of 
cholinergic motor axons, primary nociceptive sensory axons (which may contribute to 
dysfunctional pain), and cerulospinal axons [348-350]. On the other hand, BDNF 
promotes regeneration of raphaespinal, rubrospinal and reticulospinal motor axons and 
proprioceptive sensory axons [351-353]. NT3 has an effect similar to BDNF, but might 
also have an effect on the corticospinal tract [354, 355]. These findings indicate that 
different populations of axons in the CNS show distinct patterns of growth factor 
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sensitivity, which is explained by the divergent profile expression of high-affinity 
tyrosine kinase receptors by different populations of neurons [356]. Other factors, such as 
bFGF, VEGF, and GDNF, also demonstrated to have a beneficial effect after 
administration in SCI models. However, more preclinical data using these factors are 
needed [357-359]. The majority of studies using this kind of treatment only reported on 
histological outcomes, and the studies in which behavioral outcomes were measured just 
described modest functional recovery. Moreover, the delivery of growth factors in 
chronic SCI models might be less effective due to the loss of appropriated receptors by 
injured neurons [360]. 
Unfortunately, a clinical trial using systemic delivery of NGF in diabetic neuropathic 
patients failed to demonstrated efficacy and safety [361]. However, in other clinical trial 
performed by Tuszynski and colleagues the implantation of autologous fibroblasts 
genetically modified to express NGF into the forebrain of Alzheimer disease patients do 
not result in adverse side effect and revealed to slightly reduced the rate of cognitive 
decline[362]. Furthermore, a clinical trial using bFGF in nine chronic SCI patients 
revealed to be safe and to promote sensory and motor recovery to some extent (difficult 
to distinguish from any possible placebo effect) [363]. 
 
Neurotrophins bind to the neuronal membranes via distinct tyrosine kinases receptors. 
However, the fact that neurotrophins signaling elevate the intrinsic levels of cAMP 
seems to indicate that distinct neurotrophins activated the same intracellular signaling 
pathway [364]. Then an intrinsic molecular approach targeting this pathway might result 
in higher beneficial effects than those observed with the use of a single neurotrophin. In 
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addition, exogenous elevation of cAMP has been shown to promote axonal regeneration 
when prophylactically applied [365, 366]. Obviously, this is not clinically relevant. 
Moreover, the administration of cAMP may result in undesirable side effects [367-369]. 
In order to avoid side effects, others strategies have been proposed to increase cAMP 
levels. For instance the use of rolipram, a molecule that prevents cAMP hydrolysis, has 
been show to attenuate oligodendrocytes death and to restore a respiratory pathway [370, 
371]. The effect of rolipram has been more pronounced when in combination with cells 
[372, 373]; although this was not always the case [374]. These findings suggest that 
approaches aimed to increase the intrinsic levels of cAMP may be important in future 
treatments for SCI repair. 
 
9.3. Combinatorial Therapies 
 
9.3.1. Searching for synergistic effects 
Due to the complexity of SCI there is the expectation among researchers that 
combinatorial therapies will be a more effective strategy to promote recovery than a 
single therapeutic approach alone. In this sense, therapies that combine cell 
transplantation, activation of growth promoting programs and/or attenuation of growth 
inhibitory pathways have been explored. After an extensive overview in literature, it was 
possible to find several studies using combinatorial therapies (see table 2), of which over 
half of them demonstrated synergistic effects between the subjects combined. For 
instance, Pearse and colleagues demonstrated that the transplantation of Schwann cells 
combined with the modulation of cAMP levels (both by direct injection of cAMP and 
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inhibition of cAMP hydrolysis by injecting rolipram) enhances axonal sparing and 
myelination, promotes growth of serotonergic fibers into and beyond grafts, and 
significantly improves locomotion [372]. Moreover, the combination of autologous PNS 
bridges and ChABC showed to work synergistically in three different studies. Using this 
strategy it was possible to accomplish superior axonal regeneration and extension for 
longer distances, functional synapses, significant motor improvements, and restoration of 
the respiratory pathways in a level not possible to achieved using a single therapy alone 
[375-377]. 
The use of cells in combination with other therapeutic approaches is the most commonly 
found in literature, being the SCs, bmMSCs and OECs the most frequently exploited. 
Normally, these cells are used in combination with trophic factors, being the NT3, BDNF 
and FGF often applied. Unfortunately, approximately one third of the studies using 
combinatorial approaches did not assesse for synergistic effects between the components 
employed. In these studies the authors usually demonstrated that the combined treatment 
lead to a better outcome than using one component alone, however, they did not 
controlled the experiment for all possible combinations of components. In this sense, it is 
impossible to conclude about promising synergistic effects. 
Few studies published negative data, however, the combined use of OECs and SCs failed 
to demonstrate any synergistic effects in two different experiments [217]. Furthermore, 
this combination seems to lead to some antagonistic effects on the role of SCs, since only 
the SCs alone were able to promote functional recovery. However, Fouad and colleagues 
showed that this negative result may be overcome by matrix modification. The 
combinatorial treatment employing OECs, SCs, and ChABC significantly improved 
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motor function and increased the number of myelinated axons and serotonergic fibers that 
grew trough the graft and into the caudal spinal cord [337]. 
Bretzner and colleagues also demonstrated that OECs in combination with cAMP did not 
provide additional benefits compared with either treatment alone. On the other hand, the 
use of OECs and rolipram resulted in greater axonal density within the graft and 
improved motor performance in a cylinder test [373]. 
The combinatorial therapy is a very promising approach to treat the injured spinal cord; 
however, more preclinical date is needed to fully understand the beneficial or detrimental 
effects of the therapies that are being proposed. Nevertheless, one clinical trial using 
autologous bone marrow mesenchymal stem cells combined with granulocyte 
macrophage-colony stimulating factor (GM-CSF) was already performed in South Korea 
and showed some promising results [378]. No serious clinical events were observed and 
30.4% of the acute and subacute patients improved from ASIA A to B or C. The patients 
with chronic injuries did not improve. Long-term and a large scale multicenter clinical 
study is required to determine the precise therapeutic effect of this approach. 
 
Table I.2. Combinatorial therapies aimed for SCI regeneration. 
    
Reference Methodology SCI Model Outcomes 
    
Ziv, PNAS, 
2006 [379] 
NSCs + myelin 
vaccination. 
Acute model of 
contusion. 
Synergistic effects observed. Smaller 
lesion site in the CT group; Less 
activated macrophages and microglia; 
Significant motor improvements. 
 
Karimi-
Abdolrezaee, 
PNAS, 2006 
[152] 
NSCs + PDGF-
AA + bFGF + 
EGF + 
Minocycline. 
Chronic model of 
compression. 
Synergistic effects observed but not 
accessed for all possible combinations. 
51% of NSCs differentiated into 
oligodendrocytes and ensheathed the 
axons; Improved locomotion observed by 
BBB, grid-walk and footprint analyses. 
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Table I.2. Combinatorial therapies aimed for SCI regeneration. (continued) 
    
Reference Methodology SCI Model Outcomes 
    
Meng, Cell. 
Biol. Int., 2008 
[380] 
NSCs + bFGF 
expressing AECs. 
Subacute model of 
contusion. 
Synergistic effects observed. 
Electrophysiological and locomotor 
improvements. 
 
Ishii, J. 
Neurosci. Res., 
2006. 
[381] 
NSCs + anti-
CNTF antibody 
Acute model of 
hemisection. 
Synergistic effects not assessed. 
Reduction of the glial scar; NSCs 
differentiation into neurons, 
oligodendrocytes and astrocytes; 
Increasing number of CST fibers; 
Behavioral function not assessed. 
 
Kim, Acta 
Neurochir., 
2006. [382] 
bmMSCs + bFGF. Subacute model of 
contusion. 
Synergistic effects not assessed. Cavity 
volume decreased in CT group; CT 
promotes significant motor improvement. 
 
Lu, Exp Neurol., 
2005. [383] 
bmMSCs + 
BDNF. 
Acute model of 
transection. 
Synergistic effects not assessed. CT 
enhanced the growth of serotonoergic, 
coerulospinal and sensory axons. 
However, functional recovery was not 
observed. 
 
Lu, J. Neurosci., 
2005. [384] 
bmMSCs + NT3 + 
cAMP 
Acute model of 
transection. 
Synergistic effects observed. Sensory 
axons regenerated into and beyond the 
leions in CT group only. Functional 
outcomes were not observed. 
 
Chiba, 
Neuropathology, 
[385]. 2010 
bmMSCs + 
ROCK 
 Synergistic effects observed in CST 
regeneration only. ROCK did not 
increase the therapeutic effects of 
bmMSCs on motor activity. 
 
Fang, PLoS One, 
2010. 
[386] 
bmMSCs + 
PACAP 
Subacute model of 
contusion. 
Synergistic effects observed. CT 
increased the number of neuronal fibers, 
and increased the levels of antioxidant 
enzymes in the injury site, leading to 
better functional recovery. 
 
Yoon, Stem 
Cells, 2007. 
[378] 
bmMSCs + GM-
CSF. 
ASIA A patients. Synergistic effects not assessed. No 
serious clinical events; 30.4% of the 
acute and subacute patients improved 
from ASIA A to B or C; No significant 
improvements in chronic group. 
 
Deng, 
Cytotherapy, 
2008. [189] 
OECs + bmMSCs. Acute model of 
contusion 
Synergistic effects observed. Significant 
motor improvements observed by 
electrophysiology and BBB test. 
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Table I.2. Combinatorial therapies aimed for SCI regeneration. (continued) 
    
Reference Methodology SCI Model Outcomes 
    
Ruitenberg, 
Brain, 2005. 
[387] 
OECs + NT3. Acute model of 
hemisection. 
OECs alone or in combination with NT3 
decreased the lesion volume. 
Anterograde tracing showed a 
significantly greater number of distal 
CST axons only in the CT group. 
Treatment do not improved functional 
outcomes. 
 
Bretzner, J. 
Neurosci., Res., 
2010. [373] 
OECs + cAMP or 
rolipram 
Acute model of 
compression. 
CT of OECs plus rolipram resulted in 
greater axonal density within the graft 
and improved motor performance in a 
cylinder test. OECs plus cAMP do not 
resulted in synergistic outcomes. 
 
Takami, PNAS, 
2002 and Pearse, 
Glia, 2007 [217, 
388] 
OECs + SCs Subacute model of 
contusion 
Both studies fail to demonstrated 
synergistic effects between OEC and 
SCs. Myelinated axons were found 
within regions of SCs but not OECs; 
More retrograde traced axons in SCs and 
SCs/OECs group than in OECs alone; 
Significant motor improvements only 
observed in SCs group. 
 
Cao, Brain, 
2004. [389] 
OECs + SCs. Acute model of 
transection. 
Synergistic effects not assessed. 
Increased amount of fibers in the lesion 
site. CST regeneration. Functional 
recovery observed in the BBB and 
inclined plane tests. 
 
Fouad, J. 
Neurosci., 2005. 
[337] 
OECs + SC + 
ChABC. 
Acute model of 
transection. 
Synergistic effects not assessed. 
Increased number of myelinated and 
serotonergic fibers in the CT group. 
Significant improvements observed in 
BBB and in forelimb/hindlimb coupling 
test. 
 
Menei, EJN, 
1998. [390] 
SC + BDNF Acute model of 
transection. 
Synergistic effects not assessed. More 
axons in the CT grafts than SCs alone. 
More retrogradelly labeled neurons in the 
CT group. Functional outcomes not 
assessed. 
 
Pearse, Nat. 
Med., 2004. 
[372] 
SC + cAMP + 
rolipram. 
Subacute model of 
contusion. 
Synergistic effects observed. CT 
promotes significant supraspinal and 
proprioceptive axon sparing and 
myelination. Growth of serotonergic 
fibers into and beyond SCs grafts. 
Significant improvements in locomotion 
observed by BBB, gridwalk testing and 
footprint analysis. 
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Table I.2. Combinatorial therapies aimed for SCI regeneration. (continued) 
    
Reference Methodology SCI Model Outcomes 
    
Xu, Exp. 
Neurol., 1995. 
[234] 
SC + BDNF + 
NT3 
Acute model of 
transection. 
Synergistic effects observed. 
Significantly more myelinated fibers in 
the CT group. More retrogradelly labeled 
neurons in the CT group. Functional 
outcomes not assessed. 
 
Guest, J. 
Neurosci. Res., 
1997. [391]  
SC + IN-1 or 
aFGF 
Acute model of 
transection. 
Synergistic effects not assessed. 
SC grafts alone do not supported CST 
regeneration and do not prevented die-
back. SCs plus IN-1 supported some 
sprouting but die-back continued. SCs 
plus aFGF supported regeneration and 
reduce die-back. Functional outcomes not 
assessed. 
 
Nikulina, PNAS, 
2004. 
[392] 
Fetal tissue + 
rolipram 
Acute model of 
hemisection. 
Synergistic effects not assessed. CT 
resulted in an increase axon regrowth 
into the transplant and reduces gliosis. 
Significant improvement in motor 
function was observed. 
 
Kimura, Neurol. 
Res., 2005. [393] 
ES cells + 
thyroxine 
Chronic model of 
contusion. 
Synergistic effects not assessed. 
ES cells alone improved motor function. 
No additional improvement was observed 
with the use of thyroxine. 
 
Cao, J. 
Neurosci., 2010. 
[394] 
OPCs + CNTF Subacute model of 
contusion. 
Synergistic effects observed in 
histological and electrophysiology 
outcomes, but not in motor behavior. 
CNTF significantly increased the 
percentage of adult OLs derived from 
grafted OPCs. CT increased the number 
of remyelinated axons and partially 
restored the conduction through the 
demyelinated fibers. Motor 
improvements observed using the BBB 
scale. 
 
Houle, 
 J. Neurosci., 
2006. [377] 
 
Tom, 
J. Neurosci., 
2009. [376] 
 
PNS grafts + 
ChABC 
Acute and chronic 
model of hemisection 
Synergistic effects observed. More axons 
regenerated and extended for longer 
distance after CT than controls. 
Regenerating fibers were able to perform 
synaptics. Functional motor 
improvements observed after CT. 
 
Alilain, Nature, 
2011. [375] 
PNS graft  + 
ChABC  
Acute model of 
hemisection 
Synergistic effects observed. CT 
increased the regeneration of 
serotonergic axons. Recovery of 
diaphragmatic function and restoration 
respiratory pathways. 
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Table I.2. Combinatorial therapies aimed for SCI regeneration. (continued) 
    
Reference Methodology SCI Model Outcomes 
    
Yick, J. 
Neurotrauma, 
2004. [395] 
ChABC + LiCL. Acute model of 
hemisection. 
Synergistic effects observed. CT 
significantly increased axonal 
regeneration and improved motor 
function in a greater extent than controls 
or single treatment. 
  
García-Alías, J. 
Neurosci., 2011. 
[396] 
ChABC + NT3 + 
NR2D expression 
Acute model of 
hemisection. 
Synergistic effects observed. More 
axonal sprouting in the CT group than 
single treatment alone. Electrophysiology 
improvements observed in the CT group 
only. CT animals presented more body 
stability and interlimb coordination than 
single treatment alone. 
  
Bai, Eur. J. 
Physiol., 2010. 
[397] 
ChABC + 
Clenbuterol 
Acute model of 
transection 
Synergistic effects observed. More axons 
myelinated by peripheral SCs in the CT 
group. CT promoted supraspinal axons 
regeneration and improved hindlimb 
function. 
 
Nothias, 
Neurorehabil. 
Neural Repair, 
2005. [398] 
BDNF + NT3 + 
Serotonergic 
agonists + 
Exercise. 
Subacute model of 
transection. 
Synergistic effects observed. Individual 
treatments stimulated axonal growth and 
prevented muscle atrophy, but did not 
improved motor scores. Only CT resulted 
in improvements in motor function. 
 
Klapka, EJN, 
2005. [399] 
cAMP + Iron 
chelator. 
Acute model of 
hemisection. 
Synergistic effects not assessed. CT 
improved CST repair and reduce axonal 
loss. CT resulted in functional recovery 
in the open field, horizontal ladder and in 
CatWalk test. 
 
Ditor, J. 
Neurosci. Res., 
2007.[400] 
MgSO4 + PEG Acute model of 
compression. 
MgSO4 + PEG treatment increased dorsal 
myelin sparing, reduced lesion volume, 
improved locomotor recovery and 
reduced pain but did not provide 
additional benefit compared with either 
treatment alone. 
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9.3.2. Tissue Engineering 
Tissue engineering (TE) holds great promising for the regeneration of different tissues, 
such as, bone, cartilage, nervous, muscular and others [401-406]. This interdisciplinary 
field combines the knowledge from physics, materials science, engineering, chemistry, 
biology, and medicine in an integrated manner with the ultimate goal of restore, maintain, 
or improve tissue function [407]. In order to do so, TE usually combines cells, bioactive 
molecules and biomaterials. The biomaterial, a 3D scaffold, plays a central role in any TE 
approach and should be carefully chosen. 
For a successful result, scaffolds should possess a number of properties and 
characteristics defined as essentials in TE. Namely, scaffolds should: i) be biocompatible, 
i.e., it should not elicit an immune response after host implantation; ii) have desirable 
physical characteristics, this include, high porosity, large surface area, large pore size, 
fully interconnected geometry, and adequate mechanical strength; iii) be biodegradable, 
the ideal scaffold should only be totally degraded by the time the injury site is totally 
regenerated; and iv) have desirable surface properties, i.e., the scaffold should provide 
chemical and topographical signals to modulate cell organization. Taking in account all 
of these properties, scaffolds should be able to act as substrate for the initials phase of 
cell adhesion, guide cell behavior, such as migration, proliferation, differentiation, 
maintenance of phenotype and apoptosis, and, finally, temporarily act as a mechanical 
support for tissue regeneration [408-410]. 
Polymers, both from natural and synthetic origins, need to be processed in order to 
construct a 3D scaffold. Through the years a series of processing techniques were 
developed with the aim of producing scaffolds that can be used for SCI regeneration. 
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Among them are solvent casting techniques, phase inversion, fiber bonding, 
electrospinning, high pressure based methods, freeze drying and rapid prototyping 
technologies [411-414]. 
To date, 3D devices investigated for SCI repair include hydrogels, sponges, guidance 
tubes and nanofibrous scaffolds [415]. Hydrogels are viscous, crosslinked liquids that can 
be advantageous for filling the gap in a transected cord or filling the acellular cavity of 
contusion injuries. Hydrogels may also be used as vehicles to uniformly disperse living 
cells or drugs into the spinal cord [414, 416]. Moreover, some hydrogels have tissue-like 
mechanical abilities, similar to those of CNS tissue [417, 418], and can be easily 
modified to mimic the ECM matrix [419]. In contrast, sponges are highly porous 3D 
scaffolds with a wide surface area for cell transplantation [420]. Sponges have the 
disadvantage of mechanical weakness. Alternatively, tubes are porous hollow cylindrical 
channels that can guide regenerating axons and provide local, sustained release of 
therapeutic agents [421]. Finally, nanofibrous scaffolds, particular those with aligned 
fiber orientation, can provide a better environment for neural cell orientation, attachment, 
migration, proliferation, and differentiation than traditional scaffolds [422, 423]. 
However, the processing technique used to obtain these nanofibrous is limited to viscous 
polymer solutions and the scaffolds developed possess small pore size [424]. It is 
important to note that the use of scaffolds for SCI repair is still emerging, so, what 
constitutes an optimal scaffold remains to be defined. 
 
Several authors have reported the improvement of both histologic and behavioral 
outcomes after the implantation of biomaterials (usually combined with cells or drugs) in 
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SCI models. For instance, Hejcl and colleagues reported that the implantation of the 
synthetic non-degradable hydrogel PHPMA (poly-(2-hydroxypropyl)-methacrylamine) 
modified with the amino acid sequence RGD and combined with bmMSCs in a chronic 
contusion SCI model improved both sensory and motor functions 6 months post-injury. 
Moreover, 5 weeks after the implantation the cavity was successfully bridged with axons 
myelinated by SCs and also with blood vessels and astrocytes [425]. Other three authors 
reported significantly improvements in motor behavior after the implantation of guidance 
channels developed from the PHEMA-MMA (poly-(2-hydroxyethyl)-metthacrylamine-
co-methyl metacrilate) polymer [426-428]. In one study the scaffolds significantly 
promote the regeneration of sensory axons through the bridge [427], others reported a 
decrease in scar tissue formation [426]. However, other study described few invasion of 
regenerating axons into the channels [428]. 
Another successful approach using synthetic polymers is the implantation of the 
biomaterial PEG (polyethylene glycol). PEG is known to seal and repair cell membrane 
breaches produced by injury, decrease excitotoxicity, and inhibit the production of free 
radical [429-431]. The use of PEG micelles by Shi and colleagues showed to decrease 
lesion volume and attenuate macrophage response. These results were correlated with 
improved motor outcomes [429]. Piantino and co-workers also reported that the 
implantation of the composite PEG-PLA (PEG-poly-lactic acid) hydrogel containing 
NT3 improved BBB score and ladder walker performance, and increased the number of 
axons [432]. 
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In another study, Teng and colleagues reported that the combination of NSCs and 
synthetic PLGA (poly-lactic-co-glycolic acid) scaffolds with aligned porosity reduce scar 
formation and improved functional recovery [433]. 
A synthetic matrix composed by peptide amphiphile (PA) molecules that self-assemble 
into cylindrical nanofibers and display bioactive epitopes, on their surfaces (IKVAV-PA) 
also demonstrated to improve motor function. Furthermore, IKVAV-PA nanofibers 
reduced astrogliosis, decreased cell death and promoted regeneration of ascending and 
descending track axons through the lesion site [434]. 
 
Several researchers prefer natural origins biomaterials rather than the synthetics ones. 
The main advantage of these materials is their potential bioactive behavior, without any 
further chemical adjustment. Some of them are also components of the human body, 
which greatly increase their capability to interact with the host’s tissue. For instance, 
collagen, a major constituent of the ECM, has been used to fill the gap in transection 
models of SCI. Moreover, the NeuroGen
TM
 Nerve Guide, a commercial product made 
from type I collagen, received FDA approval for marketing in 2001. After implantation in 
SCI rodents, collagen already demonstrated to increase the number axons either when 
used alone [435], in combination with NT3 [436] or even when used to fill PHEMA-
MMA [427] and chitosan [437] tubes. These histologic observations were usually 
correlated with functional improvements. The use of collagens is, however, controversial, 
given that this molecule is a component of the glial scar. 
The ECM extract from the Engelberth Holm Swarm sarcoma is also used as a natural 3D 
structure to support axon regeneration. This extract is commercial known as Matrigel 
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and contains several bioactive molecules, such as, laminin, fibronectin, and 
proteoglycans, with laminin predominating [438]. Lee and colleagues reported that the 
injection of matrigel combined with human NSCs in SCI dogs led to NSCs differentiation 
into neurons and oligodendrocytes, increased sensory axonal regeneration, and resulted in 
functional improvements [439]. In a recent study from Patel and co-workers, matrigel 
was combined with SCs and injected in a contusion rat model of SCI. This approaches 
allowed the cell infiltration through the gel, increased angiogenesis and SCs survival, 
facilitated intralesional axon growth, and promoted functional recovery both in 
overground locomotion and grid walk test [440]. 
Fibrin, the major constituent of the blood clots, is probably the most widely gel used in 
SCI. Fibrin contains several cell biding receptors and function as bridging molecule for 
many types of cells. It is usually used as a vehicle for cell transplantation or drug 
delivery, or even in conjugation with synthetic hydrogels [441]. Taylor and colleagues 
demonstrated that a fibrin gel engineered to release NT3 after degradation by invading 
cells, increased nervous cells infiltration and diminished the glial scar [442]. Moreover, 
the use of fibrin in combination with cAMP and pre-differentiated NSCs resulted in 
extensive axonal regeneration into the injury site of fully transected rats, and improved 
functional recovery after 6 weeks [443]. In addition to these applications, fibrin glue is 
regulary used for stabilization of cellular bridges to the implantation site [444, 445]. 
The oceans are an almost unlimited source of natural biomaterials for TE. Agarose and 
Alginate are two examples of polysaccharides derived from seaweed that were also 
employed as 3D constructs for SCI repair. Kim and colleagues injected an agarose 
hydrogel combined with PLGA nanoparticles and MP in a hemisection rat model of SCI 
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and reported a decrease on the lesion volume, macrophages invasion, proteoglycans 
content and oxidative stress. These histological outcomes were correlated with improved 
behavioral function [446]. Alternatively, Tobias and co-workers demonstrated that 
engineered-modified fibroblasts to produce BDNF encapsulated in alginate 
microcapsules can be delivery to the spinal cord without the need for 
immunesuppression. Moreover this constructs promoted growth of regenerating axons 
and improved the function of affected limbs [447]. 
 
Here we only report on biomaterials that improved both histological and behavioral 
outcomes. However, it is possible to find much more work in literature using different 
polymers that demonstrated to have some potential for SCI repair. A review published in 
May 2011 by Perale and colleagues identified 35 different hydrogels that aimed the repair 
of the spinal cord [416]. Nowadays the number is probably higher, and more will be 
described. It is important to note that many studies did not access or failed to demonstrate 
motor improvements after biomaterial implantation, and even the approaches that showed 
better functional outcomes needed more pre-clinical data in order to gain robustness 
(more information about TE in SCI can be found on Gilbert et al. review [448]). 
One challenge for the clinical success of TE is the replication from independent labs of 
many of the approaches proposed until now. This is particular complicated because even 
the labs that use the same biomaterials, most of the time combined them with different 
cells or different bioactive molecules. With the possible combinations increasing the 
probability of independent labs used the same approaches decrease. Another challenge 
for TE is to start moving from transection to contusion/compression models of injury. 
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These models better mimic the clinical situation. However, they do represent higher 
challenge for scientists given that they lost the available space for scaffold implantation.  
In brief, TE owns great potential for SCI treatment; yet, more pre-clinical experiments 
are needed until moved to a clinical situation. 
 
10. Final Remarks 
 
Spinal cord injury (SCI) remains a frequent and devastating problem of modern society. 
Through a comprehension of essential pathophysiologic mechanisms involved in the 
evolution of SCI, treatments aimed at ameliorating neural damage were being developed. 
Although there are no fully restorative treatments for SCI, various rehabilitative, cellular 
and molecular therapies have been tested in animal models. Many of these have reached, 
or are approaching, clinical trials. However, until now none of them successfully treat the 
patients. Although utility of these therapeutic options provides modest benefits, there is a 
critical need to identify novel methodologies to treat or repair the injured spinal cord in 
hope to improve patient’s quality of life. To stimulate CNS axons to regenerate, one 
essential repair strategy is to promote the neurons’ intrinsic capacity to do so. Another 
effective method is to overcome the myelin and glial scar inhibition. Moreover, 
transplantation of tissues or cells, combined with permissive trophic factors, cell adhesion 
molecules and/or biomaterials, is essential for creating a growth-permissive topography 
to promote axonal regeneration across the injury site. It is now of general consensus that 
successful functional recovery will not simply rely on a single therapeutic approach. 
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Future clinical regenerative approaches will likely include combination of multiple 
strategies. 
Challenges ahead comprise testing whether some of the most promising strategies in 
animal models are reproducible by different independent laboratories. Unfortunately, the 
facilities of research excellence in spinal cord injury (FORE-SCI) have been incapable to 
replicate studies from others laboratories. This inability to confirm potentially important 
outcomes with confidence has prevented new approaches from moving forward to 
clinical studies. The approaches that prove to be reliable also face the challenge of 
showing that the promising results in animal models are also beneficial for human 
patients suffering from SCI. However, it is imperative that translation studies be made in 
the most rigorous and informed fashion to determine safety and possible efficacy of the 
therapeutic approach. With this in mind, the International Campaign for Cures of Spinal 
Cord Injury Paralysis (ICCP) supported an international panel tasked with reviewing the 
methodology for clinical trials in spinal cord injury (SCI), and making recommendations 
on the conduct of future trials [449-452]. It is expected that these guidelines will provide 
a basis for the design of trials and for future revisions leading to continually improving 
generations of valid SCI clinical trial protocols. 
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CHAPTER II 
Materials & Methods 
This chapter describes the materials and experimental methods used in the scope of this 
thesis. Although each part of the work is accompanied by its specific materials and 
methods section, this chapter intents to condensate and compile the relevant information 
on this matter. This exercise is expected to provide the reader a more comprehensive 
view of experimental and analytical tools used, as well as to facilitate their use by 
others. 
 
1. Materials 
1.1 Starch Polycaprolactone (SPCL) 
A blend material consisting of 30/70% (wt) corn starch and polycaprolactone was used 
to produce tubular porous scaffolds. The objective of combining these materials is the 
improved performance they might confer ultimately to the tissue engineered construct in 
an in vivo scenario. Starch is a natural polymer made of a combination of two polymeric 
carbohydrates, amylose and amylopectin [1, 2]. Amylose is a linear polymer of several 
thousand glucose residues α(1→4)-linked, while amylopectin consists of α(1→4)-linked 
glucose residues with α(1→6) branch points (Fig. 1). Starch is a renewable and 
inherently biodegradable polymer that has been put forward as a cell support material in 
combination with synthetic polymers such as polycaprolactone (PCL), polylactic acid 
(PLA), ethyl vinyl alcohol (EVOH), and cellulose acetate (CA). Several studies have 
been conducted with these materials, mainly in bone tissue engineering [3-6]. 
Chapter II. Materials & Methods 
124 
Polycaprolactone (Fig. 1a) is a semicrystalline biodegradable polymer belonging to the 
family of poly-α.hydroxyl polyesters. PCL has a low melting point of around 60ºC, low 
viscosity, and it is easy to process [7]. PCL has been previously approved by FDA for 
medical applications and has also been extensively studied for tissue engineering 
applications [8, 9]. The SPCL blend used was obtained from Novamont S.p.A., Italy. 
 
 
1.2. Gellan Gum 
Gellan Gum (GG) is a linear anionic polysaccharide produce by bacterial fermentation 
and its basic structural unit is compose of glucose, rhamose and glucuronic acid (Figure 
2). This material was initially described by Moorthouse and colleagues in 1981 [10] and 
has a broad use in the food industry and biomedical fields, mostly due to its processing 
into transparent gels that are resistance to heat and acid stress [11]. It is also FDA 
approved since 1992 [12]. Gellan Gum has an ionotropic gelation strongly influenced 
by the chemical nature and quantity of cations present in the solution. Divalent cations 
promote a strongest gelation than monovalent cations [11] In tissue engineering, this 
 
Figure II.1. The polymeric form of caprolactone (A) is added to corn starch (B) to form 
the SCPL polymer. 
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material has been suggested mostly for cartilage regeneration [13, 14]. The Gellan Gum 
was purchased from Sigma-Aldrich, St. Louis, USA. 
 
 
 
 
 
2. Scaffolds Production 
2.1 Starch Polycaprolactone Scaffolds 
Tubular SPCL scaffolds were developed by rapid prototyping techniques. Rapid 
prototyping is a computerized fabrication technique that can rapidly produce a highly 
complex tree-dimensional physical objects using data generated by computer assisted 
design (CAD) systems, computer-based medical imaging modalities, digitizers and 
other data makers [15]. Rapid prototyping uses the underlying concept of layered 
manufacturing and whereby each part of the 3D objects is constructed in a layer-by-
layer manner [16]. 
The SPCL tubular scaffolds were processed in a two-step methodological approach: 
1) Porous sheets featuring different pore geometries were produced by 3D plotting rapid 
prototyping (Bioplotter®; Envisiontec GmbH, Marl, Germany), using two different 
inter filament orientations (90º and 45º); 
 
Figure II.2. Chemical structure of Gellan Gum. This polymer is composed of 
repeated tetrasaccharide units of glucose, glucuronic acid, and rhamnose residues in 
a 2:1:1 ratio  
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2) Tubular scaffolds were obtained by rolling up porous sheets around a cylinder and 
subsequent heat treatment at 65º C during 30 min for inducing the adhesion between 
filaments.  
Up to six different porous tubular scaffold designs were obtained featuring a single or 
double layer combined with three different filaments’ oriented relative to the tube main 
axis: filaments oriented at 0º and 90º relative to the tube main axis (90/1-2, further 
referred as 90/1 and 90/2 for structures with one or two layers), filaments oriented at 0º 
and 45º relative to the tube main axis (45/1-2, further referred as 45/1 and 45/2), and 
filaments oriented at 45º relative to the tube main axis (X/1-2, further referred as X/1 
and X/2). As example of the adopted scaffold references, processing combination 90/2 
refers to a double layer scaffold featuring filaments’ orientated at 0º and 90º relative to 
the tube main axis, while 45/1 refers to a single layer scaffold featuring filaments’ 
orientated at 45º relative to the tube main axis. 
 
2.2 Gellan Gum Hydrogels 
Gellan gum powder was mixed with distilled water under constant stirring at room 
temperature. The solution was progressively heated to 90ºC, under which complete and 
homogenous dispersion of the material was obtained. The solution was kept at this 
temperature during 20 minutes. Afterwards, CaCl2 (Merck, DE) was added to obtain a 
final concentration of 0.03% (w/v) in the gellan gum solution and the temperature was 
progressively decreased to 50ºC. The gellan gum was then injected in the desired 
structures and allowed to rest at room temperature for 3 minutes in order to form a solid 
gel. With the purpose of obtain the hybrid scaffold (Chapter III), gellan gum was used 
in a 1% (w/v) concentration. In chapter VI gellan gum concentration used was 0.5% 
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(w/v). Moreover, in that chapter gellan gum was not heated until 90ºC. Instead, and in 
order to protect the GRGDS sequence, gellan gum power was dissolved by overnight 
incubation in distilled water. 
 
2.3 Three-Dimensional Hybrid Structures 
The integration of gellan gum hydrogel into the central canal of the SPCL tubular 
scaffolds was performed by placing the tubular scaffolds into a specially designed mold 
(fig. 3), and by filling the empty volume with a gellan gum hydrogel obtained as 
described above. 
 
 
 
 
 
 
3. Gellan Gum Functionalization by Click Chemistry 
Click chemistry was introduced by Barry Sharpless in 2001 and describes chemistry 
tailored to generate substances quickly and reliably by joining small units together [17]. 
The reactions in click chemistry must be wide in scope, give very high chemical yields, 
generate only inoffensive byproducts, and be physiologically stable. Some of these click 
chemistry reactions, included the one used in the scope of this thesis, are based on the 
  a 
Figure II.3. Schematic representation of the mold used to combine 
the SPCL and the gellan gum hydrogel. (a) SPCL scaffolds. 
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Figure II.4. Immobilization of the GRGDS peptide in the gellan gum hydrogel by 
Diels-Alder click chemistry. 
novel principles introduced by the Otto Diels and Kurt Alder. The Diels-Alder reaction 
is an organic chemical reaction between a conjugated diene and an alkene to form a 
substituted cyclohexene [18]. These principles were applied in the work described in 
chapter VI aiming the immobilization of a bioactive peptide in the gellan gum hydrogel. 
In order to do so, 3 separated protocols had to be performed (Fig. 4). First the gellan 
gum was modified with a furan group, then a maleimide-modified GRDGS sequence 
had to be synthesized, and finally the furan and maleimide were combined in order to 
create a GRGDS-modified gellan gum. 
 
 
 
3.1 Synthesis of Furan-Modified Gellan Gum Hydrogel 
Gellan gum (Sigma, USA) was first dissolved in 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer (100 mM, pH 5.5) at 37 ºC. 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM, Sigma, USA) and furfurylamine (Furan, 
Acros Organics, Belgium) were then added in a 4:1 molar ratio (relative to the –COOH 
groups in gellan gum) and stirred at 37 ºC for 48 hours. The solution was then dialyzed 
(Mw cutoff 12-14kDaltons, Spectrum Labs, USA) alternately against distilled water and 
PBS (0.1M and pH 7.2) for 5 days. Finally, water was removed by lyophilization to 
obtain furan-modified gellan gum (furan-GG) as a white powder. 
1
H-NMR spectra were 
used to analyze the degree of furan substitution.  
1
H-NMR was recorded in D2O on a 
Varian Mercury-400 MHz NMR spectrometer (Palo Alto, USA). As a negative control, 
GG was incubated with furan in the absence of DMTMM. 
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3.2 Synthesis of Maleimide-Modified GRGDS Peptide 
Maleimide-modified GRGDS (mal-GRGDS) peptide was prepared by linear solid-phase 
synthesis (SPS) using standard Fmoc chemistry [19]. Fmoc-serine Wang resin 
(Anaspect, USA) with a loading capacity of 0.48 mmol/g was swollen in DMF (Sigma, 
USA) for 30 minutes. The solution was then drained and 20% of piperidine (Caledon, 
Canada) in DMF was added. After 30 minutes of incubation the resin was washed with 
DMF and tested for free amines using 1 % trinitrobenzene sulfonate, TNBS (TCI 
America, USA), in DMF. The first building block (Fmoc-asp-OH, 3.0 equivalents, all 
amino acids are from NovaBiochem, Germany) was pre-mixed with 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate, HCTU (3.0 
equivalents, Anaspect, USA) in DMF for 15 min, then transferred to the SPS flask. 
Diisopropylethylamine, DIPEA (4.0 equivalents, Sigma, USA) in DMF), was then 
added and the flask was stirred for 24 hours. To verify if the coupling reaction had 
reached completion, the TNBS test was performed (negative test outcome). The Fmoc 
deprotection and coupling steps were repeated until 5 amino acid residues (GRGDS) 
were coupled to the resin. To conjugate the maleimide linker to the deprotected N-
terminus of the peptide, 4 equivalents of maleimidopropionic acid (TCI America, USA) 
and 12 equivalents of diisopropylcarbodiimide (Sigma, USA) were pre-mixed in 
dichloromethane (Sigma, USA) for 45 minutes and then added to the SPS flask and 
stirred for 24 hours. The maleimide-modified GRGDS (mal-GRGDS) sequence was 
then cleaved from the resin using 95% trifluoroacetic acid (Caledon, Canada) in water. 
The peptide was allowed to precipitate in cold diethyl ether for 30 minutes. Then, the 
precipitate was recovered by centrifugation. Finally, the product was purified by HPLC 
(Shimadzu, Japan) in a C18, 250 x 10 mm, 5 um, 100Å column. A mobile phase 
gradient from 5 % to 20 % (Acetonitrile (w/ 0.1 % TFA):ddH2O (w/ 0.1 % TFA)) over 
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30 minutes was performed. A 90% yield was obtained and the product was confirmed 
by 
1
H NMR and mass spectrometry (MS). 
 
3.3 Immobilization of Mal-GRGDS Peptide on Furan-GG Hydrogel 
Immobilization of maleimide-containing GRGDS (mal-GRGDS) to furan-modified 
gellan gum was performed by via Diels-Alder chemistry between the maleimide 
functional group of the peptide with the furan group of the gellan gum. Furan-GG was 
first dissolved in MES buffer (100 mM, pH 5.5) at 4 mg/ml and 37 ºC and then 
incubated with mal-GRGDS in a 1:5 furan-maleimide molar ratio for 48h under 
constant stirring. The solution was then dialyzed (Mw cutoff 12-14kDaltons, Spectrum 
Labs, USA) alternately against distilled water and PBS (0.1M and pH 7.2) for 5 days. 
Finally, the water was removed by lyophilization to obtain GRGDS-modified Gellan 
Gum (GRGDS-GG) as a white powder. The amount of peptide immobilized on the 
hydrogel was calculated by amino acid analysis. 
 
4. Physicochemical Characterization Techniques 
4.1. Scanning Electron Microscopy 
Scanning electron microscopy (SEM) provides images of the surface of a given sample 
by scanning it with a high-energy beam of electrons. SEM was used for analysis of 
morphology/porosity of the different SPCL tubular scaffolds. For this purpose, all 
samples were coated with Au/Pd via ion-sputtering prior to observation in a Stereoscan 
360 scanning electron microscope (Leica Cambridge Co., Cambridge, United 
Kingdom). 
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4.2. Micro-Computed Tomography 
Micro-computed tomography (μ-CT) provides valuable information on the 3D 
morphology of a chosen sample. Some of its advantages includes its non-destructive 
and the possibility to assess in a quantitative way parameters such as porosity, pore size 
and interconnectivity [20]. The architecture and porosity of the tubular scaffolds was 
analyzed by μ-CT using a desktop micro CT scanner (SkyScan 1072, Belgium) at a 
voltage of 40 kV and a current of 248 μA. Isotropic slice data were obtained by the 
system and reconstructed into 2D XY slice images. Around 600 slice images per sample 
were compiled and subsequently employed in the rendering of 3D XYZ images in order 
to obtain quantitative architectural parameters. A µCT analyzer and a µ-CT volume 
realistic 3D Visualization software, from SkyScan (Belgium), was used as an image 
processing tool for reconstruction and creation/visualization of 3D scaffold 
representations. 
 
4.3. Dynamic Mechanical Analysis 
Dynamic mechanical analysis (DMA) is a technique used to investigate the viscoelastic 
properties of polymeric materials. DMA measures the dynamic response of a particular 
polymeric system, being particularly adequate to evaluate the performance of 
biomaterials when working under the cyclic solicitations generated by the human body 
physiological movements [21]. Tubular scaffolds analysis was carried out using a 
uniaxial compression loading scheme at 37º C, under both dry and wet (Phosphate 
Buffered Saline - PBS 0.1M and pH 7.2) conditions. DMA was performed in a Tritec 
2000B equipment (Triton Technology Ltd, Nottinghamshire, United Kingdom). 
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Scaffolds were subjected to compression cycles of increasing frequencies ranging from 
0.1 and 70 Hz with constant amplitude displacements of 0.1 mm. 
 
4.4. Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) is a phenomenon which occurs when the nuclei of 
certain atoms are immersed in a static magnetic field and exposed to a second 
oscillating magnetic field. Some nuclei experience this phenomenon, and others do not, 
dependent upon whether they possess a property called spin. 
1
H NMR is the application 
of nuclear magnetic resonance in NMR spectroscopy with respect to hydrogen nuclei 
within the molecules of a substance. This is a nondestructive technique that allows 
determining the structure of organic compounds [22]. Simple NMR spectra are recorded 
in solution, and solvent protons must not be allowed to interfere. In this thesis, 
1
H NMR 
was employed in chapter VI to analyze the degree of furfurylamine substitution in the 
gellan gum hydrogel. For this propose, gellan gum was dissolved in deuterated water 
(D2O) and the 
1
H NMR spectra were obtained with a Varian Mercury-400 MHz NMR 
spectrometer (Palo Alto, USA). The one-dimensional 
1
H NMR spectra were acquired at 
25ºC, using a 45º pulse, a spectral width of 6.4 kHz and an acquisition time of 2.992 
seconds. 
 
4.5. High-Performance Liquid Chromatography 
High-Performance Liquid Chromatography (HPLC) is a highly improved form of 
column chromatography that is used in biochemistry and analytical chemistry to 
identify, quantify, and purify the individual components of a solution. Compounds are 
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separated by injecting a plug of the sample mixture onto the column. The different 
components in the mixture pass through the column at different rates due to differences 
in their interaction behavior between the mobile liquid phase and the stationary phase. 
HPLC was used in chapter VI to purify the GRGDS peptide. The product was purified 
in a Shimadzu equipment (Japan) with a C18, 250 x 10 mm, 5 um, 100Å column. A 
mobile phase gradient from 5 % to 20 % (Acetonitrile (w/ 0.1 % TFA):ddH2O (w/ 0.1 
% TFA)) over 30 minutes was performed, and a 90% yield was obtained. 
 
4.6. Anino Acid Analysis 
Amino acid analysis refers to the methodology used to determine the amino acid 
composition or content of proteins, peptides, and other pharmaceutical preparations. It 
involves the hydrolyzation of the protein/peptide to its individual animo acid 
constituents and the samples are typically derivatized for analysis. This technique was 
employed in chapter VI to calculate the amount of GRGDS immobilized on the gellan 
gum, using a Waters Pico-Tag System. Samples were dried in pyrolyzed borosilicate 
tubes in a vacuum centrifugal concentrator and subjected to vapour phase hydrolysis by 
6N HCl with 1% phenol at 110°C for 24 hours under pre-purified nitrogen atmosphere. 
After hydrolysis, excess HCl was removed by vacuum, hydrolyzates washed with 
redrying solution and derivatized with phenyisothiocyanate (PITC) to produce 
phenylthiocarbamyl (PTC) amino acids. The derivatization method is accomplished at 
room temperature. Derivatized amino acids were redissolved in phosphate buffer and 
quantified using reverse phase HPLC. 
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5. Cell Isolation and Expansion 
5.1. Rat Lung Fibroblast Cell Line 
The rat lung fibroblasts cell line L929, acquired from the European Collection of Cell 
Cultures (ECACC), was used for the cytotoxicity tests described on chapter III. The 
cells were grown as monolayers in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma), supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% of an 
antibiotic–antimycotic mixture (Sigma). For the MEM extraction tests, cells were 
seeded in 12 well plates (n=3, 1x10
5
 cells/well), while for the MTS test cells were 
seeded in 96 well plates (n=3, 1.8x10
4
/well). In both cases cells were incubated for 
24h at 37°C, in a 5% (v/v) CO2 cell culture incubator. 
 
5.2. Human Oligodendrocyte Cell Line 
On chapter III, human oligodendrocyte cell line MO3-13 was encapsulated within the 
gellan gum hydrogel. For this purpose, cells were first grown as monolayer cultures in 
DMEM (Sigma) supplemented with 10% FBS (Gibco) and 1% antibiotic–antimycotic 
mixture (Sigma) until confluence. Trypsin (Sigma) was used to detach the cells from the 
culture flasks before the experiments were conducted. 
 
5.3. Olfactory Ensheathing Cells 
Olfactory ensheathing cells (OECs) were harvested from olfactory bulbs of 4-days-old 
Wistar rats, according to the protocol described by Ramon-Cuéto et al. [23]. Briefly, 
upon dissection all meninges were removed and the tissue was digested with 0,125% 
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Collagenase (Sigma) for 20h at 37 ºC. The digested tissue was mechanically dissociated 
with a pipette and then filtrated through a 70 µm cell strainer (BD Falcon). After 
centrifugation at 1000rpm for 10 min, cells were resuspended and plated in uncoated 
plates for 18h. A posterior change to uncoated plates for 36h was made, as it is expected 
that most of the fibroblasts and astrocytes will attach in the first and second period, 
respectively. Finally, cell suspensions were transferred to poly-D-lysine treaded flasks 
and cultured in DMEM/F12 (Gibco) with 10% of FBS (Gibco) and 1% of antibiotic-
antimycotic solution (Sigma) at 37 ºC and 5% CO2 (v/v). OECs were then enriched by 
the supplementation with Bovine Pituitary Extract (5µg/ml, Gibco) and Forskolin 
(2µg/ml, Sigma). These cells were used in the work described on chapters V, VI, and 
VII. 
 
5.4. Schwann Cells 
Schwann cells (SCs) were obtained from sciatic nerves of 4-weeks-old male Wistar rats, 
according to the protocol described by Mauritz et al. [24] Upon dissection, sciatic 
nerves were cut into 3 fragments each and incubated in DMEM-F-12 (Gibco), with 10% 
Fetal Bovine Serum (FBS, Gibco), 1% Penicillin-Streptomycin antibiotic (Pen-Strep, 
Gibco), Forskolin (2µg/ml, Sigma) and Bovine Pituitary Extract (5µg/ml, Gibco).  
Following 7 days of incubation at 37ºC and 5% CO2, the nerve fragments were 
enzymatically dissociated with Collagenase solution (320U/ml) (Sigma) containing 
5U/ml of DNase (Worthington) for 20 hours. After mechanical dissociation, the 
collagenase was removed by repeated centrifugations. Cells were then allowed to grow 
in Poly-D-Lysine coated flasks. These cells were used in the work described on chapter 
V. 
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5.5. Bone Marrow Stromal Cells 
Bone Marrow Stromal Cells (BMSCs) acquired from Lonza (Switzerland), were 
cultured in α-MEM (Invitrogen/Gibco) supplemented with 10% FBS and 1% antibiotic-
antimycotic mixture. The culture medium was changed every 2/3 days. Upon 
confluence, cells were trypsinized and passaged to new T75 flasks. These cells were 
used in the work described on chapter VII. 
 
5.6. Human Umbilical Cord Perivascular Cells 
Human umbilical cord perivascular cells (HUCPVCs) were isolated according to the 
procedure originally described by Sarugaser et al. [25]. Pieces of cord were dissected by 
first removing the epithelium of the umbilical cord section along its length to expose the 
underlying Wharton’s jelly. Each vessel, with its surrounding Wharton’s Jelly matrix, 
was then pulled away, after which the ends of each dissected vessel were tied together 
with a suture creating “loops” that were placed into a solution of 0.5–0.75 mg/mL 
collagenase (Sigma) with phosphate-buffered saline (PBS, Gibco). After 18 h, the loops 
were removed from the suspension, which was then diluted with PBS to reduce the 
viscosity of the suspension and centrifuged. Following the removal of the supernatant, 
cells were resuspended in culture media, α-MEM (Gibco) supplemented with 10% FBS 
(Gibco) and 1% antibiotic/antimycotic (Sigma), counted using a hemocytometer and 
platted out in T75 flasks at a density of 4,000 cells/cm
2
. The culture medium was 
changed every 2/3 days. Upon confluence, cells were trypsinized and passaged to new 
T75 flasks. These cells were used in the work described on chapter VII. 
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5.7. Human Adipose Stem Cells 
Human adipose stem cells (ASCs) were a kind gift from Prof. Jeff Gimble from the 
Pennington Biomedical Research Center on Baton Rouge, USA. The cells were isolated 
as previously described [26]. These cells were used in the work described on chapter 
VII. 
 
5.8. Neural Stem Cells 
Neural stem cells (NSCs) were isolated from the subependymal region of the lateral 
ventricles in the forebrain of adult male Wistar rats as previously described [27]. Cells 
were grown in neurobasal medium (Invitrogen), with 2% of B27 neural supplement 
(Invitrogen), 1% of L-glutamine (Sigma), 1% of penicillin–streptomycin (Sigma), 20 
ng/ml EGF (recombinant human EGF; Invitrogen), 20 ng/ml bFGF (recombinant human 
bFGF; Invitrogen) and 2 ng/ml heparin (Sigma). Cell number and viability were 
determined with a hemocytometer and the trypan blue exclusion test. Dissociated cells 
were plated in complete media and incubated in a humidified atmosphere at 37 ºC with 
5% of CO2. Neurospheres were observed within 2–3 weeks, after which cells were 
passaged weekly. These cells were used in the work described on chapter VI. 
 
6. Cell/Materials Experiments 
6.1. Seeding of OECs or SCs on SPCL Scaffolds 
To ensure adherence of cells, SPCL scaffolds were coated with poly-D-lysine before 
cell seeding. Cells were centrifuged at 1200 rpm for 5 min and then resuspended in a 
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small volume of medium to yield a solution with a density of 5x10
4
 cell/10µl. 
Subsequently, scaffolds were transferred to empty wells and 10µl of cell suspension 
were dropped on the top of the inner lumen of the semi tubular scaffolds. After an 
incubation of 2 h in a humidified atmosphere at 37 ºC and 5% CO2, SPCL scaffolds 
were transferred to new wells containing complete medium (for composition details 
refer to OECs or SCs cell culture section) and incubated for 2, 7, 14 and 21 days for the 
in vitro assays. This proceeding was used in the work described in chapter V. 
 
6.2. Encapsulation of Oligodendrocytes in Gellan Gum Hydrogel 
In the work described in chapter III, the oligodendrocyte cell line M03 was encapsulated 
in 1% (w/v) of gellan gum hydrogel. Cells and hydrogel were prepared as described 
above (section 5.2 and 3.2, respectively). Then, cells were ressuspended (20 x10
4
 
cells/ml) in the gellan gum solution and injected into central canal of SPCL tubular 
scaffolds. The Cell/Scaffolds constructs were then allowed to rest at room temperature 
for 3 minutes to form a solid gel. Then, constructs were incubated in standard culture 
medium DMEM (Gibco) with 10% of FBS (Gibco) and 1% of antibiotic/antimicotic 
(Sigma) for 7 days at 37º C in a 5% (v/v) CO2 cell culture incubator. For this period, the 
distribution of viable cells was evaluated by confocal microscopy (Fluoview FV 1000, 
Olympus) in combination with calcein-AM staining (Sigma). 
 
6.3. Neural Stem Cells Culture in GRGDS-Gellan Gum Hydrogel 
In the work described in chapter VI, bioactivity of GRGDS was assessed by the analysis 
of NSCs growth, morphology and differentiation when cultured on the modified gellan 
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gum hydrogel for 2 and 7 days.  NSCs were mechanically dissociated into a single cell 
suspension and either seeded on the surface or encapsulated into GRGDS-GG hydrogel 
in complete medium (as described in Section 5.8). The cell density was 2 × 10
4
 
cells/cm
2
 and hydrogels were incubated in a humidified atmosphere at 37 ºC and 5% of 
CO2. Furan-modified GG was used as a control. Cell growth and morphology was 
evaluated following phalloidin/DAPI staining and differentiation following 
immunocytochemistry (ICC). Analysis was carried out using a Zeiss Observer Z1 
microscope with a Yokogawa confocal scan unit; images were captured and processed 
using Volocity 4.3.2 software. 
 
6.4. OECs and NSCs Co-Culture in GRGDS-Gellan Hydrogel 
In the work described in chapter VI, it was evaluate the potential synergistic or 
antagonistic effects between OECs and NPCs within the GRGDS-GG hydrogel. OECs 
(1 × 10
5
 cells/cm
2
) and NPCs (4 × 10
4
 cells/cm
2
), obtained as described in section 5, 
were encapsulated together in the GRGDS-GG hydrogel. Both cells were pre-labeled 
before encapsulation. A green tracer was used for OECs labeling (C34554, Invitrogen) 
and NPCs were labeled with a far red tracer (C34553, Invitrogen). Both labeling 
protocols were performed according to the manufacturer instructions. Cell interactions 
and growth were then analyzed by confocal analyses after 7 days of culture. 
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7. Co-Cultures Studies 
7.1. OECs and NSCs Co-Culture 
To evaluate the potential beneficial or detrimental effects between OECs and NPCs, 
direct and transwell co-culture experiments were performed. OECs (1 × 10
5
 cells/cm
2
) 
and NSCs (4 × 10
4
 cells/cm
2
), obtained as described in section 5, were seeded either 
simultaneously on the same fibronectin coated cover glass or in indirect contact with 
OECs cultured on the fibronectin coated cover glass and NSCs on the transwell. Cells 
were allowed to grow in complete NSCs culture medium (see section 5.8) for 24h and 
then cultured in the absence of the growth factors FGF and EGF. In the direct co-culture 
experiment, in order to clearly identify one cell population from another, OECs were 
labeled (according to manufacturer instructions) with a cell tracing reagent (C34554, 
Invitrogen) before seeding. After 7 days of incubation, cell growth and NSCs 
differentiation was assessed by ICC. Analysis was performed using an Olympus BX61 
fluorescence microscope. OECs and NSCs cultured alone were used as controls. This 
work is described in chapter VI. 
 
7.2. OECs and Mesenchymal Stromal Cells Co-Culture 
In the work described in chapter VII, potential positive or negative effects of the cell 
secretome of OECs and bmMSCs, HUCPVCs or ASCs was evaluated using a transwell 
system. OECs were seeded (1 × 10
5
 cells/cm
2
) on a poly-D-lysine coated well and 
MSCs were seeded (4 × 10
4
 cells/cm
2
) on the transwell. Cell proliferation, metabolic 
activity and differentiation were assessed after 2 and 7 days in culture. ICC analysis was 
performed using an Olympus BX61 fluorescence microscope. OECs and Mesenchymal 
Chapter II. Materials & Methods 
141 
stromal cells cultured alone were used as controls. Cells were obtained and maintained 
as described in section 5 of this chapter. 
 
8. In Vitro Biological Testing 
8.1. MTS Test 
MTS test is based on the bioreduction of the substrate, 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethoxyphenyl)-2(4-sulfofenyl)-2H-tetrazolium (Promega), into a brown 
formazan product by dehydrogenase enzymes in metabolically active cells, and is 
commonly used for cell viability evaluation. This test was used in the work described on 
chapter III to assess the possible citotoxicity of SCPL/Gellan Gum constructs 
leachables. Moreover, MTS test was also used in the work described on chapter V and 
VI to assess the metabolic activity of cells after seeding in SPCL scaffolds or after co-
cultures studies. After each specific time point, complete culture medium was replaced 
by serum-free medium containing MTS in a 5:1 ratio and incubated in a humidified 
atmosphere at 37 ºC and 5% CO2. After 3h of incubation, the optic density for 
triplicates of each sample (n=3) was measured at 490 nm in a microplate reader. 
 
8.2. Minimum Essential Medium Extraction Test 
In the work described in chapter III, the citotoxicity of the developed scaffolds was 
assessed using MTS and minimum essential medium (MEM) extraction tests. The 
objectives of the MEM extraction tests are to evaluate changes in cell morphology 
and/or cell growth inhibition derived from possible toxic leachables released from the 
scaffolds. The test was performed according to ISO/EN 10993 part 5 guidelines [28]. 
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Briefly, leachable-conditioned medium was collected after 7, 14, 21, and 28 days of 
incubation at 37ºC. The ratio material weight to extract fluid was constant and equal to 
0.2g/ml for porous samples, while for latex the ratio of material outer surface to 
extraction fluid was 2.5 cm
2
/ml. After each period the extracts were filtered through a 
0.45 μm pore size filter. Latex extracts were used as negative controls for cell viability, 
while standard culture medium was used as positive control for cell viability. The cell 
line L929, expanded and cultured was described in section 5.1, was used in this test. 
After 24h of culture, the standard culture medium was removed from the wells and an 
identical volume, 1 ml, of extraction fluid was added. Cultures were then incubated with 
the extracts for 72h, after which it was conducted a live/death assay by staining live 
cells with calcein-AM (1mg/ml; Molecular Probes) and non-viable cells with propidium 
iodide (PI, 0.1 mg/ml, Molecular Probes). Upon staining, cultures were observed under 
a fluorescence microscopy (Olympus BX-61). 
 
8.3 DNA Quantification 
The accurate determination of DNA concentration is essential for many processes in 
molecular biology and physiology and includes both gel- and cuvette-based methods. 
The recently introduced fluorescent dye, PicoGreen, has several advantages over other 
methods due to its sensitivity and specificity for double-stranded DNA (dsDNA) [29]. 
In the work described in chapter V, PicoGreen fluorescent assay was used to calculate 
cell proliferation. The samples were collected on each specific time point, washed twice 
with a sterile PBS solution and transferred into microtubes containing 1 mL of ultra-
pure water. Samples were incubated for 1 hour at 37ºC in a water-bath and then stored 
in a -80ºC freezer until testing. Prior to DNA quantification constructs were thawed and 
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sonicated for 15 minutes. Samples and standards (ranging between 0 and 2µg.mL-1) 
were prepared per each well of an opaque 96-well plate were added 28.7µL of sample 
or standard plus 71.3µL of PicoGreen solution and 100 µL of Tris-EDTA buffer. 
Triplicates were made for each sample or standard. The plate was incubated for 10 
minutes in the dark and fluorescence was measured on a microplate reader (BioTek) 
using an emission of 490 nm and an absorbance wavelength of 520 nm. A standard 
curve was created and sample DNA values were read off from the standard graph. 
 
8.4. Cell Proliferation ELISA, BrdU 
The colorimetric 5-bromo-2’-deoxyuridine (BrdU) assay (Roche) was employed in the 
work described in chapter VII, with the aim of quantify the DNA synthesis during cell 
activation and proliferation. This ELISA assay measures proliferative cells by 
quantitating BrdU incorporated into newly synthesized DNA of replicating cells. It is a 
nonradioactive alternative to the [
3
H]-thymidine-based cell proliferation assay with 
comparable sensitivity. To perform the assay, BrdU was added to the cell cultures for 
24 hours and after that the medium was removed. The cells were then fixed and its 
DNA denatured with FixDenat (Roche) in a single step, after which the anti-BrdU 
peroxidase antibody (Roche) was added. The immune complexes were detected by the 
quantification of the substrate reaction product, measuring the optical density at 370 nm 
(reference filter set at 492 nm) in a multiplate reader (BioRad). 
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8.5. Phalloidin/DAPI Staining 
In the work described in chapter V, VI and VII, cell adhesion, morphology and 
distribution were assessed using a phalloidin/DAPI staining protocol. Phalloidin is a 
heptapeptide toxin, produced by poisonous mushroom Amanita phalloides, that binds 
tightly and specifically to polymerized actin filaments. For this reason, biotinylated and 
fluorescent phalloidins are used in various analysis techniques to label, identify, 
quantify and stabilize F-actin in fixed and permeabilized tissue sections, cell cultures or 
cell free experiments [30]. In contrast, DAPI (diamidino-phenylindole, dihydrochloride) 
is a popular nuclear counterstain for the use in multicolor fluorescent techniques. Its 
blue fluorescence stands out in vivid contrast to green, yellow, or red fluorescent probes 
of others structures. To perform the phalloidin/DAPI staining protocol, cells were fixed 
with 4% of PFA for 30 min at room temperature and then treated with 0.3% TritonX-
100. After washing several times with PBS, 0.1µg/ml of phalloidin (Sigma) was added 
to the cells for 30 min. Finally, cell nuclei were counterstained with DAPI (1µg/ml, 
Invitrogen) for 10 min. 
 
8.6. Immunocytochemistry 
Immunocytochemistry (ICC) is a microscopic method for determining the presence, 
subcellular localization, and relative abundance of an antigen of interest, most 
commonly a protein, in cultured cells [31]. This technique was used in the work 
described in chapter V, VI and VII, being employed the following antibodies: 
monoclonal rabbit anti-β-III tubulin (Chemicon) for neurons identification; monoclonal 
mouse anti-GFAP (Chemicon) for astrocytes; monoclonal mouse anti-O4 (R&D 
Systems) for oligodendrocytes; monoclonal mouse anti-Nestin (Millipore) for 
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progenitor cells; polyclonal rabbit anti-p75 (Millipore) for OECs; and monoclonal 
rabbit anti-S100 (Invitrogen) for OECs and SCs. For all immunohistochemical 
procedures, the appropriate controls were obtained by omission of the relevant primary 
antibody. Cells on the substrates were fixed with PBS solution containing 4% PFA for 
20 min (on glass) or 1 h (on the hydrogel) at room temperature and then washed with 
PBS. After cell membrane permeation (except for p75, O4 and S100 antibodies) and 
blocking by treating with 0.3% Triton X-100 (Sigma) and 10% of FBS solution at room 
temperature for 1 h, each specific primary antibody solution was added for 1 h. After 
washing with 0.5% of FBS in PBS, the samples were exposed to the specific secondary 
antibody (Invitrogen) for 1h and then washed with 0.5% FBS. Finally, cell nuclei were 
counterstained with 1 μg/ml DAPI (Invitrogen) for 1h. 
 
9. In Vivo Testing 
9.1. Animals 
Eight weeks old male Wistar rats (Charles River), housed in light and temperature 
controlled rooms and fed with standard diet, were used in the studies described in 
chapter III and V. The Animal Care Committee of the Research Institute approved the 
animal protocols in accordance with standardized Animal Care Guidelines [32]. 
Handling was performed for 3 days before the surgery. Following SCI surgery rats were 
kept under heat lamps and received vitamins and antibiotics. Bladder evacuation was 
done manually. Throughout the treatment and recovery period, animals were examined 
for symptoms of illness or potential reaction to the treatment. 
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9.2. Spinal Cord Injury Surgery 
All animals were anesthetized by intraperitoneal injection of a mixture (1,5:1) of 
ketamine (60 mg/ml, Imalgen, Merial) and medetomidine hydrochloride (0.4 mg/ml, 
Dorbene Vet, Laboratorios SYVA S.A.). Once anaesthetized, fur was shaved from the 
surgical site and the skin disinfected with chlorohexidine (AGB). Then a dorsal midline 
incision was made from T6–T11 and the paravertebral muscles retracted. A 
laminectomy was performed at the junction T8–T9 in which the spinous processes were 
removed and the spinal cord exposed. Two hemisections were performed, 3 mm apart 
on the left side, and the tissue in between removed. After scaffolds implantation, 
paravertebral muscles and skin were separately closed with Vicryl sutures (Johnson and 
Johnson). The incision of control animals was closed after SCI, without scaffold 
implantation. 
In the work described in chapter III this surgery was used in order to study the 
histocompatibility of scaffolds developed. SPCL/gellan gum constructs were implanted 
in the defect site, with the SPCL phase aligned with the vertebral bone while the gellan 
gum was facing, and filling, the injured spinal cord.  
In the work described in chapter V, this surgery was employed in order to study the 
effects of spine stabilization on motor behavior. After SCI, SPCL scaffolds were 
implanted at the vertebral bone level, juxtaposed to the spinal cord. Bone cement 
(Biomet, USA) was used to fix the scaffolds margins to bone. Animals were divided 
into 2 experimental groups: animals with spine stabilization through SPCL scaffolds 
implantation (SPCL, n=9) and animals without spine stabilization (SCI, n=5). A third 
group of animals, subjected to laminectomy only, were used as controls (Sham, n=5). 
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9.3. Subcutaneous Implantation of SPCL/Gellan Gum Constructs – Biocompatibility 
Assays 
All animals were anesthetized by intraperitoneal injection of a mixture (1,5:1) of 
ketamine (60 mg/ml, Imalgen, Merial) and medetomidine hydrochloride (0.4 mg/ml, 
Dorbene Vet, Laboratorios SYVA S.A.). Once anaesthetized, four incisions were 
performed (reaching a maximum of 1.5 cm each) being two in the interscapular region 
and another two in the lumbar region. With the help of a forceps two side pockets were 
created through each of the incisions and SPCL/gellan gum scaffolds were 
subcutaneously implanted. Four scaffolds were implanted per animal, being two on the 
anterior region and other two on the posterior region. The incision sites were sutured 
and the rats transferred to heating recovery compartments and when the recovery from 
anesthesia was confirmed they were returned to their respective compartments and kept 
under food and drink ad libitum. The hybrid structures stayed implanted subcutaneously 
in the back of the animals for 7, 14, 21 and 28 days. 
 
9.4. Motor Behavior Analysis by BBB Score 
In the work described in chapter V, the motor behavior of all rats were assessed with the 
Basso, Beattie, Bresnahan Locomotor Rating Scale (BBB) [33] on day 3 and 2, 5, 7, 9, 
12 weeks after injury. The BBB is a 21-point scale designed to assess hindlimb 
locomotor recovery following thoracic spinal cord injury. A BBB score of 0 indicates 
no hindlimb movement. A BBB score of 1 through 8 indicates joint movement, but no 
weight support. A BBB score of 9 through 20 indicates an ability to support weight and 
use the limb for locomotion but with some degree of abnormality. A BBB score of 21 
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corresponds to the locomotion of a normal rat. Detailed information can be found in 
Table 1. 
Table II.1. Basso, Beattie, Bresnahan Locomotor Rating Scale [33] 
0 No observable hindlimb movement 
1 Slight movement of one or two joints, usually the hip and/or knee 
2 Extensive movement of one joint or extensive movement of one joint and slight movement of one other joint 
3 Extensive movement of two joints 
4 Slight movement of all three joints of the HL 
5 Slight movement of two joints and extensive movement of the third 
6 Extensive movement of two joints and slight movement of the third 
7 Extensive movement of all three joints of the HL 
8 Sweeping with no weight support or plantar placement of the paw with no weight support 
9 Plantar placement of the paw with weight support in stance only (i.e. when stationary) or occasional, frequent 
or consistent weight-supported dorsal stepping and no plantar stepping 
10 Occasional weight-supported plantar steps; no FL/HL coordination 
11 Frequent to consistent weight-supported plantar steps and no FL/HL coordination 
12 Frequent to consistent weight-supported plantar steps and occasional FL/HL coordination 
13 Frequent to consistent weight-supported plantar steps and frequent FL/HL coordination 
14 Consistent weight-supported plantar steps; consistent FL/HL coordination, and predominant paw position 
during locomotion is rotated (internally or externally) when it makes initial contact with the surface as well as 
just before it is lifted off at the end of stance; or frequent plantar stepping, consistent FL/HL coordination, and 
occasional dorsal stepping 
15 Consistent plantar stepping and consistent FL/HL coordination and no toe clearance or occasional toe 
clearance during forward limb advancement; predominant paw position is parallel to the body at initial contact 
16 Consistent plantar stepping and consistent FL/HL coordination during gait and toe clearance occurs frequently 
during forward limb advancement; predominant paw position is parallel at initial contact and rotated at lift-off 
17 Consistent plantar stepping and consistent FL/HL coordination during gait and toe clearance occurs frequently 
during forward limb advancement; predominant paw position is parallel at initial contact and lift-off 
18 Consistent plantar stepping and consistent FL/HL coordination during gait and toe clearance occurs 
consistently during forward limb advancement; predominant paw position is parallel at initial contact and 
rotated at lift-off 
19 Consistent plantar stepping and consistent FL/HL coordination during gait, toe clearance occurs consistently 
during forward limb advancement, predominant paw position is parallel at initial contact and lift-off, and tail 
is down part or all of the time 
20 Consistent plantar stepping and consistent coordinated gait, consistent toe clearance, predominant paw 
position is parallel at initial contact and lift-off, and trunk instability; tail consistently up 
21 Consistent plantar stepping and consistent gait, consistent toe clearance, predominant paw position is parallel 
throughout stance, and consistent trunk stability; tail consistently up 
 
Chapter II. Materials & Methods 
149 
9.5. Open Field Test 
The open field test is commonly used to assess exploratory and anxiety-like behavior in 
laboratory animals. Moreover, the open field is also a versatile test that allows the 
assessment of locomotor behavior by measuring the amount of rearing activity and the 
total distance travelled by the animals [34]. The test was performed in an arena 
(43.2 cm × 43.2 cm) with transparent acrylic walls (Med Associates Inc.) placed in a 
brightly illuminated room. Animals started the test at the arena’s centre and were given 
5 min to explore it. Total distance travelled in the arena and number of rearings was 
automatically registered by equipment sensors. This test was used in the work described 
in chapter V. 
 
9.6. RotaRod Test 
The rotarod test is used to assess motor coordination and balance in rodents. Animals 
have to keep their balance on a rotating rod. It is measured the time (latency) it takes the 
rat to fall off the rod, rotating at different speeds or under continuous acceleration. The 
work described in chapter V was performed in rotarod equipment from TSE systems. 
Each animal was placed on a 10-cm diameter, 15-cm long rod, rotating at constant 
speed. Impairment of motor coordination was defined as the inability of rats to remain 
on the rotating rod for a 60s test period. Experimentally animals were pre-trained on the 
rotating track 24 h before the proper test. The protocol consisted of 3 days of testing at 
4, 8 and 12 rpm in, respectively, 1
st
, 2
nd
 and 3
rd
 day for a maximum of 60s in four trials, 
with a 10 min interval between each trial. The latency to fall (in seconds) was recorded 
by equipment sensors. 
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9.7. Tissue Preparation 
In the work described in chapter III and V, and after each defined time point, rats were 
deeply anesthetized by an intraperitoneal injection of sodium pentobarbital (Ceva Saude 
Animal). Then, animals were perfused through the ascending aorta with 4% 
paraformaldehyde in PBS. A 2.5-3 cm length of spine and spinal cord, centered on the 
site of hemisection and scaffolds placement, was carefully removed and fixed in neutral 
buffered formalin. After decalcification, spinal cord and spine were carefully spitted 
being then embedded in paraffin and processed for hematoxylin–eosin staining. 
 
9.8. Hematoxylin-Eosin Staining 
Hematoxylin-Eosin (HE) stain is a popular staining method in histology. It is the most 
widely used stain in medical diagnosis. This protocol can be employed in a variety of 
fixed tissues and displays a broad range of cytoplasmatic, nuclear, and extracellular 
matrix (ECM) features. In a typical tissue, nuclei are stained bleu by hematoxylin, 
whereas cytoplasm and ECM are colored in various shades of red, pink and orange by 
eosin [35]. In the work described in chapter III and V, histological processing was 
conducted by dehydrating the samples in increasing ethanol concentrations, embedding 
them in paraffin and cutting for posterior analysis using a microtome (Leica RM2155). 
HE staining was performed immersing tissue sections in hematoxylin and eosin 
solutions using an automatic processor (Leica TP1020-1). The slides were then washed 
in distilled water, dehydrated and finally cleared in xylene substitute and mounted using 
Microscopy Entellan® (Merk & Co., Inc.). 
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10. Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, USA). Differences among groups were assessed by one 
way ANOVA test by the two-way ANOVA test followed by the Tukey post-hoc test or 
by the Bonferroni post-hoc test. A p-value of ≤ 0.05 (95% confidence level) was set as 
the criteria for statistical significance. 
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Chapter III. 
Development and Characterization of a Novel Hybrid Tissue Engineering Based 
Scaffold for Spinal Cord Injury Repair.* 
 
Abstract 
 
Spinal cord injury (SCI) represents a significant health and social problem and therefore 
it is urgent to develop novel strategies that can specifically target it. In this context, the 
objective of the present work was to develop a new range of 3D tubular structures 
aimed at inducing the regeneration within SCI sites. Up to six different 3D tubular 
structures were initially developed by rapid prototyping - 3D bioplotting – based on a 
biodegradable blend of starch. These structures were then further complemented by 
injecting Gellan Gum, a polysaccharide based hydrogel, in the central area of structures. 
The mechanical properties of these structures were assessed by DMA, under both dry 
and wet conditions, and their morphologies/porosities analysed by micro-CT and SEM. 
Biological evaluation was carried out for determining their cytotoxicity, using both 
MEM extraction and MTS tests, as well as by encapsulation of an oligodendrocyte like 
cell (M03-13 cell line) within the hydrogel phase. The histomorphometric analysis 
showed a fully interconnected network of pores with porosity ranging from 70%-85%. 
Scaffolds presented compressive modulus ranging from 17.4 to 62.0 MPa and 4.42 to 
27.4 MPa under dry and wet conditions respectively. Cytotoxicity assays revealed that 
the hybrid SPCL/Gellan Gum scaffolds were non cytotoxic as they did not cause major 
alterations on cell morphology, proliferation and metabolic viability. Finally, 
preliminary direct contact assays showed that the hybrid scaffolds could support the in 
vitro culture of oligodendrocyte like cells. Further work will focus on the behaviour of 
these scaffolds when implanted in SCI animal models. 
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Development and characterization of a novel hybrid tissue engineering-based scaffold 
for spinal cord injury repair, Tissue Engineering Part A, 16(1) : 45-54 
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1. Introduction 
 
Spinal Cord Injury (SCI) results in a devastating condition with enormous financial [1-
4], social and personal costs [5]. It is estimated that the annual incidence of SCI in the 
United States alone is approximately 40 cases per 1 million. It is commonly 
characterized by a primary injury that leads to a cascade of cellular and biochemical 
reactions which cause further damage. The latter is known as "secondary injury" being 
characterized by microvascular alterations, edema, ischemia, necrosis, free radicals 
formation, lipid peroxidation, excitatory neurotransmitter accumulation, inflammatory 
response and other molecular changes contributing to further neural damage [2,6-9].  
 
Current approaches used in clinical practice are mainly based on the use of 
pharmacological agents, like methylprednisolone [10,11]. However, its use is quite 
controversial as recent studies failed to reveal conclusive beneficial outcomes [12, 13]. 
Therefore, it is imperative to find novel therapeutic strategies that can specifically target 
SCI regeneration.  
 
In recent years, different approaches have been proposed in order to develop valid 
strategies for SCI repair such as biomolecular [14-17], cellular [18-23] and biomaterial 
based therapies [24-28].  However, due to the complexity of SCI repair it is unlikely 
that a single strategy will be adequate to tackle the problem. It is probable that only by 
following an integrated strategy, such as that presented by Tissue Engineering (TE) 
[29], it will be possible to develop a successful approach. In this field, it is of general 
agreement that a scaffold, a 3D biodegradable structure, plays a central role in the aid of 
the regenerative process. In recent years, natural based biodegradable polymers have 
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emerged as a possible biomaterial source for scaffold development within the SCI field 
[28,30-34]. Among these, polysaccharides are particularly appealing due to their 
structural similarities to components of host tissues. Moreover, they can also be 
enzymatically degraded in biological systems, allowing for better control of endogenous 
degradation rate along with other properties [35,36]. 
 
Within the present study we aimed at developing a new biphasic tubular scaffold for 
SCI regeneration. It is comprised of two natural polysaccharide based biomaterials: 
starch/poly-ε-caprolactone blend (SPCL) and gellan gum. SPCL has been originally 
proposed by Reis and colleagues for a wide range of applications including the culture 
of neurons, astrocytes and oligodendrocytes [37-43]. Gellan gum is an anionic 
exocellular polysaccharide secreted from the Sphingomonas paucimobilis bacterium. It 
is composed of repeated tetrasaccharide units of glucose, glucuronic acid, and rhamnose 
residues in a 2:1:1 ratio [44]. It was originally used as a thickener/gelling agent in food 
applications, and was recently proposed as a hydrogel for regenerative medicine 
purposes [44]. The hybrid structures proposed in this report consist of a SPCL semi-
rigid tubular porous structure filled by a gellan gum hydrogel concentric core. In this 
concept the SPCL tubular structure assures mechanical stability to the entire construct, 
namely by establishing a connection to the adjacent vertebral bone. In this sense the 
SPCL phase is aimed at mimicking the bone functions while the gellan gum hydrogel is 
aimed as a cell encapsulation system to support axonal regeneration in the injured spinal 
cord. 
 
In this report we address the mechanical and preliminary biological characterization of 
SPCL/gellan gum hybrid tubular structures. Our results reveal that these novel 
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structures exhibit adjustable mechanical performance and porosity, minimal cytotoxicity 
and support the encapsulation of oligodendrocyte like cells. Moreover it was also 
observed that these 3D hybrid structures caused a minimal inflammatory reaction when 
implanted subcutaneously and in a hemisection spinal cord injury in Wistar rats. 
 
2. Materials and Methods  
 
2.1. Materials 
The materials used in this work were a 30/70 (wt%) biodegradable blend of corn-starch 
with poly-ε-Caprolactone (SPCL) and a polysaccharide gellan gum hydrogel 1% (w/v) 
(Sigma, Saint Louis, USA). 
 
2.2. Development of SPCL tubular scaffolds 
The SPCL tubular scaffolds were processed in a two step methodological approach: 
1) Porous sheets featuring different pore geometries were produced by 3D plotting rapid 
prototyping (Bioplotter®; Envisiontec GmbH, Marl, Germany) [45,46] using two 
different inter filament orientations (90º and 45º); 
2) Tubular scaffolds were obtained by rolling up porous sheets around a cylinder and 
subsequent heat treatment at 65º C during 30 min for inducing the adhesion between 
filaments.  
Up to six different porous tubular scaffold designs were obtained featuring a single or 
double layer combined with three different filaments’ oriented relative to the tube main 
axis: filaments oriented at 0º and 90º relative to the tube main axis (90/1-2, further 
referred as 90/1 and 90/2 for structures with one or two layers), filaments oriented at 0º 
and 45º relative to the tube main axis (45/1-2, further referred as 45/1 and 45/2), and 
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filaments oriented at 45º relative to the tube main axis (X/1-2, further referred as X/1 
and X/2). As example of the adopted scaffold references, processing combination 90/2 
refers to a double layer scaffold featuring filaments’ orientated at 0º and 90º relative to 
the tube main axis, while 45/1 refers to a single layer scaffold featuring filaments’ 
orientated at 45º relative to the tube main axis. 
 
2.3. Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used for analysis of morphology/porosity of 
the different SPCL tubular scaffolds. For this purpose, all samples were coated with 
Au/Pd via ion-sputtering prior to observation in a Stereoscan 360 scanning electron 
microscope (Leica Cambridge Co., Cambridge, United Kingdom).  
 
2.4. Micro-computed tomography 
The architecture and porosity of the tubular scaffolds was analyzed by micro-computed 
tomography (μ-CT) using a desktop micro CT scanner (SkyScan 1072, Belgium) at a 
voltage of 40 kV and a current of 248 μA. Isotropic slice data were obtained by the 
system and reconstructed into 2D XY slice images. Around 600 slice images per sample 
were compiled and subsequently employed in the rendering of 3D XYZ images in order 
to obtain quantitative architectural parameters. A µCT analyzer and a µ-CT volume 
realistic 3D Visualization software, from SkyScan (Belgium), was used as an image 
processing tool for reconstruction and creation/visualization of 3D scaffold 
representations. 
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 2.5. Dynamic Mechanical Analysis 
Dynamic mechanical analysis (DMA) was carried out using a uniaxial compression 
loading scheme at 37º C, under both dry and wet (Phosphate Buffered Saline - PBS 
0.1M and pH 7.2) conditions. DMA was performed in a Tritec 2000B equipment 
(Triton Technology Ltd, Nottinghamshire, United Kingdom). The frequency range used 
between 1 and 70 Hz. 3 replicates were conducted for each type of scaffold 
morphology. 
 
2.6. Development of the 3D Hybrid Systems 
The integration of gellan gum hydrogel into the central canal of the SPCL tubular 
scaffolds was performed by placing the tubular scaffolds into a specially designed 
mould, and by filling the empty volume with a gellan gum hydrogel as previously 
described by Oliveira et al. [44]. 
 
2.7. In vitro cytotoxicity assessment 
In order to assess the short-term cytotoxicity of the developed scaffolds, the following 
guidelines described by Salgado and colleagues were used [47]: MEM extraction and 
MTS tests, both with 7, 14, 21, and 28 days of extraction period. In all tests the ratio 
material weight to extract fluid was constant and equal to 0.2g/ml for porous samples, 
while for latex (negative control for cell viability) the ratio of material outer surface to 
extraction fluid was 2.5 cm
2
/ml. After each period the extracts were filtered through a 
0.45 μm pore size filter. These assays are particularly suitable for assessing the possible 
toxic effect of leachables extracted from biomedical polymers. The objectives of the 
MEM extraction test are to evaluate changes in cell morphology and growth inhibition, 
whereas the MTS test determines whether cells are metabolically viable. In both cases, 
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latex extracts (same extraction periods) were used as positive controls for cell death, 
while standard culture medium (formulation described bellow) was used as negative 
control for cell death.  
  
2.7.1 Cell culture 
The present experiment used a cell line of rat lung fibroblasts-L929, obtained from the 
European Collection of Cell Cultures (ECACC). Cells were grown as monolayers in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma, St. Louis, USA), supplemented 
with 10% fetal bovine serum (FBS, Gibco) and 1% of an antibiotic–antimycotic mixture 
(Sigma, St. Louis, USA). For the MEM extraction tests, cells were seeded in 12 well 
plates (n=3, 1x10
5
 cells/well), while for the MTS test cells were seeded in 96 well plates 
(n=3, 1.8x10
4
/well). In both cases cells were incubated for 24h at 37°C, in a 5% (v/v) 
CO2 cell culture incubator. 
 
2.7.2 MEM extraction test 
Twenty four hours after cell seeding, culture medium was removed from the wells and 
an identical volume, 1 ml, of extraction fluid was added. Cultures were then incubated 
with the extracts for 72h, after which it was conducted a live/death assay by staining 
live cells with calcein-AM (1mg/ml; Molecular Probes, Oregon, USA) and non-viable 
cells with propidium iodide (PI, 0.1 mg/ml, Molecular Probes). Upon staining, cultures 
were observed under a fluorescence microscopy (Olympus BX-61, Hamburg, 
Germany).   
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2.7.3. MTS test 
The metabolic viability of the L929 cells following exposure to extracts was determined 
by the bioreduction of [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] (MTS, Promega, USA), into a brown formazan product 
by dehydrogenase enzymes. The extraction procedure was performed as previously 
described, using, in this turn, 200 µl of extraction fluid per well [47]. After 72 h of 
incubation, extracts were removed and a mixture of DMEM with MTS (5:1 ratio) was 
added to each well. Cells were then incubated for 3 h at 37°C in a 5% CO2 cell culture 
incubator after which O.D. was determined at 450 nm using a 96 well plate reader 
(Tecan Sunrise, Männedorf, Switzerland). 
 
2.8. Histocompatibility evaluation   
2.8.1. Subcutaneous implantation 
Young male Wistar rats (8 weeks old) were purchased from Charles River, housed in 
light- and temperature-controlled rooms, and fed a standard diet. The maintenance and 
manipulation of animals were in accordance with standardized Animal Care Guidelines 
[48]. Hybrid 3D tubular scaffolds with one and two layers were implanted 
subcutaneously in the back of the animals for 7, 14, 21 and 28 days. At the end of the 
implantation period, rats were sacrificed. The scaffolds were removed from the animals, 
fixed in 3.7% formalin, embedded in Technovit 7100 (Kuzere, Germany) and processed 
for eosin-haematoxylin staining. 
 
2.8.2. Hemisection SCI model 
Young male Wistar rats (8 weeks old) were purchased from Charles River, housed in 
light- and temperature-controlled rooms, and fed a standard diet. The maintenance and 
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manipulation of animals were in accordance with standardized Animal Care Guidelines 
[48]. In order to expose the spinal cord a laminectomy was performed at T8-T8 level. 
Once exposed, a unilateral defect was performed on the spinal cord, by removing 
around 2-3mm of the latter. After this 3D semi-tubular scaffolds were implanted in the 
defect site, with the SPCL phase aligned with the vertebral while the gellan gum was 
facing, and filling, the injured spinal cord. The scaffolds were removed from the 
animals, fixed in 3.7% formalin, decalcified, paraffin embedded and finally processed 
for eosin-haematoxylin staining. 
 
2.9. Encapsulation assays 
For the cell encapsulation experiments within the gellan gum hydrogel, the human 
oligodendrocyte cell line MO3-13 was used. For this purpose, cells were grown as 
monolayer cultures in DMEM supplemented with 10% FBS and 1% antibiotic–
antimycotic mixture until confluence. At this time cells were encapsulated in 2 different 
cellular densities (8 and 20 x10
4
 cells/ml) and injected into central canal of SPCL 
tubular scaffolds. Cell/Scaffolds constructs were then incubated in culture medium 
(DMEM, Gibco, 10% FBS, Gibco, 1% antibiotic/antimicotic, Sigma) for 7 days at   37º 
C in a 5% (v/v) CO2 cell culture incubator. For this period, the distribution of viable 
cells was evaluated by confocal microscopy in combination with calcein-AM staining 
(Fluoview FV 1000, Olympus, Germany). 
 
2.10. Statistical analysis 
Statistical evaluation was performed using the ‘one way ANOVA’ test followed by the 
Tukey post-test, to assess the statistical differences between groups in the porosity and 
cytotoxicity analyses. Statistical differences evaluation on mechanical tests was 
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performed using a ‘two way ANOVA’ test followed by a Bonferroni post-test. 
Statistical significance was defined for p<0.05. 
 
3. Results and Discussion  
 
The objective of this work was to develop a novel biphasic 3D tubular structure 
composed by a biodegradable semi-rigid polymer and a hydrogel-like material. 
Comparing with other currently used strategies for scaffold based SCI repair, our 
scaffold design has the advantages of combining the guidance stabilization from the 3D 
tubes, including the regeneration of vertebral bone, with the amenable conditions of 
hydrogel based material for cell and tissue migration. In this sense, our novel scaffold 
combines the beneficial effects of both strategies, overcoming the limitations of each 
strategy by itself. For instance, guidance tubes are able to stabilize the injured area from 
the mechanical point of view, while they act simultaneously as a physical guidance for 
SCI regeneration and protect the regenerating area from the invasion of adjacent 
connective tissue [2]. However, often this guidance tubes lack the signalling cues that 
allow a more efficient cell and tissue migration along the injured area [49]. Regarding 
hydrogels, it is know that they are quite versatile for SCI applications due to their cell 
encapsulation properties, peptide grafting and growth factor loading [28].  Nevertheless, 
in contrary to guidance tubes, hydrogels do not stabilize the injured area and have a 
limited capacity to avoid infiltration by the surrounding tissue [28]. The chosen 
biomaterials for the development of the 3D biphasic scaffolds have also several others 
advantages. Both of them are polyssachacarides prone to normal degradation in vivo and 
both SPCL and gellan gum are easily integrated in different tissues. For instance, SPCL 
has been previously shown to allow the formation of bone extracellular matrix in vitro 
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and bone in vivo [39,41], which is one of the main objectives of the SPCL phase under 
the concept herein presented. Furthermore, this thermoplastic biomaterial is quite 
versatile from the processing point of view, allowing the use of rapid prototyping 
technologies for the development of the tubular structure. This is advantageous, as RP 
allows the processing of highly reproducible scaffolds. On the other hand, gellan gum 
rapidly polymerize either at room temperature or at 37ºC which allows the 
encapsulation of relevant cell populations [50,51] without compromising their viability, 
as shown in the present manuscript (see below). Moreover, gellan gum is quite 
amenable for chemical modification, and thus is makes possible to graft and align 
relevant peptides that can promote axonal migration, such as RGD and IKVAV. In this 
context, standard aqueous-phase peptide synthesis methodologies will be used on the 
polysaccharide backbone to promote adequate binding of the sequences of interest to the 
gellan gum. This will be achieved by activating the carboxylic groups of the sugar 
molecules to which the pre-synthesized sequence of interest will be bound.   
 
In order to develop the 3D guidance structure, a tubular scaffold was developed by 
combining rapid prototyping with a post-processing thermal treatment. As it can be 
observed in Figure 1, the proposed processing methodology was quite versatile allowing 
for the development of 3D tubular scaffolds with configurable outer layer thickness, 
fibre/filament orientation and pore geometry. Fibre orientation ranged from 0º to 90º 
and resulted from the design adopted during the rapid prototyping stage. 
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Morphological analysis conducted by SEM and -CT demonstrated that the developed 
processing technique allowed the production of structures with a precise tubular 
geometry with fully interconnected pore networks. Further analysis conducted using μ-
CT revealed that scaffolds had fully interconnected network of pores with 
approximately 85% porosity for structures featuring a single outer layer and around 
71% porosity for structures featuring double outer layers (Figure 2). The differences in 
porosity observed were related to the outer thickness of the SPCL tubular structures, as 
the different orientations of the fibres did not affect the overall porosity of the scaffolds. 
 
Figure III.1. SPCL tubular scaffolds, a) μ-CT image of 90/1 type structure; b) SEM 
of 90/2 type structure; c) μ-CT image of 45/1 type structure; d) SEM of 45/2 type 
structure; e) μ-CT image of X/1 type structure; f) SEM of X/2 type structure; g) μ-
CT image of the top view of two layers type scaffolds; h) SEM of the top view of 
one layer type scaffolds. 
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The porosity values are in the range of those found in the literature for similar purposes. 
[52] 
 
 
 
 
 
 
 
 
 
 
In order to assess their mechanical properties, the different tubular scaffolds were 
subjected to dynamic compression testing. The objective of these experiments was to 
evaluate their mechanical integrity and simultaneously determine their respective 
stiffness. Tests were carried out, at 37ºC in dry and wet conditions, in order to simulate 
and study the influence of physiologic conditions on the mechanical properties of the 
tubular scaffolds, namely the influence of water absorption. Moreover, to detect 
eventual mechanical collapse of the structure or layer detachment, the scaffolds were 
submitted to an increasing frequency test. Nevertheless, no major variation of storage 
modulus was detected upon the increase of frequency (Figure 3 a and b), which testifies 
the resilience of the scaffolds developed. Dry and wet tests revealed significant 
differences in the stiffness of the developed scaffolds. In the dry tests the  90/2 samples 
obtained the highest value, followed in decreasing order of magnitude by structures 
45/2, 90/1, X/2, 45/1 and X/1 (Figure 3c, p<0,05). Under wet conditions, as it would be 
 
Figure III.2. Percentage values of porosity of each structure type. Mean ± sd 
(n=3), *** statistical significance for p< 0,001. 
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expected, there was a decrease in stiffness. Consistent with the dry test observations, 
conditions 90/2 and 45/2 had the highest values. However, in this case, the third 
condition that presented higher stiffness was X/2 followed by 90/1, 45/1 and X/1 
(Figure 3d). The stiffness of the different tubular scaffolds at 1 Hz under dry and wet 
conditions is plotted in Figure 3e. The differences observed were related with different 
fibre orientations and scaffold thicknesses. Scaffolds with two layers had higher 
stiffness values as compared to the equivalent single layer structures. On what concerns 
to fibre orientation, scaffolds with aligned fibres along the tube axis had higher 
resistance to compression force. Our results revealed that, 90/1 and 90/2, as well as 45/1 
and 45/2 conditions contained higher stiffness values when compared to those of X/1 
and X/2 structures. For 90/1-2 and 45/1-2 scaffolds, half of the fibers were aligned in 
the same direction of the applied compression force. However, while for 90/1-2 
scaffolds, approximately half of the fibres were aligned orthogonally to the compression 
force, for 45/1-2 conditions, the remaining half were diagonally aligned (45º relative to 
the compression force). In theory, 45/1-2 and X/1-2 conditions should present higher 
stiffness as compared to those experimentally observed, due to the stiffness contribution 
of diagonally orientated fibres - cosine (45º). The lower values of stiffness observed for 
scaffolds featuring diagonally orientated structures is probably due to buckling of the 
structure, which occurs upon compression due to geometrical instability of the structure. 
As previously shown (Figure 3e), under wet conditions, all scaffolds exhibited a 
decrease in stiffness, which can be explained by the water absorption. Water acts as 
plasticicer of the polymer, reducing its resistance to plastic deformation [53]. In SPCL, 
starch is the main water absorbent since PCL has low water uptake ability [53]. 
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Furthermore, it could also be observed that the relative decrease in stiffness was larger 
in single layer structures. This can be explained by the larger surface area/total volume 
ratio of single layered structures as compared to double layered structures. In double 
layered scaffolds, the stacking of porous sheets reduces the relative surface area, which 
ultimately results in less water absorption. It is important to note that the mechanical 
tests with the SPCL structures were performed prior to gellan gum incorporation. Since 
the stiffness of gellan gum hydrogel is three orders of magnitude smaller than SPCL, no 
relevant mechanical effect would be expected for structures containing the hydrogel. 
 
Figure III.3. Dynamic Mechanical Analyses of each scaffold type developed, a) Dry 
compressive modulus evaluation in function of frequency; b) Wet compressive 
modulus evaluation in function of frequency; c) Rigidity comparison at 1 Hz in dry 
conditions; d) Rigidity comparison at 1 Hz in wet conditions, e) Comparison at 1 Hz 
between the dry and wet tests. Mean ± sd (n=3), *** Statistical significance for p< 
0,001, ** for p< 0,01 and * for p> 0,05. 
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Under dry conditions, the elastic modulus for gellan gum was determined to be 79.7 ± 
7.56 kPa, as characterized by Oliveira et al. [44]. 
 
Following the physical characterization of tubular scaffolds, the hydrogel phase was 
injected into the central canal of the tubes. This process allowed the formation of the 
biphasic structure presented in Figure 4. As it can be observe, the two phases were fully 
integrated in the system, being the central canal of the 3D SPCL tubular structure 
entirely filled with the gellan gum hydrogel. The main benefit of the proposed hybrid 
system arises from the individual potential advantages of each material. The SPCL 
frame is aimed at assuring the structural stiffness of the construct, while the gellan gum 
hydrogel is expected to create an amenable nerve regeneration environment. 
 
 
Figure III.4. First generation of FMSS, a) After maintain in 
culture with DMEM medium; b) FMSS loupe view (10x).  
 
Biological assays were performed upon the development of the hybrid SPCL/gellan 
gum structures. Their cytotoxicity was determined by MTS and MEM extraction tests 
on a L929 cell line, while cell encapsulation assays were carried out with an 
oligodendrocyte-derived cell line. Since the SCPL layer will be used to connect to 
adjacent bone, the stiffness of the SPCL tubular structures is very important, as they 
will support directly the development of a mineralized tissue. In this sense, from all the 
developed structures, 90/2 samples were chosen for biological assays, as these present 
the best mechanical performance. Regarding cytotoxicity assays, MEM extraction tests 
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associated with calcein/PI staining revealed that the extracts obtained from the hybrid 
3D tubular structures did not cause cell death among L929 cells. The cell density, 
morphology and viability were very similar between the extracted incubated cells and 
the cells grown in DMEM (positive control) (Figure 5a). These results were in contrast 
to cells grown in latex, and were then further confirmed by the MTS test (Figure 5b), 
under which L929 cells produced large amounts of a brown formazan product after 
incubation with the tested extracts. This is an indicator of normal metabolism as they 
were able to incorporate and metabolize MTS. MTS incorporation under these 
conditions was similar to the negative control. These results were supportive of a lack of 
cytotoxic effect of these hybrid structures. 
 
A)                                                                   B) 
 
Figure III.5. Cytotoxicity assays. (A) MEM extraction evaluation of cell line L929 in 
four time-points of incubation (7, 14, 21 and 28 days) and three different conditions 
(positive control, negative control and FMSS extract). Viable cells were stained with 
calcein-AM and non-viable cells with PI. (B) MTS evaluation for cell line L929 in four 
time-points of incubation (7, 14, 21 and 28) and three different conditions (positive - 
DMEM - and negative - Latex - controls and FMSS extract). Mean ± sd (n=3), *** 
Statistical significance for p< 0,001. 
 
These favorable results were further confirmed by preliminary in vivo tests. In this case 
the 3D tubular hybrid structures were either subcutaneously implanted on Wistar rats 
(Figure 6a and 6b) or in a hemissection model of SCI (Figure 6c and 6d). In the 
subcutaneous model rats developed an initial, but mild, inflammatory reaction detected 
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after 1 week of implantation (Figure 6a), which faded by the fourth week (Figure 6b) 
indicating a possible biocompatible character of the scaffolds. Moreover, we also 
observed no formation of fibrotic capsules, supportive of the lack of inflammatory 
response triggered by the implanted scaffolds. Finally, it was possible to confirm that 
pore size, geometry and properties of the structure facilitated cells and connective tissue 
penetration within the scaffold. Similar results were also obtained for the SCI model, 
regarding the inflammatory response. As it can be seen in Figures 6 c) and d) no major 
inflammation processes were found. Moreover, it was possible to observe bone tissue 
(Figure 6c) forming around SPCL struts. Nevertheless, the results of this preliminary 
experiment will be further confirmed in future experiments. 
 
 
Figure III.6. Scaffolds were implanted subcutaneously (a, b) and 
in a hemisected spinal cord (c, d). In both cases histological 
sections were stained with hematoxylin–eosin. After 1 (a) and 4 
(b) weeks of subcutaneous implantation, the tested hybrid 
scaffolds were well integrated within the surrounding tissue with 
minimal inflammatory response. Similar results were also 
obtained for the hemisection model (c, d), where it could be 
observed the formation of bone near SPCL struts. 
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The interaction of central nervous system cell populations with the developed structures 
is extremely important since they will be one of the mediators of nerve regeneration 
induction within the hydrogel phase. Therefore, preliminary cell encapsulations assays 
were performed using the MO3-13 human oligodendrocyte cell line. The rationale for 
using these cells was based on future approaches that can be used, namely the use of 
oligodendrocyte progenitors to foster remyelination repair in the affected SCI areas. As 
previously described the cell population was first encapsulated within the gellan gum 
hydrogel prior to injection in the tubular structure. Confocal laser microscopy 
observation revealed that the hydrogel phase of the hybrid structure supported the in 
vitro culture of MO3-13 cells during the culturing period (up to one week). The cells 
were preferentially dispersed within the gellan gum matrix, being either at the centre 
(Figure 7a) or at the vicinities (Figure 7b) of the hydrogel. 
 
 
Figure III.7. Direct contact evaluation of cell line M0III encapsulation on 
FMSS. The green points are oligodendrocytes-like cells that appear 
dispersed on gellan gum matrix (a) and near the SPCL fibbers (b). Cells 
stained with calcein-AM. 
 
4. Conclusions  
 
With the present work it was possible to show that 3D plotting, a rapid prototyping 
technology was successfully used in the development of starch based scaffolds to be 
employed in future applications for SCI regeneration. We also showed that the 
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developed SPCL tubular scaffolds possessed configurable mechanical performance, 
pore sizes and interconnectivity values adequate for cell/tissue based regenerative 
applications. We also demonstrated that the different orientations of the fibres and the 
number of layers in the developed structures influenced their mechanical properties. 
Moreover, we demonstrated that SPCL/gellan gum hybrid structures were non-cytotoxic 
and disclosed an apparent biocompatible response in vivo. Finally, it was also possible 
to observe that these structures allowed the in vitro culture of oligodendrocyte like cells 
for periods up to one week. Further work is ongoing using these hybrid systems in 
animal models, in order to determine their potential to therapeutic intervention of SCI, 
as well the functionality of improved of gellan gum hydrogels in terms of cell adhesion 
and guidance upon division. 
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Chapter IV. 
Benefits of Spine Stabilization with Biodegradable Scaffolds in Spinal Cord Injured 
Rats* 
 
Abstract 
Spine stabilization upon spinal cord injury (SCI) is a standard procedure in clinical 
practice, but rarely employed in experimental models. Moreover, the application of 
biodegradable biomaterials for this would come as an advantage as it would eliminate 
the presence of a non-degradable prosthesis within the vertebral bone. Therefore, in the 
present work, we propose the use of a new biodegradable device specifically developed 
for spine stabilization in a rat model of SCI. A 3D scaffold based on a blend of starch 
with polycaprolactone (SPCL) was implanted, replacing delaminated vertebra, in male 
Wistar rats with a T8-T9 spinal hemisection. The impact of spinal stabilization on the 
locomotor behavior was then evaluated for a period of 12 weeks. Locomotor evaluation, 
assessed by Basso, Beatie and Bresnahan (BBB) test, rotarod and open field analysis, 
revealed that injured rats subjected to spine stabilization significantly improved their 
motor performance, including higher coordination and rearing activity when compared 
to SCI rats without stabilization. Histological analysis further revealed that the presence 
of the scaffolds not only stabilized the area, but simultaneously prevented the 
infiltration of the injury site by connective tissue. Overall, these results reveal that SCI 
stabilization using a biodegradable scaffold at the vertebral bone level, leads to an 
improvement of the motor deficits and is a relevant element for the successful treatment 
of SCI. 
Chapter IV. Benefits of Spine Stabilization with Biodegradable Scaffolds in Spinal Cord Injured Rats 
188 
 
*These chapter is based on the following publication: 
Silva NA, Sousa RA, Fraga, JS, Fontes M, Leite-Almeida H, Cerqueira R, Almeida A, 
Sousa N and Reis RL, Salgado AJ, “Benefits of Spine Stabilization with Biodegradable 
Scaffolds in Spinal Cord Injured Rats”, Tissue Engineering Part C, 2012, Epup ahead 
of print. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter IV. Benefits of Spine Stabilization with Biodegradable Scaffolds in Spinal Cord Injured Rats 
189 
1. Introduction 
Spinal cord injury (SCI) represents a significant health and social problem. It was 
estimated that approximately 500,000 people, in the US and Europe alone, have to deal 
each day with the burden of having a spinal cord injury (SCI). Importantly, the 
incidence of SCI lies between 10.4 and 83 per million inhabitants each year, in western 
countries [1, 2]. 
Currently, medical practice for SCI patients is mainly based on 3 steps: stabilization of 
the spine, using metallic/vertebral spinal fusions [3]; decompression of the cord [4]; and 
administration of the anti-inflammatory drug methylprednisolone (MP) [5]. Regarding 
spine stabilization, there is presently an open debate among physicians concerning the 
timing of surgery, even though there is strong evidence within the literature that early 
surgical stabilization consistently leads to shorter hospital stays, shorter intensive care 
unit stays, less days on mechanical ventilation, and less pulmonary complications [3]. 
Nevertheless, the use of metallic devices, such as spinal fusions, have some 
disadvantages, namely the potential need of a second surgery to remove it as well as 
interfering with magnetic resonance imaging during postoperative follow-up [6]. 
Dynamic stabilization is a promising alternative to traditional spinal fusions, Cakir and 
colleagues [7], for instance, presented favorable short-term results when this system was 
applied. However, the longevity of a dynamic stabilization construct in an active adult, 
with constant motion, is an important consideration. Some devices have been 
abandoned because of failure over time [8]. Moreover, Goldstein and colleagues 
demonstrated that the infection rate in patients undergoing dynamic stabilization is 
higher than that for instrumented fusion [9]. We believe that biocompatible scaffolds 
that can act as stabilization devices and at same time promote bone regeneration are a 
very promising alternative to both traditional and dynamic devices. Biodegradable tools 
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have been studied, namely in the form of 3D scaffolds. However, to date, none of this 
have been specifically designed for spine stabilization after SCI [6]. Surprisingly, in rat 
SCI models, spine stabilization is not performed at all. However, the majority of the 
surgical procedures used in rat SCI models comprise a laminectomy which may affect 
the locomotor behavior and trunk stability of the animals.  In this sense, the absence of 
spine stabilization may compromise the regenerative process of the spinal cord tissue 
after the injury.   
In order to specifically target this problem we previously reported the development and 
characterization of a biodegradable scaffold composed of a blend of starch with 
polycaprolactone (SPCL) aimed for spine stabilization. SPCL scaffolds were fabricated 
by rapid prototyping and have shown to disclose appropriate mechanical performance, 
in vitro non-cytotoxic behavior and in vivo biocompatibility [10]. Moreover, SPCL has 
been originally proposed by our group for a wide range of tissue engineering 
applications including bone regeneration [11-13]. In this sense, the objective of the 
present study was to evaluate to what extent the stabilization of the vertebral column 
through the implantation of the referred scaffold is feasible and whether it promotes 
beneficial motor effects. 
 
2. Materials & Methods 
2.1. Processing of SPCL scaffolds.  
The SPCL scaffolds were processed as previously reported [10]. Briefly, porous sheets 
featuring inter filament orientations of 90º were produced by 3D plotting, a rapid 
prototyping technology (Bioplotter®, Envisiontec GmbH, Germany). Tubular scaffolds 
were obtained by rolling up porous sheets around a cylinder and subsequent heat 
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treatment at 65º C during 30 min for inducing the adhesion between filaments. Scaffolds 
were then cut in semi-tubular structures (Fig. 1a and b). All the materials were sterilized 
with ethylene oxide. 
 
2.2. Animals 
Eight week old male Wistar rats (Charles River, Barcelona), housed in light and 
temperature controlled rooms and fed with standard diet, were used in this study. The 
Animal Care Committee of the Research Institute approved the animal protocols in 
accordance with standardized Animal Care Guidelines [14]. After SCI, the animals were 
divided into 2 experimental groups: animals with spine stabilization through SPCL 
scaffolds implantation (SPCL, n=9) and animals without spine stabilization (SCI, n=5). 
A third group of animals, subjected to laminectomy only, were used as controls (Sham, 
n=5). Handling was performed for 3 days before the surgery. 
 
2.3. Surgery and post-operative care 
All animals were anesthetized by intraperitoneal injection of a mixture (1,5:1) of 
ketamine (60 mg/ml, Imalgen, Merial, Portugal) and medetomidine hydrochloride (0.4 
mg/ml, Dorbene Vet, Laboratorios SYVA S.A., Spain). Once anaesthetized, fur was 
shaved from the surgical site and the skin disinfected with chlorohexidine (AGB, 
Spain). Then a dorsal midline incision was made from T6–T11 and the paravertebral 
muscles retracted. A laminectomy was performed at the junction T8–T9 in which the 
spinous processes were removed and the spinal cord exposed. Two hemisections were 
performed, 3 mm apart on the left side, and the tissue in between removed. SPCL 
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scaffolds were implanted at the vertebral bone level, juxtaposed to the spinal cord, 
providing spine stabilization (Fig 1c). Bone cement (Biomet, USA) was used to fix the 
scaffolds margins to bone. Paravertebral muscles and skin were then separately closed 
with Vicryl sutures (Johnson and Johnson, USA). The incision of control animals was 
closed after SCI, without SPCL implantation. Following surgery rats were kept under 
heat lamps and received vitamins (duphalyte, Farmoquil, Portugal), analgesic 
(butorphanol tartrate, 1mg/ml, Fort Dodge, Spain) and antibiotic (enrofloxacine, 
1mg/ml, Bayer, Germany). Bladder evacuation was done manually. Throughout the 
treatment and recovery period, animals were examined for symptoms of illness or 
potential reaction to the treatment. 
 
2.4. Assessment of locomotor function by BBB test 
All rats were assessed with the Basso, Beattie, Bresnahan Locomotor Rating Scale 
(BBB) [15] on day 3 and 2, 5, 7, 9, 12 weeks after injury. The BBB is a 21-point scale 
designed to assess hindlimb locomotor recovery following thoracic spinal cord injury. A 
 
 
Figure IV.1. Scanning electron microscope pictures of SPCL scaffolds used for spine 
stabilization (a,b). Schematic representation of spine stabilization using SPCL 
scaffolds (c). The biodegradable scaffolds were implanted at the vertebra level using 
bone cement. 
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BBB score of 0 indicates no hindlimb movement. A BBB score of 1 through 8 indicates 
joint movement, but no weight support. A BBB score of 9 through 20 indicates an 
ability to support weight and use the limb for locomotion but with some degree of 
abnormality. A BBB score of 21 corresponds to the locomotion of a normal rat. 
 
2.5. Motor behavior analyses in an open field chamber 
The open field is a versatile test that permits the assessment of motor behavior by 
measuring the amount of rearing activity and the total distance travelled by the rats [16]. 
The OF was performed in a square (43.2 cm × 43.2 cm) arena with transparent acrylic 
walls (Med Associates Inc., St. Albans, VT, USA) placed in a brightly illuminated 
room. Animals started the test at the arena’s center and were given 5 min to explore it. 
Total distance travelled in the arena and number of rearings was automatically 
registered by equipment sensors. 
 
2.6. Rotarod test 
Motor coordination of the animals was evaluated in a rotarod equipment (TSE systems, 
Germany). Each animal was placed on a 10-cm diameter, 15-cm long rod, rotating at 
constant speed. Impairment of motor coordination was defined as the inability of rats to 
remain on the rotating rod for a 60s test period. Experimentally animals were pre-
trained on the rotating track 24 h before the proper test. The protocol consisted of 3 days 
of testing at 4, 8 and 12 rpm in, respectively, 1st, 2nd and 3rd day for a maximum of 60s 
in four trials, with a 10 min interval between each trial. The latency to fall (in seconds) 
was recorded by equipment sensors. 
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2.7. Tissue preparation 
Twelve weeks after the scaffold implantation, the rats were deeply anesthetized by an 
intraperitoneal injection of sodium pentobarbital (Ceva Saude Animal, Portugal). Then, 
animals were perfused through the ascending aorta with 4% paraformaldehyde in PBS. 
A 2.5-3 cm length of spine and spinal cord, centered on the site of hemisection and 
scaffold placement, was carefully removed and fixed in neutral buffered formalin. After 
decalcification, spinal cord and spine were carefully spit and then embedded in paraffin 
and processed for hematoxylin–eosin staining. The tissue was sectioned on the coronal 
plane and apoptotic cells, vacuolated neurons and tissue infiltration/organization was 
evaluated on three tissue slices of each subdivision (dorsal, median and ventral cord). 
Apoptotic cells and vacuolated neurons were counted both rostral and caudal to the 
injury center and on the left side of the cord. 
 
2.8. Statistical analysis 
To assess if the values come from a Gaussian distribution the BBB, Open Field, 
Rotarod, and histological data was analyzed using the Kolmogorov-Smirnov test. Then, 
to evaluate statistical differences among groups a ‘two way ANOVA’ test followed by a 
Bonferroni post-test was performed. Statistical significance was defined for p<0.05. All 
data are presented as mean ± SEM. 
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3. Results 
3.1. Locomotor Function Evaluation by BBB test 
Left hindlimb function was evaluated one day after the hemisection injury. Only the 
animals that were completely paralyzed were selected for the study. From the initial 24 
animals subjected to surgery, two died during the surgical procedure (from groups sham 
and SCI) and another two died during the experimental protocol (from groups SCI and 
SPCL). Motor evaluation began 3 days after surgery and continued each 2-3 weeks for 3 
months. In all experiments the identity of the animals was kept blind to the observer. 
After SCI, SPCL scaffolds were implanted in the vertebral column of 9 animals (Fig. 1). 
Five weeks after, animals stabilized with SCPL scaffolds presented significant motor 
improvements when compared to the non-stabilized group (Fig. 2). Moreover, these 
differences persisted up to 12 weeks. Injured animals subjected to spine stabilization 
presented, extensive movements of all three joints of the left hindlimb (SPCL, 7.3±1.5 
in the BBB score), whereas rats without spine stabilization presented slight to extensive 
movements of just one joint (SCI, 1.8±1.1 in the BBB score) (Fig. 2). Animals from 
sham group scored 21 (maximum) in BBB scale, showing that laminectomy alone did 
not affect the animals motor skills (Fig. 2). 
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Figure IV.2. BBB locomotor scale evaluation of SCI rats with spine stabilization 
(SPCL, n=9), without spine stabilization (SCI, n=5) and animals subjected only to a 
laminectomy (Sham, n=5). The BBB test showed significant motor skill 
improvement in rats with spine stabilization (p<0.05), comparing to those without 
stabilization. Sham animals did not present motor impairments (p<0.001). Values 
are shown as mean ± SEM, *p<0.05; **p<0.01; ***p<0.001. 
 
3.2. Open Field Analyses 
Unlike the BBB, the Open Field (OF) test is dependent on animal motivation to explore 
a new environment. Since the repetition of the same environment could lead to a 
decrease of the exploratory behavior, the OF test was not performed each 2 weeks. 
Instead, OF analyses were carried out in the first and last weeks of the experimental 
protocol and in different rooms. The total distance traveled in the OF arena just after the 
surgery was not significantly different between groups (266.6±19.3cm for SPCL and 
361.5±99.0cm for SCI). However, at 12 weeks the total distance travel by animals with 
a spine stabilized was significantly greater than that seen in the non-stabilized animals 
(1272.6±184.4cm for SPCL and 673.5±161.0cm for SCI) (Fig.3a). Moreover, the 
number of rearings (exploratory behavior where animals stand up only in their 
hindpaws) was also assessed. Once again animals from both groups had a similar 
performance after surgery (5.4±1.7 for SPCL 4.3±1.8 and for SCI) while at 12 weeks, 
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animals with SPCL implantation performed significantly more rearing activity than 
non-stabilized animals (25.7±3.8 for SPCL and 12.5±2.8 for SCI) (Fig.3b). Importantly, 
despite a remarkable difference to sham animals in distance and rearings after surgery, 
12 weeks after stabilization, animals did not show statistical differences (Fig.3). 
 
Figure IV.3. Distance and rearing behavior evaluation. When tested in an open field 
apparatus, injured rats with spine stabilization (SPCL) performed significantly better 
(p<0.05), both in distance traveled (a) and in number of rearings (b), comparing to non-
stabilized animals (SCI). Comparing to the sham group, spine stabilized animals 
(SPCL) performed worse in the first week (p<0.05) however at 12 weeks both groups 
performed equally, showing motor improvements. Values are shown as mean ± SEM, 
*p<0.05; ***p<0.001. 
 
In addition to the above results, we also performed the open field test in animals that did 
not suffer any surgery which was used as baseline. Interestingly, these animals 
performed significantly more rearings (p<0.01) than the sham animals but covered 
approximately the same distance (Fig.4). This data indicates that, although the 
himdlimb function of the sham animals was not affected (distance covered), they 
presented specific difficulties on rearing behavior. This difference on rearing behavior is 
most likely due to the absence of spine stabilization on sham animals. 
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Figure IV.4. Open field analysis one week upon surgery. When tested in an open field 
apparatus, rats with a laminectomy (sham) performed significantly less rearing than 
control animals (rats without any surgery) (a). Both control and sham animals covered 
the approximately the same distance (b) and SCI animals presented significantly less 
distance covered and rearings. Values are shown as mean ± SEM, *p<0.05; **p<0.01. 
 
3.3. RotaRod Test 
To assess motor coordination, a rotarod test was performed in the last week of the 
experiment. Once again, this test was not performed throughout all the experimental 
protocol because the falls from the rotating rod could lead to further injuries. The test 
was performed on 3 consecutive days. In first, at 4 rpm, spine stabilized animals latency 
to fall from the rotating rod was significantly higher than non-stabilized animals 
(27.1±8.6s for SPCL and 2.2±1.2s for SCI). However, at 8 and 12 rpm (respectively day 
2 and 3) both stabilized and non-stabilized animals showed lack of motor coordination. 
The latency to fall happened only a few seconds from the start of the trial (8rpm, 
4.1±1.1s; 12rpm, 4.9±1.8s for SPCL and 1.8±1.9; 2.7±1.6 for SCI). Once again, sham 
animals successfully executed the test, showing that their motor coordination was not 
affected by the laminectomy (Fig. 5). 
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Figure IV.5. Motor coordination assessment. In the Rotarod test, 
rats with stabilization presented significantly higher motor 
coordination at 4rpm (p<0.05), however, for more demanding task 
(8rpm and 12 rpm), rats performed equal to non-stabilized animals. 
Sham animals successfully performed the test, showing no motor 
coordination impairment. Values are shown as mean ± SEM, 
*p<0.05; ***p<0.001. 
 
 
3.4. Histological Characterization 
Hematoxylin and eosin (H&E) staining was performed to assess the effects of spine 
stabilization on the spinal cord organization, surrounding tissue infiltration and axon 
vacuolization after a SCI. A decrease of connective tissue infiltration into the spinal 
cord after the injury in animals subjected to spine stabilization was observed (Fig. 6a 
and b). As shown in figure 6a, animals without scaffold implantation have a higher 
connective tissue infiltration. Less connective tissue infiltration was observed in treated 
animals after injury (Fig.6b). When observed at higher magnification it was possible to 
detect less cell death and less vacuolated neurons in injury animals with spine 
stabilization then in non-stabilized animals (Fig. 6d, e, g and h). We observed that the 
number of apoptotic cells was significantly different between groups. There was a 4.9 
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fold increase (ratio to intact spinal cord) in the number of apoptotic cells found in the 
spinal cord tissue of non-stabilized animals and only a 2.0 fold increase (ratio to sham 
spinal cord) in the spinal cord of animals with spine stabilization (Fig. 6g). A similar 
trend was observed in the number of vacuolated neurons. Animals without spine 
stabilization presented significantly more vacuolated neurons (10.1 fold increase) than 
stabilized animals (3.6 fold increase; Fig. 6h). The histological analysis of the vertebral 
bone revealed that SPCL scaffolds were able to support new bone formation. The 
typical morphology of newly formed bone is characterized by a high number of cells 
and extracellular matrix more intensely stained for hematoxylin than eosin [17]. Both of 
these features were found in the tissue between the SPCL fibers (Fig.6f). Moreover, it 
was also possible to observe a few attributes typical in mature bone, such as some 
possible lamellar organization as well as spaces within the bone matrix, known as 
lacunae, which contain osteocytes. These results revealed that newly formed bone 
involving the SPCL fibers started maturation. This is contrary to what is seen in animals 
that did not receive SPCL implants. In those animals we only observe the formation of 
granulation tissue and apparently no bone formation yet (Fig. 6i). The granulation tissue 
(mainly formed by fibroblast and periosteal cells) is a standard response after bone 
fractures. This new loose connective tissue provides a temporary extracellular matrix 
that supports new bone formation. 
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Figure IV.6. Histological analyses of spinal cord tissue and vertebra bone stained with 
Hematoxylin and Eosin. (a) Injured rats without spine stabilization (SCI) presented 
higher vertebral canal tissue infiltration (red arrows) than the ones with stabilization 
(SPCL) (b). The laminectomy alone did not affect the spinal cord of Sham animals (c). 
With higher magnification was possible to observe more cell death (green arrows 
pointing to chromatin condensation) and more vacuolated neurons (yellow arrows 
pointing to cyst-like structures) in rats without stabilization (d) than in those with with 
SPCL stabilization (e). In animals without stabilization both apoptotic cells (g) and 
vacuolated neurons (h) were present in greater numbers than in animals with 
stabilization. (e) At the vertebral level was possible to observe that newly bone was able 
to grow between the SPCL fibers (blue arrows). Moreover was possible to observe 
some signals of bone maturation, as the presence of lacunas, small spaces on bone 
matrix filled by osteocyte (black arrows). (i) In animals without SPCL implantation it 
was only possible to observe the formation of granulation tissue (gray arrow) and no 
bone formation. Scale bar of a), b) and c): 1 mm; scale bar of d), e), f) and i): 200 µm; 
spinal cord figures are from dorsal region; values are shown as mean ± SEM, 
***p<0.001. 
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4. Discussion 
Biodegradable materials have been successfully used in various clinical applications. 
These materials were first introduced more than 30 years ago by Kulkarni and 
colleagues [18] for use as absorbable sutures. After that, absorbable polymers have been 
successfully employed for various methods of fixation for small bones fractures [19]. 
Recently these implants have been studied for spine surgery; nonetheless, the use of 
metallic spinal fixation is still the standard clinical practice [6]. Moreover, until now 
none of the developed biodegradable implants were specifically designed for spine 
stabilization after a SCI. 
We show that spine stabilization is an important element in the therapeutic intervention 
of SCI whenever there is a laminectomy. In fact, animals subjected to spinal 
stabilization presented significant motor recovery. These animals were able to recover 
from no apparent movement on the left paw, after surgery, to extensive movement of all 
three joints in the hindlimb (7 on the BBB scale), at 12 weeks. On the other hand, 
animals without spinal stabilization by the SPCL scaffolds, only recovered from no 
apparent movement to slight/extensive movements of one joint (2 on the BBB scale). 
The BBB results here presented for injury animals without treatment are in concordance 
with other previously published experiments [20, 21]. However, others also report a 
greater motor recovery from control animals (between 6 and 8 on the BBB scale) [22, 
23]. These variations may be explained by different protocols in the post-operative care 
performed by each lab. For instance, some authors use fibrin as a natural sealant or to 
stabilize tissue grafts within the spinal cord [24, 25]. That protocol may influence the 
motor recovery of control rats, given that, it was previously described that fibrin alone 
promotes tissue regeneration [26]. 
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Due to the subjectivity inherent to BBB test, the motor function of the animals was also 
assessed by the rotarod and open field test methods. Analysis of motor coordination, 
balance, motor control and trunk stability were performed with these tests. Moreover, 
there is lower interference by the observer in rotarod and open field tests since the 
motor analysis is generated by software. The results from open field analyses showed 
that animals with spine stabilization were able to walk longer distances and execute a 
higher number of rearings than non-stabilized animals. Either distance or rearing 
performance is correlated with the motor improvements observed in the BBB test. Once 
again, the benefits of spine stabilization were confirmed. The greater amount of rearing 
activity may be correlated by an increase in trunk stability due to the implanted 
scaffolds. Moreover, the rearing behavior showed that the SPCL scaffolds are 
mechanically able to support the body weight of the animals when they stand up. 
Furthermore, we previously reported that rapid prototyping allow us to adjust the 
mechanical properties of SPCL scaffolds [10]. In this sense, the higher mechanical 
strength required in case of implantation in bigger animal models or in humans can be 
achieved. The mechanical properties of the SPCL scaffolds are also strongly linked to 
polymers degradation rate. Previous studies showed that SPCL present a slow 
degradation rate [27] and here we observed that they allow bone ingrowth; so, it is 
expectable that the vertebral bone is completely repaired after total reabsorption of the 
scaffold by the human body in order to avoid catastrophic failure. However, studies 
with longer implantation periods are still needed. 
The results from rotarod revealed that motor coordination and balance are partially 
improved. To perform this test the rats had to walk over a constant moving rod in a 
coordinated way or they fall off the drum. The results showed that animals with the 
spine stabilized by the scaffolds, unlike the non-stabilized animals, were able to perform 
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a coordinated motor behavior at 4rpm. However, when the difficulty of the task 
increased to 8 and 12 rpm, all of the animals were not able to adequately perform the 
test. These results support the fact that stabilization provided by the implanted scaffold 
improves the motor function of SCI animals.  Both the lack of coordination in more 
demanding tasks and the BBB score (just 7) corroborate the fact that spine stabilization 
should be combined with other strategies to promote nervous tissue repair. 
The results presented here can be explained by the fact that the stabilization of the cord 
prevented further tissue damage derived from animal movements. Unlike humans, most 
SCI animal models perform body movements a few minutes after the surgery. However, 
these animals suffered a laminectomy which will provoke trunk instability and most of 
the times, trunk torsion. In this sense, prevention of vertebral column instability will 
avoid further mechanical impacts between bone and spinal cord. Moreover, SPCL 
scaffolds were implanted in the open wound, establishing a connection to the adjacent 
vertebral bone and decreasing the infiltration of connective tissue, as it was possible to 
observe by histological analyses. Thus, it is most likely that the conjugation of spine 
stabilization and reduction of connective tissue infiltration provided by SPCL scaffolds 
protects the spinal cord, leading to the decrease in cell death and a smaller amount of 
vacuolated neurons observed in the spinal cord tissue of the stabilized rats. 
The locomotor behavior improvements herein described may be explained by 
spontaneous neural plasticity after SCI. Previous studies demonstrated central nervous 
tissue is able to undergo anatomical rearrangement after a SCI. For instance, Weidner 
and colleagues [28] verified that transection of the dorsally projecting corticospinal tract 
(CST) led to spontaneous sprouting of the ventral CST projection. Moreover, this 
plasticity was responsible for motor improvements in the forelimb. Additionally, 
Bareyre and co-workers [29] demonstrated that some of the transected CST axons that 
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would normally innervate lumbar segments sprouted into the cervical cord to innervate 
propriospinal neurons. This led to a novel, indirect motor pathway to lumbar motor 
circuits, which was responsible for motor recovery. In this sense, the protection against 
further damage to both damage and intact fibers that the scaffold is able to provide after 
the SCI, seems to create a more suitable environment for plasticity to take place. 
These results show a correlation between spine stabilization and motor recovery in SCI 
rats. However, after an overview of the literature, it was almost impossible to find 
references to spine stabilization after a SCI in rat/mouse animal models. With exception 
of the Tator lab, that use a metallic device [30], researchers rarely have tried to mimic 
the standard clinical practice after SCI. An interesting attempt to improve scaffold 
alignment after implantation in the spinal cord revealed that spine stabilization (using 
steel wires) prevents scoliosis and reduces kyphosis in SCI rats [31]. Unfortunately, the 
authors did not assess motor recovery by the BBB test; nonetheless, this study 
reinforces our conception that the absence of spine stabilization may jeopardize the 
regenerative process. In this sense, current and future attempts to develop a successful 
treatment for SCI [32] might have to take into account this process. It is important to 
refer that the choice of the biomaterial and 3D architecture of the stabilization device 
might be crucial, as the results herein reported suggest that a device which prevents 
surrounding connective tissue infiltration into the spinal cord and allows the vertebral 
bone to regenerate contributes to nervous tissue reorganization. Other tissue engineering 
approaches to promote spine regeneration are mainly focused on intervertebral disc 
regeneration [33]. However, Dong and coworkers [34] demonstrated that laminae of the 
vertebral arch can be successfully reconstructed using collagen scaffolds and bone 
marrow stromal cells. In a SCI situation, collagen scaffolds would have to be combined 
with metallic devices to promote spine stabilization, given that, collagen present weak 
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mechanical properties. In any case, this is an interesting work showing that tissue 
engineering can successfully regenerate vertebral bone.    
The hemisection model here employed preserve the integrity and function of one side of 
the cord which usually is sufficient to maintain bladder and bowel function resulting in 
less post-operative care and reduced animal death. Nonetheless, in future studies it will 
be important to analyze the benefits of spine stabilization in other models, namely the 
contusion model which reveal features similar to those seen in the clinical context. 
Moreover, future studies may also be focused on the use of mathematical models of 
human spine in order to study the applicability of SPCL scaffolds in patients. The finite 
element model (FEM) is the most common spine model and its incorporate realistic 
geometry of the vertebrae and physical properties of the soft tissue connecting the 
vertebrae [35]. With FEM it is possible to study kinematics (intervertebral motions), 
kinetics (motions in response to applied loads), and internal strains and stresses of the 
human spine [35]. In this sense, it would be possible to study the response of the SPCL 
scaffolds to mechanical stresses usually found in the human body. Additionally, the 
spine model may be combined with a SCI mathematical model, as the one described by 
Russell and colleagues [36], in order to further understand the neuroprotective effect of 
SPCL stabilization in a SCI situation.    
In conclusion, in this work we present a biodegradable scaffold specifically designed for 
spine stabilization of SCI in the rat that can also provide support for bone ingrowth. 
More importantly, we also revealed that stabilization by SPCL scaffolds leads to an 
improvement of the motor skills of affected animals. Therefore, researchers currently 
testing treatments for SCI repair might have to take into account the use of spine 
stabilization in combination with their approaches. Further work will be focused on the 
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combination of spine stabilization and regeneration comprising SPCL scaffolds in 
combination with a hydrogel loaded with cells for SCI repair. 
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Chapter V. 
 
Interactions Between Schwann and Olfactory Ensheathing Cells with a 
Starch/Polycaprolactone Scaffold aimed at Spinal Cord Injury Repair* 
 
Abstract 
Spinal cord injury (SCI) represents a major world health problem. Therefore it is urgent 
to develop novel strategies that can specifically target it. We have previously shown that 
the implantation of starch-based scaffolds (SPCL) aimed for spine stabilization on SCI 
animals leads to motor skills improvements. Therefore, we hypothesize that the 
combination of these scaffolds with relevant cell populations for SCI repair will, most 
likely, lead to further improvements. Therefore, in this work, the ability of SPCL 
scaffolds to support the 3D culture of olfactory ensheathing cells (OECs) and Schwann 
cells (SCs) was studied and characterized. The results demonstrate for the first time that 
SPCL scaffolds were able to support the growth and migration of olfactory ensheathing 
cells (OECs) and Schwann cells. Moreover, the results indicate that two weeks of in 
vitro culture is the ideal time to reach a high number of transplantable cells. Future 
work will focus on the spine stabilization of SCI animals using SPCL scaffolds loaded 
with OECs or SCs for SCI regeneration. 
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*These chapter is based on the following publication: 
Silva NA, Sousa RA, Oliveira AO, Sousa N, Salgado AJ, Reis RL, Interactions 
Between Schwann and Olfactory Ensheathing Cells with a Starch/Polycaprolactone 
Scaffold aimed at Spinal Cord Injury Repair, J Biomed Mater Res Part A 
2012:100A:470–476. 
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1. Introduction 
Motivated by the physical consequences of the World War II, the era of cell 
transplantation began with the landmark work of Georges Mathé which transplanted 
bone marrow to six persons exposed to high doses of radiation [1]. More than sixty 
years later the hematopoietic stem cell transplantation still is the only one used in 
clinical practice. Nevertheless, cell transplantation approaches are, since then, being 
extensively investigated for a wide range of diseases/injuries. In the particular case of 
spinal cord injuries, a condition that affect millions all over the world [2], two kinds of 
transplanted cells gain ground when compared to the others. Olfactory Ensheathing 
Cells (OECs), obtained from olfactory bulbs or nasal mucosa, and Schwann Cells (SCs), 
found in the peripheral nervous system, have shown to promote neuronal repair, 
remyelination and functional recovery after transplantation into the spinal cord [3-7]. 
Both cell types are known to express similar molecular markers, such as p75 and S100 
and to display a similar morphological phenotype in culture.[8, 9] However, contrasting 
with SCs, which are largely involved in myelination and repair of peripheral nerve 
fibers, the OECs are known to provide support and guidance to the growth of newly 
formed axons from the olfactory mucosa to the olfactory bulbs. Moreover, they are also 
known to be able migrate through the glial scar [10].  
Recent modest results of clinical trials [11, 12] emphasize the need of further studies to 
understand the mechanism of action and transplantation of these cells. One of the 
problems associated with cell transplantation therapies is cell survival in vivo, since 
extensive cell death is usually observed after transplants [13, 14]. This fact is mainly 
related with the lack of matrix support of transplanted cells, as well as the inflammation 
in the local of injury [15]. For these reasons we propose the delivery of cells within a 
scaffold that is not implanted directly in the injury site, thus avoiding the cell death by 
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the lack of matrix support and decreasing the effects of inflammation on the fate of 
transplanted cells. Hence, within this work, we tested the ability of a previous 
developed and characterized natural starch-based scaffold (SPCL, starch poly-ε-
caprolactone) [16] to support the 3D culture of OECs and SCs. We have previously 
shown significant motor recovery in SCI animals due the spine stabilization by using 
the above referred scaffolds [17]. Moreover, it was previously demonstrated that OECs 
and SCs are able to secrete neurotrophic factors such as nerve growth factor, brain-
derived neurotrophic factor and glia cell line-derived neurotrophic factor [18, 19].  
Additionally, the secretome of these two cells has previously shown to have a positive 
effect on axonal growth both in vitro [20-22] and in vivo[23-25]. Therefore the presence 
of these cells on the areas of the scaffold which face the spinal cord, will allow a 
localized deliver of neurotrophic factors to the injured area, fostering regeneration to 
occur. In this sense, combining the secretome effects of OECs and SCs with the 
previously observed beneficial effects of spine stabilization provided by the SPCL 
scaffolds implantation may lead to further locomotory recovery. 
To do so, we first need to figure out if it is possible to culture OECs and SCs on the 
SPCL scaffolds. Therefore, in the present report we assessed the proliferation, metabolic 
activity, adhesion, morphology and distribution of primary OECs and SCs when 
cultured in a 3D fashion on SPCL scaffolds. The results revealed that SPCL scaffolds 
were able to support the growth and migration of both OECs and SCs. Moreover, we 
determined that two weeks of in vitro pre-incubation is the ideal time to achieve a 
higher number of cells on these scaffolds. 
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2. Materials & Methods 
2.1. Semi tubular SPCL scaffolds development  
The SPCL scaffolds were developed as previously reported by Silva et al. [16]. Briefly, 
porous sheets featuring inter filament orientations of 90º were produced by 3D plotting, 
a rapid prototyping technology (Bioplotter®, Envisiontec GmbH). Tubular scaffolds 
were obtained by rolling up porous sheets around a cylinder and subsequent heat 
treatment at 65º C during 30 min for inducing the adhesion between filaments. Two 
different porous tubular scaffold designs were obtained featuring a single or double 
layer, further referred as 90/1 and 90/2 for structures with one or two layers, 
respectively. After being processed and in order to acquire semi tubular form, the 
tubular scaffolds were cut in the middle with the aid of a blade. 
 
2.2. Scanning Electron Microscope Analyses 
Scanning electron microscopy (SEM) was used for analysis of morphology of the 
different SPCL tubular scaffolds. For this purpose, all samples were coated with Au/Pd 
via ion-sputtering prior to observation in a Stereoscan 360 scanning electron microscope 
(Leica Cambridge Co., Cambridge, United Kingdom). 
 
2.3. Cell Culture 
2.3.1. Isolation and culture of Olfactory Ensheathing Cells 
OECs were harvested from olfactory bulbs of 4-days-old Wistar rats, according to the 
protocol described by Ramon-Cuéto et al. [26]. Briefly, upon dissection all meninges 
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were removed and the tissue was digested with 0,125% Collagenase (Sigma) for 20h at 
37 ºC. The digested tissue was mechanically dissociated with a pipette and then filtrated 
through a 70 µm cell strainer (BD Falcon). After centrifugation at 1000rpm for 10 min, 
cells were resuspended and plated in uncoated plates for 18h. A posterior change to 
uncoated plates for 36h was made, as it is expected that most of the fibroblasts and 
astrocytes will attach in the first and second period, respectively. Finally, cell 
suspensions were transferred to poly-D-lysine treaded flasks and cultured in 
DMEM/F12 (Gibco) with 10% of FBS (Gibco) and 1% of antibiotic-antimycotic 
solution (Sigma) at 37 ºC and 5% CO2 (v/v). OECs were then enriched by the 
supplementation with Bovine Pituitary Extract (5µg/ml, Gibco) and Forskolin (2µg/ml, 
Sigma). Cells were seeded into the scaffolds at passage 2, being that no trypsin was 
used and cells were detached using a cell scrapper. 
 
2.3.2. Isolation and culture of Schwann Cells 
SCs were obtained from sciatic nerves of 4-weeks-old male Wistar rats, according to the 
protocol described by Mauritz et al. [27]. Upon dissection, sciatic nerves were cut into 3 
fragments each and incubated in DMEM-F-12 (Gibco no.11320-074), with 10% Fetal 
Bovine Serum (FBS, Gibco 10106-169), 1% Penicillin-Streptomycin antibiotic (Pen-
Strep, Gibco no.15140-148), Forskolin (2µg/ml, Sigma) and Bovine Pituitary Extract 
(5µg/ml, Gibco).  Following 7 days of incubation at 37ºC and 5% CO2, the nerve 
fragments were enzymatically dissociated with Collagenase solution (320U/ml) (Sigma 
no.C0130-1G) containing 5U/ml of DNase (Worthington Lot 51M5139) for 20 hours. 
After mechanical dissociation, the collagenase was removed by repeated 
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centrifugations. Cells were then allowed to grow in Poly-D-Lysine coated flasks. As for 
OECs, SCs were also seeded into the scaffolds at passage 2. 
 
2.4. Immunocytochemistry 
Immunostaining was performed as follows. SC or OEC-covered cover-slips were fixed 
in 4% paraformaldehyde for 20 min and then washed with PBS. After cell blocking by 
treating them with 10% of FCS in PBS (Gibco) for 1 h, Rabbit anti-S100 primary 
antibody (Invitrogen) was incubated for 1h. After washing with PBS cells were exposed 
to the secondary antibody Alexa Fluor 488 rabbit anti-rat IgG (Molecular Probes) for 1 
h. Finally, cell nuclei were counterstained with DAPI (1µg/ml, ThermoScientific) for 5 
min and washed with PBS. Primary antibody was omitted to produce negative controls. 
Samples were observed under an Olympus BX-61 Fluorescence Microscope (Olympus). 
 
2.5. Seeding of OECs or SCs on SPCL scaffolds 
To ensure adherence of cells, SPCL scaffolds were coated with poly-L-lysine before 
cell seeding. Cells were centrifuged at 1200 rpm for 5 min and then resuspended in a 
small volume of medium to yield a solution with a density of 5x10
4
 cell/10µl. 
Subsequently, scaffolds were transferred to empty wells and 10µl of cell suspension 
were dropped on the top of the inner lumen of the semi tubular scaffolds. After an 
incubation of 2 h in a humidified atmosphere at 37 ºC and 5% CO2, SPCL scaffolds 
were transferred to new wells containing complete medium (for composition details 
refer to OECs or SCs cell culture section) and incubated for 2, 7, 14 and 21 days for the 
in vitro assays. 
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2.6. Proliferation Evaluation 
In the time points mentioned above, proliferation, through double-stranded DNA 
quantification, was assessed. The fluorescent dye Picogreen was used to acquire the 
total amount of dsDNA [28]. Briefly, after cell lysis by osmotic and thermal shock three 
components of QuantiT
TM
 PicoGreen dsDNA Assay Kit (Invitrogen), Tris-HCl-EDTA 
(50%), Picogreen dye (35,45%) and cell lysated (16,35%), were mixed in an opaque  96 
well plate. The fluorescent intensity, proportional to the amount of dsDNA, was 
measured at an excitation wavelength of 485/20 nm and at an emission wavelength of 
528/20 nm, in a microplate reader (Bio-Tek). The dsDNA concentration for triplicates 
of each sample (n=3) was calculated using a standard curve relating quantity of dsDNA 
and fluorescence intensity. 
 
2.7. Metabolic Activity Assay 
Cell viability was measured using the CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (Promega). This assay is based on the bioreduction of a tetrazolium 
compound (MTS), into a water-soluble brown formazan product. This conversion is 
accomplished by NADPH or NADH production by the dehydrogenase enzymes in 
metabolically active cells. Complete culture medium was replaced by standard 
DMEM/F12 medium containing MTS in a 5:1 ratio and incubated in a humidified 
atmosphere at 37 ºC and 5% CO2. After 3h of incubation, the optic density for 
triplicates of each sample (n=3) was measured at 490 nm in a microplate reader. 
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2.8. Assessment of cell adhesion, morphology and distribution 
At each defined time culture period, the SPCL scaffolds were fixed with 4% of 
paraformaldehyde for 30 min at room temperature. Then, 0.1µg/ml of Phalloidin 
(Sigma) was added to the cells during 30 min. After washing 3 times with PBS, cell 
nuclei were counterstained with DAPI (1µg/ml, ThermoScientific) for 5 min. The SPCL 
scaffolds were then observed by confocal microscopy (Olympus). 
2.9. Statistical analysis  
To assess the statistical differences on metabolic activity and proliferation of OECs and 
SCs it was performed a ‘two way ANOVA’ test followed by a Bonferroni post-test. 
Statistical significance was defined for p<0.05. 
 
3. Results and discussion 
Ensure cell survival in vivo is one of the problems associated with cell transplantation 
therapies, since extensive cell death is usually observed after transplants [13]. The lack 
of matrix support, ischemia and local inflammation are some of the factors related with 
poor cell survival after cell based therapies [15]. Typical cells preparations for injection 
imply enzymatic digestion of the matrix. When cells that normally grow in attachment 
are kept in suspension, a pathway of cell death called anoikis is initiated [29]. Anoikis, a 
greek word for homelessness, is described in cell biology as programmed cell death 
generated by loss of matrix attachments [30]. In addition, it is well known that after SCI 
ischemia and inflammation occur [31]. These two events generate oxygen free radicals 
and inflammatory cytokines that can directly damage graft cells via cell membrane 
damage or trigger signaling pathways that result in caspase activation and cell death 
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[15]. In order to cell-based regenerative medicine approaches become a successful 
therapy, these issues should be addressed. Okano et al.[32, 33], proposed the use of cell 
sheets, avoiding in this way the loss of cell matrix support. Others targeted specific 
molecular pathways aimed at cell death blockage [34]. We consider that the delivery of 
cells, with a trophic ability, within a scaffold that is not implanted directly in the injury 
will avoid the cell death by anoikis and decrease the effects of inflammation on the fate 
of transplanted cells. 
We have recently shown that the spine stabilization by SPCL scaffolds implanted in the 
vertebral column of SCI rats lead to significant improvements [17]. However, the spine 
stabilization alone will not successfully treat the injured animals, and therefore further 
actions are needed to repair the spinal cord. Thus, in this work we investigated the 
ability of SPCL scaffolds to support cells aimed for SCI repair. In this way the scaffolds 
will act as a stabilization device and at same time will allow a localized deliver of 
neurotrophic factors to the injured spinal cord produce by the OECs or SCs. 
 
3.1. 3D culture of OECs on SCPL scaffolds 
OECs and SCs were analyzed, prior seeding on SPCL scaffolds, by 
immunocytochemistry against S100 receptor (Figure 1a and 1b). Subsequently, cells 
were seeded in the inner core of SPCL scaffolds with one layer (90/1, Figure 1c) or two 
layers (90/2, Figure 1d). Cell adhesion, migration, proliferation and metabolic activity 
were assessed 2, 7, 14 and 21 days after the seeding. 
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Figure V.1. Cells and scaffolds before the 3D cultured.  The presence 
of OECs (a) and SCs (b) after cell isolation was confirmed by 
immunocytochemistry against S-100 protein (green) and nuclei 
counterstained with DAPI (blue).  OECs and SCs were then seeded on 
the inner core of single (c) or double (d) layer SPCL scaffolds. 
 
The quantification of dsDNA revealed a significant increase of cell proliferation from 
day 2 to day 21, both on single and double layer SPCL scaffolds (Figure 2a). 
Furthermore, only at the second day of culture, the quantity of OECs on single layer 
scaffolds is significantly higher than in double layer scaffolds, demonstrating a more 
efficient cell seeding on 90/1 scaffolds. Interesting, either for 90/1 and 90/2 scaffolds, 
the quantity of dsDNA did not increase from day 2 to 1 week in culture, which indicates 
that these cells need a time to adapt to the new 3D surface. Moreover, cells cultured on 
single layer scaffolds did not presented significant cell proliferation between 2 and 3 
weeks. On the contrary on 90/2 scaffolds dsDNA significant increases between 2 and 3 
weeks were observed. These differences can be explained by the lower porosity of the 
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90/2 scaffolds. We have previously reported differences in the porosity of single and 
double layer scaffolds, being 90/2 scaffolds 15% less porous than the 90/1 ones [16]. So 
that in this condition the cells need more time to reach the confluence. The dsDNA 
quantification results are in concordance with the measured metabolic activity of OECs 
(Figure 2b), which from day 2 to day 21 increased significantly on both types of 
scaffolds. Moreover and up to 14 days in culture, OECs seeded on 90/1 scaffolds 
showed a statistically higher metabolic activity than the ones seeded in 90/2 scaffolds. 
As referred before the cell seeding was more efficient on these scaffolds than on the 
90/2 ones, a fact that is closely related with these observations, as the initial cell 
densities would be necessarily different in both. Then, again, the metabolic activity is 
significantly different between 2 and 3 weeks for double layer scaffolds but not for 
single layer.  
The assessment of migration, adhesion and morphology of OECs by confocal 
microscopy showed a low efficiency on cell seeding (Figure 2c and 2d, 48h). However, 
over time the OECs successfully colonized the entire SPCL fibers, showing that these 
cells are capable to migrate and grow in a 3D manner on SPCL scaffolds (Figure 2c and 
2d). Moreover, after 2 weeks it was possible to observe the typical spindle-shaped 
morphology of OECs, which confirmed how well adapted the cells were. Finally, it is 
possible to confirm that in 90/1 scaffolds cells were confluent at 2 weeks, but for 90/2 
the confluence was only reached at 3 weeks. All of the tests indicated that OECs culture 
on SPCL scaffolds with one or two layers should be implanted in animals after 2 or 3 
weeks of in vitro culture. 
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Figure V.2. 3D cell culture of OECs on SPCL scaffolds. A significant (p<0,05) overall 
increase over time was observed either for (a) dsDNA quantification or (b) MTS test.  
Cellular adhesion, distribution and morphology were assessed by cytoplasmic staining 
with phalloidin (red) and nuclei counterstained with DAPI (blue), followed by confocal 
observation. Despite of a low efficient cell seeding (48h), OECs were able to migrate 
and colonize all fibers of both single (c) and double (d) layer SPCL scaffold. Values are 
shown as mean ± SEM (n=3). 
 
3.2. 3D culture of SCs on SCPL scaffolds 
Contrasting with OECs, SCs adapted faster on the rigid 90/2 scaffold than in the more 
porous 90/1 scaffold. dsDNA quantification test revealed that as OECs, the SCs also 
significantly increased the number of cells from day 2 to day 21 in both types of 
scaffolds (Figure 3a). Again, as happened with OECs, the SCs also took around one 
week to adapt to the new surface, since no significant differences were detected between 
2 days and 1 week of culture. However, and in contrast to OECs, the quantity of dsDNA 
on SCs culture is always higher in the double layer scaffolds, showing that these cells 
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were better adapted to 90/2 scaffolds. Interestingly, cell proliferation stops at 2 weeks 
for both types of scaffolds, indicating that the implantation of SPCL scaffolds with SCs 
should be done after around 2 weeks of in vitro culture. By analyzing the metabolic 
activity of SCs cultured on SPCL scaffolds (Figure 3b) it was possible to confirm that 
the cells took around one week to be adapted to the scaffold (no differences between 2 
days and 1 week). No differences were found between weeks 2 and 3, reinforcing the 
idea that these cells should only be cultured on the scaffolds for periods up to two 
weeks before transplantation. It is surprising, though, the absence of significant 
differences between the one and two layers scaffolds; in other words it seems that 
despite the lower number of cells in the one layer scaffolds, they were more 
metabolically active than the cells from two layers, a difference that may be due to the 
higher porosity of the one layer scaffolds. 
The assessment of migration, adhesion and morphology of SCs by confocal microscopy 
showed a low efficient cell seeding, particular for single layer scaffolds (Figure 3c, 
48h). However, over time the SCs, as happened with OECs, also successfully colonized 
the entire SPCL fibers (Figure 3c and 3d), showing that these cells are capable to 
migrate and grow in a 3D manner on SPCL scaffolds. Finally, it was possible to confirm 
that cells reached the confluence at 2 weeks either in 90/1 and 90/2 scaffolds, and there 
was a decrease in cell number at 3 weeks. All of the tests indicated that SCs culture on 
SPCL scaffolds with one or two layers should be implanted in animals after 2 weeks of 
in vitro culture. 
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Figure V.3. 3D cell culture of SCs on SPCL scaffolds. Both (a) cell proliferation and 
(b) metabolic activity analyses revealed a significant (p<0,05) overall increase over 
time. Confocal observation after cytoplasmic staining with phalloidin (red) and nuclei 
counterstained with DAPI (blue),  revealed low efficient cell seeding (48h) particular 
for single layer scaffolds(c) than for double layer (d).  Over time, as happened with 
OECs, SCs were also able to migrate and colonize all fibers of both SPCL scaffolds. 
Values are shown as mean ± SEM (n=3). 
 
The results presented in this work show that OECs and SCs can successfully grow and 
fully colonize both single and double SPCL scaffolds. In fact, in both cases there are 
some inconsistencies between the dsDNA assay and the metabolic activity of the cells. 
However, it is important to notice that as previously described by Hutmacher et al. [35] 
the quantification of metabolic activity in three dimensions cultures by MTS test cannot 
be directly compared with proliferations assays, such as the dsDNA assays. Actually, 
while the latter are based on the Picogreen assay, which is a sensitive test that can be 
correlated with proliferation of cells with time, MTS relies only in the capability of cells 
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to metabolize MTS into a formazan salt, measuring the metabolic viability. This 
metabolic viability cannot be directly compared to cell proliferation as the cells own 
basal metabolism may be altered due to different parameters (such as: porosity, oxygen 
and nutrients availability, nature of the substrate where they are growing, etc.) that may 
or, may not, affect cell proliferation. Thus it is possible to obtain different trends for 
both assays, which do not necessarily invalidate the results obtained from them, as they 
do measure different parameters when cells are growing in 3D scaffolds. In this sense, 
the results presented in our work show, for OECs, that after 3 weeks of culturing the use 
of 90/1 or 90/2 scaffolds will not significantly affect the number of the transplanted 
cells. However, for SCs the amount of dsDNA is always significantly higher in the 90/2 
scaffolds than in 90/1 ones. This means that for these cells it would be better to use the 
90/2 scaffolds for implantation.  Concerning the metabolic activity, the results show 
some differences in the initial time points analyzed, and the cells reach the maximum 
activity after 2/3 weeks of culture. Only in the last time points it is possible to obtain 
similar results in the metabolic activity assay between single and double layers 
scaffolds. However, it is important to notice that the key time points for transplantation 
presented here can only be used for these scaffolds, since, most likely cells will respond 
in different ways to different polymers. Nonetheless, as happened with the starch-based 
scaffolds presented in this work, several others studies had shown either for OECs or 
SCs that these cells also need an initial time to adapt to scaffolds made from different 
origins [36-39]. However, other studies, in which scaffolds were seeded with cells and 
implanted in animals just after a short pre-incubation in vitro of 1-2 days suggest the 
opposite [40-42]. Nevertheless, it seems reasonable that the study of how cells behave 
on scaffolds should be performed at longer time points before the in vivo implantation, 
since the implantation of a scaffold with a higher number of cells will most likely result 
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in a higher number of cell survival and in this way, increase the cells’ related effects on 
the implanted tissue. 
 
4. Conclusions 
Within the present work it was possible to demonstrate for the first time that a starch-
based scaffold was able to support the growth and migration of OECs and SCs. 
Moreover we demonstrated the importance of studying the long time in vitro incubation 
periods on the number of cells that could be transplanted within the scaffold. For the 
structures here in studied, we demonstrated that two weeks of culture is the ideal time to 
reach a high number of transplantable cells. Further work will focus on the spine 
stabilization of SCI animals using SPCL scaffolds loaded with OECs, SCs or a 
combination of both. 
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Chapter VI. 
 
The Effects of Peptide Modified Gellan Gum and Olfactory Ensheathing Glial Cells on 
Neural Stem/Progenitor Cell Fate.* 
 
Abstract 
The regenerative capacity of injured adult central nervous system (CNS) tissue is very 
limited. Specifically, traumatic spinal cord injury (SCI) leads to permanent loss of 
motor and sensory functions below the site of injury, as well as other detrimental 
complications. A potential regenerative strategy is stem cell transplantation; however, 
cell survival is typically less than 1%. To improve cell survival, stem cells can be 
delivered in a biomaterial matrix that provides an environment conducive to survival 
after transplantation.  One major challenge in this approach is to define the biomaterial 
and cell strategies in vitro. To this end, we investigated both peptide-modification of 
gellan gum and olfactory ensheathing cells (OECs) on neural stem/progenitor cell 
(NSPC) fate.  To enhance cell adhesion, the gellan gum (GG) was modified using Diels-
Alder click chemistry with a fibronectin-derived synthetic peptide (GRGDS).  Amino 
acid analysis demonstrated that approximately 300 nmol of GRGDS was immobilized 
to each mg of GG.  The GG-GRGDS had a profound effect on NSPC morphology and 
proliferation, distinct from that of NSPCs in GG alone, demonstrating the importance of 
GRGDS for cell-GG interaction. To further enhance NSPC survival and outgrowth, they 
were cultured with OECs. Here NSPCs interacted extensively with OECs, 
demonstrating significantly greater survival and proliferation relative to monocultures 
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of NSPCs.  These results suggest that this co-culture strategy of NSPCs with OECs may 
have therapeutic benefit for SCI repair. 
 
 
*These chapter is based on the following publication: 
Silva NA, Tam RY, Cooke MJ, Sousa N, Salgado AJ, Reis RL and Shoichet MS, 2012, 
The Effects of Peptide Modified Gellan Gum and Olfactory Ensheathing Glia Cells on 
Neural Stem/Progenitor Cell Fate, Biomaterials 33:1345-1354. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI. The Effects of Peptide Modified Gellan Gum and Olfactory Ensheathing Glia Cells on Neural Stem/Progenitor Cell 
Fate 
239 
1. Introduction 
 
Traumatic spinal cord injury (SCI) usually leads to significant neurological deficits 
and disabilities that result in loss of sensory and motor function, termed paraplegia or 
tetraplegia depending on the site of injury. This can subsequently result in other related 
problems such as infections of the bladder and kidneys and dysfunction of the bowel, as 
well as heart and respiratory system. All of these problems have a negative effect on the 
physiological, psychological and social behavior of SCI patients. Current clinical 
approaches are limited and mainly based on the use of anti-inflammatory agents, such as 
methylprednisolone [1]; however, its use is controversial as recent studies failed to 
reveal conclusive beneficial outcomes [2].  Some of the other strategies that have been 
tested clinically include: minocycline [3], anti-NogoA [4] and transplantation of 
oligodendrocyte precursor cells [5].  The latter trial was recently cancelled, underlying 
the urgent need to develop therapeutic strategies that can promote regeneration after 
SCI.  
One approach currently under investigation for regeneration following SCI is the 
transplantation of cells into the spinal cord. Several groups have reported that the 
injection of cells, such as olfactory ensheathing cells (OECs) [6, 7], neural 
stem/progenitor cells (NSPCs) [8] or mesenchymal stem cells [9, 10], leads to motor 
improvements and/or tissue repair in SCI animal models. OECs are compelling because 
they support and guide olfactory axons [11], are able to grow through the glial scar [12] 
and secrete several neurotrophic factors [13]. NSPCs transplants have shown some 
functional repair, taking advantage of their ability to differentiate to neurons, 
oligodendrocytes and astrocytes [14]. However, to date no single repair strategy has 
successfully induced full functional recovery following SCI.  Extensive cell death of the 
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transplanted cells after injection, due to inflammation and/or the absence of matrix 
support [15, 16], has limited the therapeutic benefit. To enhance cell survival, we 
investigated the co-delivery of two cell types in an engineered matrix where the second 
cell type provides trophic support and the matrix contributes to overcoming cell death 
through anoikis [17].  
Biomaterials have been designed as vehicles for cell transplantation in order to 
enhance cell survival after transplantation. Hydrogels are particularly appealing for soft 
tissue applications because they can be designed to match the mechanical properties and 
water content of these tissues. For example, delivering NSPCs in chitosan tubular 
scaffolds demonstrated NSPC survival and promising results for tissue and functional 
repair [8].  The gellan gum hydrogel is compelling because it can be injected in a 
minimally-invasive way to form a gel in situ. Gellan gum (GG) is a linear anionic 
microbial polysaccharide composed of repeating units of glucose, glucuronic acid and 
rhamnose [18] and thus has multiple hydroxyl groups available for chemical 
modification. It has been studied for drug delivery and cartilage regeneration [19-21] 
and is approved by the FDA as a food additive. 
In order to better mimic the extracellular matrix (ECM), biomaterials have been 
modified with several peptide sequences [22-24] to influence biological processes, such 
as cell adhesion, growth and development [25, 26]. Cells transplanted in a material that 
mimics both the mechanical and chemical properties of native tissue have been shown 
to be more efficacious after  transplantation [27, 28]. 
Here we aim to synthesize GG with enhanced cell-ECM and cell-cell interactions for 
ultimate use in cell transplantation.  To promote cell survival and interaction with gellan 
gum, we chemically conjugated the fibronectin-derived peptide sequence GRGDS via 
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Diels-Alder click chemistry and studied the impact of GRGDS-modified gellan gum 
(GG-GRGDS) on cell fate.  To enhance cell survival beyond that provided by the ECM-
mimetic peptide sequence, cell-cell interactions are investigated. Since OECs have been 
shown to provide guidance pathways to axons and NSPCs have been shown to promote 
some functional recovery, we investigated the co-culture of these two cell types to 
determine whether the OEC affected NSPC survival and/or differentiation.  To gain a 
greater appreciation of the OEC-NSPC interaction, the two cell types were cultured in 
direct contact, in a transwell system or in the GG-GRGDS. Importantly, both OECs and 
NSPCs can be isolated from human patients [29, 30], which enhances the eventual 
feasibility of this therapeutic strategy for SCI. 
 
2. Materials and Methods 
 
2.1. Synthesis of furan-modified gellan gum hydrogel 
 
Gellan gum (Sigma, USA) was first dissolved in 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer (100 mM, pH 5.5) at 37 ºC. 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM, Sigma, USA)  and furfurylamine (Furan, 
Acros Organics, Belgium) were then added in a 4:1 molar ratio (relative to the –COOH 
groups in gellan gum) and stirred at 37 ºC for 48 hours. The solution was then dialyzed 
(Mw cutoff 12-14kDaltons, Spectrum Labs, USA) alternately against distilled water and 
PBS (0.1M and pH 7.2) for 5 days. Finally, water was removed by lyophilization to 
obtain furan-modified gellan gum (furan-GG) as a white powder. 
1
H-NMR spectra were 
used to analyze the degree of furan substitution.  
1
H-NMR was recorded in D2O on a 
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Varian Mercury-400 MHz NMR spectrometer (Palo Alto, USA). As a negative control, 
GG was incubated with furan in the absence of DMTMM. 
 
2.2. Synthesis of maleimide-modified GRGDS peptide 
Maleimide-modified GRGDS (mal-GRGDS) peptide was prepared by linear solid-phase 
synthesis (SPS) using standard Fmoc chemistry [31]. Fmoc-serine Wang resin 
(Anaspect, USA) with a loading capacity of 0.48 mmol/g was swollen in DMF (Sigma, 
USA) for 30 minutes. The solution was then drained and 20% of piperidine (Caledon, 
Canada) in DMF was added. After 30 minutes of incubation the resin was washed with 
DMF and tested for free amines using 1 % trinitrobenzene sulfonate, TNBS (TCI 
America, USA), in DMF. The first building block (Fmoc-asp-OH, 3.0 equivalents, all 
amino acids are from NovaBiochem, Germany) was pre-mixed with 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate, HCTU (3.0 
equivalents, Anaspect, USA) in DMF for 15 min, then transferred to the SPS flask. 
Diisopropylethylamine, DIPEA (4.0 equivalents, Sigma, USA) in DMF), was then 
added and the flask was stirred for 24 hours. To verify if the coupling reaction had 
reached completion, the TNBS test was performed (negative test outcome). The Fmoc 
deprotection and coupling steps were repeated until 5 amino acid residues (GRGDS) 
were coupled to the resin. To conjugate the maleimide linker to the deprotected N-
terminus of the peptide, 4 equivalents of maleimidopropionic acid (TCI America, USA) 
and 12 equivalents of diisopropylcarbodiimide (Sigma, USA) were pre-mixed in 
dichloromethane (Sigma, USA) for 45 minutes and then added to the SPS flask and 
stirred for 24 hours. The maleimide-modified GRGDS (mal-GRGDS) sequence was 
then cleaved from the resin using 95% trifluoroacetic acid (Caledon, Canada) in water. 
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The peptide was allowed to precipitate in cold diethyl ether for 30 minutes. Then, the 
precipitate was recovered by centrifugation. Finally, the product was purified by HPLC 
(Shimadzu, Japan) in a C18, 250 x 10 mm, 5 um, 100Å column. A mobile phase 
gradient from 5 % to 20 % (Acetonitrile (w/ 0.1 % TFA):ddH2O (w/ 0.1 % TFA)) over 
30 minutes was performed. A 90% yield was obtained and the product was confirmed 
by 
1
H NMR and mass spectrometry (MS). 
 
2.3. Immobilization of mal-GRGDS peptide on furan-GG hydrogel by Diels-Alder 
chemistry 
Immobilization of maleimide-containing GRGDS (mal-GRGDS) to furan-modified 
gellan gum was performed by via Diels-Alder chemistry between the maleimide 
functional group of the peptide with the furan group of the gellan gum. Furan-GG was 
first dissolved in MES buffer (100 mM, pH 5.5) at 4 mg/ml and 37 ºC and then 
incubated with mal-GRGDS in a 1:5 furan-maleimide molar ratio for 48h under 
constant stirring. The solution was then dialyzed (Mw cutoff 12-14kDaltons, Spectrum 
Labs, USA) alternately against distilled water and PBS (0.1M and pH 7.2) for 5 days. 
Finally, the water was removed by lyophilization to obtain GRGDS-modified Gellan 
Gum (GRGDS-GG) as a white powder. The amount of peptide immobilized on the 
hydrogel was calculated by amino acid analysis. In brief, this method involved acid 
hydrolysis of the peptide with 6 N HCl for 24 h, followed by derivatization with 
phenylisothiocyanate (PITC). The derivatized hydrolyzates were then quantified using 
reverse phase HPLC. As a negative control, mal-GRGDS was incubated with 
unmodified gellam gum. 
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2.4. Cell isolation and culture 
Neural stem/progenitors cells were isolated from the subependymal region of the lateral 
ventricles in the forebrain of adult male Wistar rats as previously described [32]. Cells 
were grown in neurobasal medium (Invitrogen, Canada), with 2% of B27 neural 
supplement (Invitrogen), 1% of L-glutamine (Sigma), 1% of penicillin–streptomycin 
(Sigma), 20 ng/ml EGF (recombinant human EGF; Invitrogen), 20 ng/ml bFGF 
(recombinant human bFGF; Invitrogen) and 2 ng/ml heparin (Sigma). Cell number and 
viability were determined with a hemocytometer and the trypan blue exclusion test. 
Dissociated cells were plated in complete media and incubated in a humidified 
atmosphere at 37 ºC with 5% of CO2. Neurospheres were observed within 2–3 weeks, 
after which cells were passaged weekly. 
Olfactory ensheathing cells were isolated from adult male Wistar rats as previously 
described [33]. Briefly, upon the olfactory bulb dissection all meninges were removed 
and the tissue was digested with 0,125% Collagenase (Sigma) for 20 min at 37 ºC. The 
digested tissue was mechanically dissociated with a pipette and then filtrated through a 
70 µm cell strainer (BD Falcon, USA). After centrifugation at 1000rpm for 10 min, cells 
were resuspended and plated in uncoated plates for 18h. A posterior change to new 
uncoated plates for 36h was made, as it is expected that most of the fibroblasts and 
astrocytes will attach in the first and second period, respectively. Finally, the cell 
suspensions were transferred to fibronectin treaded flasks (overnight coated with 
1µg/ml fibronectin solution, Sigma, USA) and cultured in DMEM/F12 (Gibco) with 
10% of FBS (Gibco) and 1% of antibiotic-antimycotic solution (Sigma) at 37 ºC and 5% 
CO2. OECs were enriched by the supplementation with Bovine Pituitary Extract 
(5µg/ml, Gibco) and Forskolin (2µg/ml, Sigma). 
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2.5. Neural stem/progenitors cells culture on GRGDS-modified gellan gum 
Bioactivity of GRGDS-GG was assessed by the analysis of NSPCs growth, morphology 
and differentiation when cultured on the hydrogel for 2 and 7 days.  NSPCs were 
mechanically dissociated into a single cell suspension and either seeded on the surface 
or encapsulated into GRGDS-GG hydrogel. The cell density was 2 × 10
4
 cells/cm
2
 and 
hydrogels were incubated in a humidified atmosphere at 37 ºC and 5% of CO2. Furan-
modified GG was used as a control. Cell growth and morphology was evaluated 
following phalloidin/DAPI staining and differentiation following immunocytochemistry 
(ICC). Analysis was carried out using a Zeiss Observer Z1 microscope with a 
Yokogawa confocal scan unit; images were captured and processed using Volocity 4.3.2 
software. 
 
2.6. Co-cultures between OECs and NSPCs 
To evaluate the potential synergistic or antagonistic effects between OECs and NSPCs, 
direct and transwell co-culture experiments were performed. OECs (1 × 10
5
 cells/cm
2
) 
and NSPCs (4 × 10
4
 cells/cm
2
), obtained as described in section 2.4, were seeded either 
simultaneously on the same fibronectin coated cover glass or in indirect contact with 
OECs cultured on the fibronectin coated cover glass and NSPCs on the transwell. Cells 
were allowed to grow in complete NSPCs culture medium (see section 2.4) for 24h and 
then cultured in the absence of the growth factors FGF and EGF. In the direct co-culture 
experiment, in order to clearly identify one cell population from another, OECs were 
labeled (according to manufacturer instructions) with a cell tracing reagent (C34554, 
Invitrogen) before seeding. After 7 days of incubation, cell growth and NSPCs 
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differentiation was assessed by ICC. Analysis was performed using an Olympus BX61 
fluorescence microscope. OECs and NSPCs cultured alone were used as controls. 
After these initial experiments, OECs and NSPCs were then encapsulated together in 
the GRGDS-GG hydrogel. Both cells were pre-labeled before encapsulation. A green 
tracer was used for OECs labeling (C34554, Invitrogen) and NSPCs were labeled with a 
far red tracer (C34553, Invitrogen). Both labeling protocols were performed according 
to the manufacturer instructions. Cell interactions and growth were then analyzed by 
confocal analyses after 7 days of culture. 
 
2.7. Immunocytochemistry and phalloidin/DAPI staining 
The following primary antibodies were used for the immunocytochemical studies: 
monoclonal rabbit anti-β-III tubulin (1:500, Chemicon, Canada) for neurons; 
monoclonal mouse anti-GFAP (1:100, Chemicon) for astrocytes; monoclonal mouse 
anti-O4 (1:200, R&D Systems, Canada) for oligodendrocytes; monoclonal mouse anti-
Nestin (1:100, Millipore, USA) for progenitor cells; and polyclonal rabbit anti-p75 
(1:100, Millipore) for OECs. For all immunohistochemical procedures, the appropriate 
controls were obtained by omission of the relevant primary antibody. Cells on the 
substrates were fixed with PBS solution containing 4% paraformaldehyde PFA for 20 
mins (on glass) or 1 h (in the hydrogel) at room temperature and then washed with PBS. 
Next, cell membrane permeation (except for p75 and O4 antibodies) and blocking by 
treating cells with 0.3% Triton X-100 (Sigma, USA) and 10% of FBS solution at room 
temperature for 1 h, each specific primary antibody solution was added for 1h (on glass) 
or 12h (on hydrogel). After washing with 0.5% of FBS in PBS, the samples were 
exposed to the specific secondary antibody (Invitrogen) for 1h (on glass) or 5h (on 
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hydrogel) and then washed with 0.5% FBS. Finally, cell nuclei were counterstained 
with 1 μg/ml DAPI (Invitrogen) for 1h. 
For the phalloidin/DAPI staining, cells were fixed with 4% of PFA for 30 min at room 
temperature and then treated with 0.3% TritonX-100. After washing several times with 
PBS, 0.1µg/ml of phalloidin (Sigma) was added to the cells for 30 min. Finally, cell 
nuclei were counterstained with DAPI (1µg/ml, Invitrogen) for 10 min. 
 
2.8. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, USA).  Differences among groups were assessed by 
two-way ANOVA followed by a Bonferroni post-hoc test (proliferation and 
differentiation analyses of NSPCs) and by t-student test (proliferation analyses of 
NSPCs and OECs in the co-cultures experiments). A p-value of ≤ 0.05 (95% confidence 
level) was set as the criteria for statistical significance. All data are presented as mean ± 
standard deviation. 
 
 
 
 
 
 
Chapter VI. The Effects of Peptide Modified Gellan Gum and Olfactory Ensheathing Glia Cells on Neural Stem/Progenitor Cell 
Fate 
248 
3. Results 
3.1. Synthesis and characterization of GRGDS-GG hydrogel 
Immobilization of the synthetic peptide (mal-GRGDS) to the gellan gum (GG) hydrogel 
was achieved in two synthetic steps (Fig 1a). First, the carboxylic acid groups of the 
glucuronic acid monosaccharide of GG were activated with DMT-MM, and then 
conjugated to furfurylamine to functionalize the GG with a furan.  By 
1
H-NMR 
analysis, the degree of furan substitution to GG was calculated to be 27% (Fig. 1b).  
This was calculated by comparing the ratio of the areas under the furan peaks at 6.26, 
6.46 and 7.65 ppm to the methyl peak at 1.2 ppm (of the rhamnose monosaccharide of 
GG).  To confirm that the furfurylamine was covalently bound to GG, and not simply 
adsorbed, a control reaction (in the absence of the coupling agent, DMT-MM) was 
similarly characterized, and analysis of this 
1
H-NMR spectrum did not show any furan 
peaks (Fig. 1c).  Second, the furan-GG hydrogel was reacted with maleimide-modified 
GRGDS peptide to yield GG-GRGDS hydrogel.  After excessive dialysis to remove 
unbound peptide, quantification by amino acid analysis of the immobilized peptide was 
calculated to be 304.0 nmol of GRGDS peptide per mg of GG (Fig. 1d). A control 
reaction (using unmodified GG) was also performed to determine the amount of 
unbound peptide adsorbed on the hydrogel. In the absence of furan substitution to GG, 
only 5.3 nmol of GRGDS/mg of GG (Fig. 1e) was detected.  Thus, approximately 300 
nmol/mg of GRGDS peptide was covalently bound to the GG by the Diels-Alder [4+2] 
cycloaddition.  
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3.2. Biological effect of GRGDS-GG on NSPCs 
NSPCs were either seeded on the surface or encapsulated within GRGDS-GG vs. 
unmodified GG hydrogels. Cell proliferation, morphology and differentiation were 
assessed after 2 and 7 days of culture. The results revealed pronounced differences in 
 
Figure VI.1. Immobilization of the GRGDS peptide into the Gellan Gum hydrogel. (A) 
Schematic representation of the Diels-Alder reaction (furan-maleimide conjugation) used 
for the GG modification. When DMT-MM and furfurylamine were incubated with the 
GG, a furan-modified gel with 27% substitution was synthesized. (B) 
1
H-NMR spectrum 
of furan-GG. The degree of substitution was calculated by comparing the ratio of the 
areas under the proton peaks at 6.26, 6.46 and 7.65 ppm (black arrows point to furan 
protons) to the peak at 1.2 ppm (white arrow point to methyl group of GG).  (C) 
1
H-NMR 
spectrum of GG, after incubation with furfurylamine in the absence of the coupling 
reagent DMT-MM. Furan peaks were not detected in the GG spectrum (D) By reverse 
phase HPLC, the amino acid analyses revealed that when furan-GG and mal-GRGDS 
were incubated together it was possible to obtain approximately 300 nmol GRGDS/mg of 
GG (gray arrows point to each amino acid). (E) In contrast, only 5.3 nmol of GRGDS 
peptide were detected in the control reaction between maleimide-modified GRGDS and 
unmodified GG. 
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NSPC behavior when cultured in the peptide-modified hydrogel relative to the 
unmodified hydrogel. In the presence of GRGDS, the cells were able to migrate and 
successfully expand throughout the hydrogel whereas in the absence of GRGDS, 
NSPCs interacted preferentially with each other, forming cell aggregates or 
neurospheres (Fig. 2). Visible cytoplasmatic extensions were observed in the GRGDS-
GG, either on the surface (Fig. 2a) or inside the gel (Fig. 2b), but not on the unmodified  
GG. 
 
Proliferation and morphological analyses revealed that in the absence of peptides, the 
cells were only able to proliferate as neurospheres. In the GRGDS-GG hydrogel cells 
proliferated as single cells. The number of single cells found either encapsulated within 
or on the gel surface was significantly higher in the GRGDS-modified hydrogel than the 
unmodified GG gel (Fig. 3a and 3b). For example, after 7 days of culture, we observed 
an average of 60 ± 29 single cells/mm
2
 on the GRGDS-GG gel surface whereas only 4 ± 
 
Figure VI.2. Morphology and dispersion of NSPCs on the GG-GRGDS. Confocal 
analyses revealed substantial differences in NSPC morphology when cultured either (A) 
on the surface or (B) encapsulated within the GG-GRGDS vs. unmodified GG gel. Cell 
spreading and visible cytoplasmatic extensions were only observed in the GG-GRGDS. 
In the unmodified GG, NSPCs proliferated as neurospheres. The cytoplasm was stained 
with the anti-F-actin / phalloidin (red) and nuclei counterstained with DAPI (blue). 
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2 single cells/mm
2 
on the GG surface. A similar trend was observed with encapsulated 
cells. The number of single cells in the GRGDS-GG hydrogel of 23 ± 7 single 
cells/mm
2
 was significantly higher than that in the GG hydrogel of 2 ± 2. Interestingly, 
while GRGDS modification influenced the number of single cells present, it did not 
affect the differentiation profile, which was largely the same (Fig 3c).  After 7 days, the 
majority of NSPCs on GRGDS-GG vs. GG hydrogels, respectively, were O4 positive 
oligodendrocytes 72±11% vs 64±30%, with relatively little differentiation into 
astrocytes 7±12% vs 0±0% and no differentiation into neurons. Moreover, as judged by 
the nestin expression, some NSPCs remained as progenitors 32±16% vs 36±19. 
 
 
Figure VI.3. Bioactivity of the GRGDS-GG hydrogel. Proliferation analyses of NSPCs 
cultured either (A) on the surface of or (B) in the gel of the GRGDS-GG and regular 
GG showed that on the seventh day a significantly higher number of single cells were 
found in the GRGDS-GG when comparing with the regular GG gel. Moreover, only in 
the GRGDS-GG a significant increase was observed from day 2 to day 7. Finally, 
immunocytochemistry revealed that the GRGDS sequence did not significantly 
influence the differentiation profile of the NSPCs (C). Values are shown as mean ± 
standard deviation (n=3 samples of 2 × 10
4
 cells/sample, *p<0.05; ***p<0.001) 
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3.3. Co-culture of OECs and NSPCs  
The interaction of OECs and NSPCs were analyzed after 7 days in culture for cell 
proliferation, and differentiation as a function of direct or indirect (i.e. same media, but 
not contact through use of a transwell) contact.  Interestingly, the differentiation profile 
of NSPCs was not altered by the presence of the OECs (Fig. 4a); however, NSPCs 
proliferated significantly more when co-cultured with OECs vs. alone. There was a 2.3 
fold increase in the number of NSPCs when co-cultured in direct contact with OECs vs. 
NSPCs alone (Fib 4b) and a 1.8-fold increase in the number of NSPCs when co-cultured 
indirectly in transwells with OECs vs. NSPC monoculture (Fig 4c). These results 
suggest that OECs secrete factors that enhance NSPCs proliferation and that the cells do 
not need to be in contact in order for this affect to be observed.  Moreover, analysis of 
cell dispersion shows that OECs and NSPCs highly interact with each other. Unlike the 
proliferative affect that the OECs had on the NSPCs, the converse was not true: the total 
number of OECs was not significantly affected by co-culture with NSPCs either in 
direct contact (Fig 4d) or indirect, transwell (Fig 4e) contact.  Notwithstanding that 
OECs do not have to be in direct contact with NSPCs to influence their proliferation, 
immunocytochemistry illustrates that OECs are closely associated with NSPCs when 
co-cultured together (Fig 5). By pre-labelling OECs green with CFSE34554 and 
counterstaining NSPCs with either nestin (red for progenitors) or O4 (red for 
oligodendrocytes), the two cell types appeared to be closely associated with each other. 
These data suggest that OECs may be able to provide a guidance pathway for NSPC 
growth. 
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Figure VI.4.  OECs and NSPCs proliferation in transwells and direct contact 
co-culture. (A) The differentiation profile of NSPCs was not affected by the 
presence of OECs. Proliferation analysis has shown that the total number of 
NSPCs is significantly higher when in culture with OECs than when cultured 
alone. This occurred both in the (B) direct cell-cell contact co-cultures and in 
the (C) indirect transwell co-cultures. OECs proliferation was not significantly 
affected by the presence of NSPCs, either in (D) direct contact or in the (E) 
indirect transwell co-culture. Values are shown as mean ± standard deviation 
(n=3 independent studies of a minimum of 4000 cells counted per study, 
*p<0.05). 
 
3.4. Co-culture of OECs and NSPCs in the GRGDS-GG hydrogel 
To gain greater insight into the interactions of OECs and NSPCs, they were co-cultured 
together in the 3D gellan gum hydrogel modified with the cell-adhesive peptide, 
GRGDS (GRGDS-GG).  To facilitate identification, the OECs were pre-labeled green 
with CFSE 34554 and the NSPCs red with DDAO-SE 34553 prior to encapsulation in 
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the GRGDS-GG hydrogel. As was observed in the 2D co-culture study, the total 
number of NSPCs was significantly higher when co-cultured with OECs than when 
cultured alone (Fig. 6a). Similar to the 2D data presented in Fig 4, the OEC proliferation 
was unaffected by the presence of NSPCs (Fig. 6b). 
 
Figure VI.5. OECs and NSPCs interact with each other during co-culture. (A) 
Monocultures of NSPCs and (B) monocultures OECs served as controls. (C) OECs 
(green, CFSE 34554) and NSPCs (red, O4) appear to be closely associated when the 
cells are cultured together in direct contact. NSPCs were identified by 
immunocytochemistry and nuclei are counterstained with DAPI (blue). 
 
4. Discussion 
Gellan gum (GG) is a natural biomaterial that has shown promise for tissue 
regeneration. It is a thermo-reversible gel that was previously shown to be 
cytocompatible with adipose stem cells, rabbit articular chondrocytes and immortalized 
oligodendrocytes [20, 34]. Until recently, most of the research on GG modification was 
focused on controlling its mechanical properties through gel network formation [21, 
35]. To the best of our knowledge, there is no literature describing the chemical 
modification of GG with ECM-derived peptides, even though the cellular 
microenvironment is defined, in part, by its chemical nature.  In order to create a 
hydrogel which mimics the chemical nature of the ECM, bioactive peptides were 
conjugated to GG, thereby providing a more suitable environment for encapsulated cells  
to survive and migrate. 
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The peptide sequence GRGDS is a ubiquitous cell-adhesive peptide, which has been 
shown to enhance cell-biomaterial interactions, support cell survival and influence cell 
morphology [22, 36]. In this work we show that it is possible to immobilize the GRGDS 
peptide to GG.  By taking advantage of the Diels-Alder click cycloaddition reaction 
between chemically modified GG-furan and maleimide-GRGDS, GG-GRGDS was 
synthesized in aqueous conditions. 
Immobilization of GRGDS to GG had a profound effect on NSPC morphology, distinct 
from that observed on NSPCs in unmodified GG alone, demonstrating the importance 
of GRGDS for cell-GG interaction.  Importantly, these morphological differences were 
 
Figure VI.6. Co-culture between OECs and NSPCs in the GRGDS-GG hydrogel. 
(A) After counting the cells was possible to observe that the number of NSPCs was 
significantly higher when co-cultured with OECs than when cultured alone. (B) In 
contrast, OEC proliferation was unaffected by the presence of NSPCs in culture. 
(C) Co-cultures of NSPCs (red, DDAO-SE 34553) and OECs (green, CFSE 34554) 
suggested some interaction between the two cell types as observed by confocal 
microscopy. (D) NSPCs and (E) OECs were cultured alone and served as controls. 
Values are shown as mean ± standard deviation (n=3 independent experiments of 
200 cells counted per experiment, *p<0.05) 
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observed both within the 3D hydrogels and on their surfaces. Unlike most studies that 
focus only on cells cultured on surfaces, herein we cultured cells both on the hydrogel 
surface and encapsulated within [36, 37]. Given that the ultimate goal involves cell 
transplantation via an injectable hydrogel, it was reassuring that the cell morphology in 
3D mirrored that in 2D.  The NSPCs were able to adhere to and extend processes within 
the GG-GRGDS hydrogel, yet their differentiation profile was not affected by the 
presence of GRGDS.  This reflects the cell-adhesive property ascribed to GRGDS and 
not a differentiation property. To achieve preferential differentiation to a given 
phenotype, GG would typically require further modification with growth factors, such 
as PDGF-AA for oligodendrocytes [38] or interferon-gamma for neurons [39]. 
The co-culture experiments of NSPCs and OECs, in direct contact or in the transwell, 
suggested that diffusible factors are responsible for the effects observed.  OECs have 
been shown to secrete several neurotrophic factors including: nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor 
(GDNF) [13], basic fibroblast growth factor (FGF2) and neurotrophin-3 (NT-3) [40]. 
This rich profile of secreted neurotrophins from OECs may explain the proliferation of 
NSPCs that we observed in our co-culture studies.  For example, NGF and FGF 
promote NSPC proliferation [41, 42]; and NT3 enhances their survival [43]. The 
combination of both mechanisms, survival and proliferation, may explain the increased 
number of NSPCs in all of the co-culture studies. 
Other than this study, very little is known about the effects of OECs on the behavior of 
NSPCs. Interestingly, Cao et al [33], also observed that OECs promoted NSPC 
proliferation, yet they also observed increased neurogenesis and oligodendrogenesis of 
NSPCs cultured with OECs. Differences in the co-culture experiments may account for 
this discrepancy.  Cao et al harvested the NSPCs from newborn mice, whereas we 
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obtained NSPCs from adult rats; moreover, they co-cultured the cells for only 3 days in 
DMEM with F12 and N2 supplements whereas we co-cultured the cells for 7 days in 
neurobasal medium with B27 supplements. 
The immunocytochemistry figures suggest that OECs and NSPCs interact with each 
other.  This interaction may be attributed to OECs expressing cell adhesive molecules, 
such as N-CAM and L1 [44], and NSPCs expressing the corresponding receptors 
[45].The cellular interactions may suggest a role for co-transplantation of OECs and 
NSPCs.  
Cell transplantation has been pursued for several years for SCI repair.  Both OECs and 
NSPCs have been investigated independently, each with some success.  Notably, 
biomaterial scaffolds have been shown to enhance cell survival after transplantation.  
For example, Cummings et al [46] showed that transplanting human NSPCs in SCI 
mice led to some locomotor recovery and remyelination. Johnson et al [47] 
demonstrated that implantation of fibrin hydrogels containing neural progenitor cells 
resulted in some functional recovery in SCI rats. Ballios et al demonstrated greater cell 
survival after transplantation in a hyaluronan/methylcellulose hydrogel compared to 
saline [48]. OECs support and guide axon elongation in their native olfactory system 
and have shown promise after spinal cord injury as well [49, 50]. OECs transplanted 
immediately or up to 2 months after SCI in rats resulted in functional recovery and/or 
tissue regeneration [51, 52]. Significantly, OECs have been tested in three separate 
clinical trials [30, 53, 54]; however, only very modest (if any) motor improvements 
were observed. Despite the promise for cell therapy, with OECs or NSPCs, the 
functional recovery has been modest, underlining the need for innovative strategies, 
such as the combined transplantation of OECs and NSPCs in a GG-GRGDS hydrogels.  
The simplicity and broad applicability of the Diels-Alder click chemistry can be easily 
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extended to other biomolecules to further promote NSPC differentiation for greater 
integration with the host tissue. This combination strategy could be powerful, with 
OECs and gellan gum providing a cellular pathway on which NSPCs could 
differentiate, thereby replacing the damaged tissue and achieving greater functional 
repair. 
 
5. Conclusions 
Using well-established Diels-Alder click-chemistry, we immobilized the GRGDS 
fibronectin-derived peptide to gellan gum hydrogels, which promoted greater adhesion 
and proliferation of neural stem/progenitor cells than gellan gum controls. Moreover, 
NSPCs co-cultured with olfactory ensheathing glia showed greater survival and 
outgrowth than NSPCs cultured alone. These results suggest that the combined use of 
NSPCs and OECs with bioengineered GG-GRGDS hydrogels may be beneficial in 
regenerative medicine cell transplantation strategies to promote repair after spinal cord 
injury. 
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Chapter VII. 
Combining Adult Stem Cells and Olfactory Ensheathing Cells: The Secretome Effect 
 
Abstract 
Adult stem cells derived from adipose (ASCs), bone marrow (bmMSCs) and umbilical 
cord (HUCPVCs) tissue are been widely tested for regenerative applications, such as 
bone regeneration. Moreover, olfactory ensheathing cells (OECs) show promise in 
promoting spinal cord injury (SCI) regeneration. Our group recently proposed the use of 
a hybrid scaffold targeting both vertebral bone repair and SCI regeneration. In this 
concept, mesenchymal stem cells and OECs should be in close contact to be influenced 
by the factors that both secrete. For this reason, herein we studied the effects of the OEC 
secretome on the metabolic activity and proliferation of ASCs, bmMSCs and 
HUCPVCs. The stem cells’ secretome effects on metabolic activity and proliferation of 
the OECs were also considered. In co-cultures of OECs with ASCs, bmMSCs or 
HUCPVCs the metabolic activity/viability, proliferation and total cell numbers were 
measured after 2 and 7 days of culture. The results demonstrated that the secretome of 
OECs has a positive effect on the metabolic activity and proliferation of mesenchymal 
stem cells from different origins, especially on ASCs. Furthermore, in general the stem 
cells’ secretome also had a positive effect on the OECs behavior, particularly when 
ASCs were in co-culture with OECs. These results suggest that the most suitable 
combination of cells to be used in our hybrid scaffold is the OECs with the ASCs. 
Finally, this work adds important knowledge to the cell therapy field, bringing new 
information about paracrine interactions between OECs and distinct mesenchymal stem. 
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1. Introduction 
Transplantation of cells with regenerative capabilities holds great promise for the 
treatment of several diseases. However, the properties of the tissue into which the cells 
are to be transplanted, as well as the intrinsic properties of the transplanted cells will 
significantly influence the success of the therapy. In spinal cord injury (SCI) the host 
environment is particularly important. For instance, after SCI an environment of 
necrosis, edema, inflammation and degeneration emerge [1]. This unfavorable host 
environment will influence the ability of the transplanted cells to engraft, proliferate, 
differentiate and thus to contribute to the repair of the damaged tissue. In order to 
improve cell survival, several authors are proposing the use of hydrogels as vehicles for 
cell transplantation [2-4]. For example, Johnson et al. reported that fibrin scaffolds can 
enhance survival of neural stem/progenitors cells (NSPCs) in a sub-acute model of SCI 
[3]. Work from the Shoichet lab shows that a combination of cyclic-AMP, fibrin and 
chitosan channels greatly enhance the survival of NSPCs after transplantation in SCI 
rats [4]. Our group recently proposed the use of a hybrid tubular scaffold that comprise 
a rigid layer (composed by a blend of starch with polycaprolactone - SPCL), 
surrounding the hydrogel gellan gum [5]. In this concept the SPCL tubular structure 
assures mechanical stability to the entire construct, namely by establishing a connection 
to the adjacent vertebral bone [6], while the gellan gum hydrogel is aimed as a cell 
encapsulation system to support axonal regeneration in the injured spinal cord. In order 
to improve bone repair, mesenchymal stem cells, such as adipose derived adult stem 
cells (ASCs), human umbilical cord perivascular cells (HUCPVCs) or bone marrow 
mesenchymal stem cells (bmMSCs), can be seeded on the SPCL layer. Previous studies 
have demonstrated that these cells have the capability to undergo osteogenic 
differentiation and secrete extracellular matrix (ECM) rich in calcium phosphates (ECM 
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typically found in bone tissues) [7-9]. Alternatively, cells such as olfactory ensheathing 
cells (OECs), that are known to support and guide olfactory axons, secrete several 
neurotrophic factors and grow through the glial scar upon transplantation [10-12], are 
suitable candidates to be encapsulated in the hydrogel phase aimed to foster axonal 
regeneration. In this sense, our therapeutic approach puts in close contact both the 
mesenchymal stem cells and the OECs, allowing the secreted factors by these cells to 
diffuse and interact with each other (see schematic representation on Figure 1). For this 
reason, in this work we studied the interactions of the OECs secretome on the 
proliferation, metabolic activity and differentiation of ASCs, HUCPVCs and bmMSCs, 
as well as the effects of the stem cells secretome on OECs behavior. In this sense, we 
expect to find the best suitable combination to be used in our hybrid scaffold. 
 
Figure VII.1. Rationality and schematic representation of the study. (A) Both adult 
stem cells (red cells seeded on the outer layer of the hybrid scaffolds), and OECs 
(green cells encapsulated on the hydrogel) secreted factors that can affect the 
biological behavior of each other. (B) Transwell system used to study the effects of 
cell secretome. (C) Hybrid scaffold developed and previously characterized [5]. (D) 
Schematic representation of the scaffold implantation, with the SPCL layer at 
vertebra bone level and the hydrogel in the nervous tissue level. 
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2. Materials and Methods 
2.1. Cell Culture 
To evaluate the potential positive or negative effects of the cell secretome of OECs and 
adult stem cells, transwell co-culture experiments were performed. OECs were seeded 
(1 × 10
5
 cells/cm
2
) on poly-D-lysine cover glass and adult stem cells were seeded (4 × 
10
4
 cells/cm
2
) on the transwell. Cell proliferation, metabolic activity and differentiation 
were assessed after 2 and 7 days in culture. Cells were obtained as described below: 
 2.1.1. Olfactory Ensheathing Cells 
Rat OECs were isolated as previously described [13]. Briefly, upon olfactory bulb 
collection, all meninges were removed and the tissue was digested with 0,125% 
Collagenase (Sigma) for 20 min at 37 ºC. The digested tissue was mechanically 
dissociated with a pipette and then filtrated through a 70 µm cell strainer (BD Falcon, 
USA). After centrifugation at 1000rpm for 10 min, cells were resuspended and plated in 
uncoated wells for 18h. A posterior change to new uncoated wells for 36h was made, as 
it is expected that most of the fibroblasts and astrocytes will attach in the first and 
second period, respectively. Finally, the cell suspensions were transferred to poly-D-
lysine treated flasks and cultured in DMEM/F12 (Gibco) with 10% of FBS (Gibco) and 
1% of antibiotic-antimycotic solution (Sigma) at 37 ºC and 5% CO2. OECs were 
enriched by medium supplementation with Bovine Pituitary Extract (5µg/ml, Gibco) 
and Forskolin (2µg/ml, Sigma). 
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 2.1.2. Human Umbilical Cord Perivascular Cells  
HUCPVCs were isolated according to the procedure originally described by Sarugaser 
et al. [14]. Pieces of cord were dissected by first removing the epithelium of the 
umbilical cord section along its length to expose the underlying Wharton’s jelly. Each 
vessel, with its surrounding Wharton’s Jelly matrix, was then pulled away, after which 
the ends of each dissected vessel were tied together with a suture creating “loops” that 
were placed into a solution of 0.5–0.75 mg/mL collagenase (Sigma, St. Louis, MO) 
with phosphate-buffered saline (PBS, Invitrogen/Gibco, Carlsbad, CA). After 18 h, the 
loops were removed from the suspension, which was then diluted with PBS to reduce 
the viscosity of the suspension and centrifuged. Following the removal of the 
supernatant, cells were resuspended in culture media, α-MEM (Invitrogen/Gibco) 
supplemented with 10% FBS (Invitrogen/ Gibco) and 1% antibiotic/antimycotic 
(Sigma), counted using a hemocytometer and platted out in T75 flasks at a density of 
4,000 cells/cm
2
. The culture medium was changed every 2/3 days. Upon confluence, 
cells were trypsinized and passaged to new T75 flasks. 
 
 2.1.3. Bone Marrow-Derived Mesenchymal Stem Cells 
BM-MSCs, acquired from Lonza (Switzerland), were cultured in α-MEM 
(Invitrogen/Gibco) supplemented with 10% FBS and 1% antibiotic-antimycotic 
mixture. The culture medium was changed every 2/3 days. Upon confluence, cells were 
trypsinized and passaged to new T75 flasks. 
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 2.1.4. Human Adipose-Derived Adult Stem Cells 
ASCs were isolated according to a protocol previously described by Dubois et al. [15]. 
All protocols were reviewed and approved by the Pennington Biomedical Research 
Center Institutional Research Boards (IRB) prior to the study. Liposuction aspirates 
from subcutaneous adipose tissue sites (abdomen, flank, thighs) were obtained from 
female subjects undergoing elective plastic surgical procedures. Tissues were then 
digested in a 0.1% collagenase type I (Worthington Biochemical Corporation, 
Lakewood, NJ) prewarmed to 37°C for 60 minutes after which they were centrifuged 
for 5 min at 300-500g at room temperature. The supernatant, containing mature 
adipocytes, was aspirated. The pellet was identified as the stromal vascular fraction 
(SVF). The SVF were suspended and plated immediately in T225 flasks in Stromal 
Medium (DMEM/F 12 Ham's, 10% fetal bovine serum (Hyclone, Logan, UT), 100 U 
penicillin/100 µg streptomycin/0.25 µg Fungizone) at a density of 0.156 ml of tissue 
digest/cm
2
 of surface area for expansion and culture. After reaching confluence cells 
were passaged and kept in stromal medium. 
 
2.2. Metabolic Activity Assay 
Cell viability was measured using the CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (Promega). This assay is based on the bioreduction of a tetrazolium 
compound (MTS), into a water-soluble brown formazan product. This conversion is 
accomplished by NADPH or NADH production by the dehydrogenase enzymes in 
metabolically active cells. Complete culture medium was replaced by standard 
DMEM/F12 medium containing MTS in a 5:1 ratio and incubated in a humidified 
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atmosphere at 37 ºC and 5% CO2. After 3h of incubation, the optic density for 
triplicates of each sample (n=3) was measured at 490 nm in a microplate reader. 
2.3. Cell Proliferation Assessment 
The cell proliferation rate was determined using the 5-bromo-2’-deoxyuridine assay 
(BrdU, Roche, USA), which quantifies the BrdU incorporation during DNA synthesis in 
replicating cells. To perform the assay, BrdU was added to the cell cultures for 24 hours 
and after that the medium was removed. The cells were then fixed and its DNA 
denatured with FixDenat (Roche, USA) in a single step, after which the anti-BrdU 
peroxidase antibody (Roche, USA) was added. The immune complexes were detected 
by the quantification of the substrate reaction product, measuring the optical density at 
370 nm (reference filter set at 492 nm) in a multiplate reader (BioRad, USA). 
 
2.4. Immunocytochemistry and phalloidin/DAPI staining 
The following primary antibodies were used for the immunocytochemical studies: 
monoclonal mouse anti-GFAP (Chemicon) for astrocytes; monoclonal mouse anti-O4 
(R&D Systems, Canada) for oligodendrocytes; and polyclonal rabbit anti-p75 
(Millipore) for OECs. For all immunohistochemical procedures, the appropriate controls 
were obtained by omission of the relevant primary antibody. Cells on the substrates 
were fixed with PBS solution containing 4% PFA for 20 min (on glass) or 1 h (on the 
hydrogel) at room temperature and then washed with PBS. After cell membrane 
permeation (except for p75 and O4 antibodies) and blocking by treating with 0.3% 
Triton X-100 (Sigma, USA) and 10% of FBS solution at room temperature for 1 h, each 
specific primary antibody solution was added for 1h. After washing with 0.5% of FBS 
in PBS, the samples were exposed to the specific secondary antibody (Invitrogen) for 1h 
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and then washed with 0.5% FBS. Finally, cell nuclei were counterstained with 1 μg/ml 
DAPI (Invitrogen) for 1h. 
For the phalloidin/DAPI staining, cells were fixed with 4% of paraformaldehyde for 30 
min at room temperature and then treated with 0.3% TritonX-100. After PBS washing, 
0.1µg/ml of phalloidin (Sigma) was added to the cells during 30 min. Finally, cell nuclei 
were counterstained with DAPI (1µg/ml, Invitrogen) for 10 min. 
2.5. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, USA). Differences among groups were assessed by two-
way ANOVA followed by a Bonferroni post-hoc test. A p-value of ≤ 0.05 (95% 
confidence level) was set as the criteria for statistical significance. All data are 
presented as mean ± standard deviation. 
 
3. Results 
3.1. Metabolic Activity Assessment 
The MTS test revealed that the OECs secretome affects the metabolic activity of 
mesenchymal stem cells in distinct time dependent manners. The mitochondrial activity 
of stem cells derived from the adipose tissue in co-culture with OECs was 1.4 fold 
higher (p<0.01) than when ASCs were cultured alone (Figure 2a). However, this 
difference was only observed after 7 days of incubation. No differences were observed 
after two days of culture. On the contrary, for the stem cells derived from the bone 
marrow and from the umbilical cord it was possible to observe a significantly higher 
metabolic activity when co-cultured with OECs after 2 days of incubation. The 
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metabolic activity of co-cultured bmMSCs was 1.7-fold higher (p<0.05) than bmMSCs 
in monoculture (figure 2b), while the co-cultured HUCPVCs presented a 2.8 fold higher 
(p<0.001) activity than cells growing in monoculture (figure 2c) For these two cell 
populations no differences were observed between controls and co-cultures after 7 days. 
Moreover, it was not observed any detrimental effect of the OECs secretome on the 
metabolic activity of all adult stem cells used. 
The study of the stem cells’ secretome effects on the metabolic activity of OECs 
revealed that, after 2 days of culture, each stem cell’s secretome produced different 
outcomes on the OECs activity. The metabolic activity of the OECs was 1.3-fold higher 
(p<0.01) when co-cultured with ASCs (Figure 2d) and HUCPVCs (Figure 2f) than 
 
Figure VII.2.  Metabolic activity of OECs and adult stem cells culture in transwell 
systems and in monoculture. Metabolic activity of (A) ASCs, (B) bmMScs and (C) 
HUCPVCs in monoculture or in co-culture with OECs. Metabolic activity of OECs in 
monoculture or in co-culture with (D) ASCs, (E) bmMSCs and (F) HUCPVCs. 
Values are shown as mean ± standard deviation (n=3 samples of 2 × 10
4
 adult stem 
cells and 1 × 10
5
 OECs/sample, *p<0.05; **p<0.01; ***p<0.001). 
 
Chapter VII. Combining Adult Stem Cells and Olfactory Ensheathing Cells: The Secretome Effect 
277 
when in monoculture. In contrast, under the effects of the bmMSCs secretome the OECs 
presented a 2.5-fold lower (p<0.001) metabolic activity than the control cells (Figure 
2e). All the effects observed after 2 days of culture, either positive or negative, were not 
observed after 7 days of culture, as the metabolic activity of OECs was similar both on 
cells in co-culture and controls. 
 
3.2. Proliferation Rate Evaluation 
The BrdU incorporation during DNA synthesis in replicating cells was used to quantify 
the proliferation rate of the stem cells and OECs. Each of the stem cells was affected in 
a similar way by the OECs secretome. After 2 days of culture, all the distinct stem cells 
that were co-cultured together with the OECs presented significantly higher 
proliferation rates than the ones growing in monoculture. Co-cultured ASCs exhibited a 
1.5-folder increased (p<0.01) on the proliferation rate than the monoculture cells (figure 
4a). Additionally, co-cultured bmMSCs and HUCPVCs presented an approximately 
2.5-fold increased (p<0.001) than monoculture cells (figure 4c and b). No differences in 
the proliferation rate of the distinct stem cells were detected after 7 days. 
The study of the stem cells’ secretome effect on the proliferation rate of OECs showed 
that just the secretome of HUCPVCs significantly influenced the OECs proliferation. 
Co-cultured OECs presented a 1.7-fold increase (p<0.01) of BrdU incorporation than 
monocultured OECs (Figure 3f). This difference was observed only at the day 2 of co-
culture since no differences were observed at day 7. OECs growing under the influence 
of the ASCs or bmMSCs secretome did not present significant differences when 
compared to OECs in monoculture both after 2 and 7 days (Figure 3d and 3e). Finally, 
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results show that both the stem cells and OECs secretomes do not negatively influence 
the proliferation rate of each other. 
 
Figure VII.3. Proliferation rate of OECs and adult stem cells culture in transwell 
systems and in monoculture. Proliferation rate of (A) ASCs, (B) bmMScs and (C) 
HUCPVCs in monoculture or in co-culture with OECs. Proliferation rate of OECs in 
monoculture or in co-culture with (D) ASCs, (E) bmMSCs and (F) HUCPVCs. 
Values are shown as mean ± standard deviation (n=3 samples of 2 × 10
4
 adult stem 
cells and 1 × 10
5
 OECs/sample, **p<0.01; ***p<0.001). 
 
3.3. Stem Cells Differentiation, OECs Purity and Total Number of Cells 
 After 2 and 7 days in co-culture the stem cells and the OECs were subjected to an 
immunocytochemistry protocol in relation to the cell density and the stem cells 
differentiation. The proliferation studies revealed that the total number of ASCs and 
bmMSCs evolved from similar levels at day 2 to significantly higher cell densities at 
day 7, only when cells were under the influence of the OEC secretome. The number of 
co-cultured ASCs was 1.8-fold higher (p<0.001) than the monocultured ASCs (figure 
4a). Moreover, bmMSCs conditioned by the OEC secretome were 1.2-fold more 
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(p<0.05) than bmMSCs in monoculture (figure 4b). In contrast, it was possible to 
observe that the factors produced by the OECs did not significantly affect the density of 
HUCPVCs (Figure 4c). 
The factors produced by the stem cells revealed to have a positive effect on the OECs. 
The number of p75 positive cells (marker for OECs) was similar after 2 days of culture; 
however, after 7 days, the density of p75 positive OECs was significantly higher when 
these cells were co-cultured with ASCSs or bmMSCs than in monoculture. The number 
of OECs conditioned by the ASCs’ secretome was 2.0-fold higher (p<0.05) than OECs 
growing solo (figure 4d). Additionally, OECs conditioned by bmMSCs’ secretome was 
1.6-fold higher than controls (figure 4e). This positive effect was not observed under the 
HUCPVCs secretome influence, in this circumstance, OECs did not significantly 
increase in number when compared to controls (Figure 4f). 
It was possible to observe that the percentage of OECs in culture significantly decreased 
over time when in monoculture (Figure 4g-i, p75 positive cells of 50.7 ± 5.1% on the 
second day and 29.1 ± 2.1% on the seventh day of culture). In other words, this 
indicates that the culture became enriched for cells other than OECs. However, when 
OECs were co-cultured with each of the stem cell types, evidence of “contaminating” 
cell types was significantly reduced (p<0.05). The percentage of OECs remained around 
50% of the total number of cells in culture, while, the monocultured OECs decrease to 
around 29% (figure 4g-i). As stated above, the proliferation rate measured following 
BrdU incorporation did not show any significant difference between co-cultures and 
controls, in this sense, it is likely that the stem cells secretome selectively promoted the 
survival of the OECs, rather than the “contaminating” cells. 
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Figure VII.4. Immunocytochemistry counting of OECs and adult stem cells culture in 
transwell systems (gray line) and in monoculture (black line). Total number of (A) 
ASCs, (B) bmMScs and (C) HUCPVCs in monoculture or in co-culture with OECs. 
Total number of p75-positive cells (OECs) in monoculture or in co-culture with (D) 
ASCs, (E) bmMSCs and (F) HUCPVCs. Percentage of OECs in monoculture or in co-
culture with (D) ASCs, (E) bmMSCs and (F) HUCPVCs. Values are shown as mean ± 
standard deviation (n=3 samples of 2 × 10
4
 adult stem cells and 1 × 10
5
 OECs/sample, 
*p<0.05; **p<0.01; ***p<0.001) 
 
Finally, immunocytochemistry studies revealed that the factors secreted by the OECs 
did not induce the differentiation of the adult stem cells herein assessed (Figure 5a, 5b 
and 5c). Moreover, the immunocytochemistry pictures also confirmed the results 
described above (Figure 6). The factors produced by the OECs significantly promoted 
proliferation of the ASCSs (Figure 5d) and bmMSCs (Figure 5e) but not the HUCPCVs 
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(Figure 5f). Additionally, the factors secreted by each of the stem cells used promoted a 
higher purity of the OECs cultures (Figure 5g-j). 
 
Figure VII.5. Images of fluorescence microscopy of adult stem cells and OECs 
either in monoculture or in transwell cultures. (A-F) The cytoplasm of adult stem 
cells was stained with the anti-F-actin dye phalloidin and nuclei counterstained with 
DAPI. (G-J)The OECs were identified with immunocytochemistry against p75 
protein. 
 
4. Discussion 
The use of cells with the capacity to repair or substitute a damaged tissue holds great 
promise for the regenerative medicine field. Due to their sui generis characteristics, 
such as the ability to differentiate and replace damaged cells, to secrete trophic factors 
and to be easily obtained from human patients, adult stem cells are potential candidates 
for clinical treatments. In context of SCI, OECs hold particular promise for promoting 
regeneration. OECs are responsible for the continuous growth of new axons into the 
CNS tissue that takes place in the adult olfactory system [10]. Moreover, several authors 
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previously demonstrated that OECs have the ability to promote regeneration of CNS 
axons both in vitro and in vivo [16-19]. However most of the data obtained until now 
suggest that no single cell therapy will be sufficient to overcome all the biological 
complications caused by SCI. For this reason, in the work herein presented we study the 
possible positive or detrimental effects of the secretome of OECs and adult stem cells 
derived from the adipose, bone marrow and umbilical cord tissue. 
The results herein presented show that the secretome of OECs exerts a positive effect on 
the metabolic activity and proliferation of mesenchymal stem cells from different 
origins (All results are summarized in table 1). However, it is possible to observe that 
this effect is higher for the ASCs than for the other stem cells, namely in proliferation. 
Moreover, the stem cells secretome also have beneficial effects in the metabolic activity 
and proliferation/survival of OECs. Again, the stem cells from adipose origin have a 
stronger impact on the OECs behavior than the other stem cells. In this sense, the most 
adequate cell type to be combined with the OECs in future studies would be the ASCs. 
It is important to point out that in future experiments, after the cell seeding (the stem 
cells on the SPCL layer, and the OECs on the hydrogel) and following the scaffold 
implantation in SCI animal models, the secreted factors produced by the stem cells will 
most likely influence the OECs behavior as well as the nervous cells from the injured 
tissue where the OECs are implanted. In this sense, the mesenchymal stem cells 
secretome can also be advantageous for the injured spinal cord site, promoting the 
growth and regeneration of damaged tissue. Previous studies demonstrated that the 
secretome of the stem cells used here have a beneficial effect on nervous cells. For 
instance, Ribeiro et al. previously reported that the secretome of bmMSCs increased the 
cell viability of hippocampal cultures as well as the number of neurons in culture [20]. 
Moreover, similar results were obtained using the conditioned medium of HUCPVCs 
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and ASCs in neuronal and glial cultures [21, 22]. To the best of our knowledge the 
results herein presented show for the first time the secretome interactions between 
OECs and ASCs, HUCPVCs and bmMSCs on the metabolic activity and proliferation 
of the cells. 
Table 1: Summary of the secretome effects between OECs and adult stem cells. 
 
Key: One arrow symbolizes a difference of 1.01 to 1.49 fold and two arrows 
symbolized a difference of 1.5 fold or higher on the parameter tested. The direction 
of the arrow (up or down) means positive or negative effects, respectively. Lines 
means no significantly different. 
 
The explanation behind the positive effects of the OECs secretome on the stem cells 
behavior may be related with the ability of OECs to produce several neurotrophic 
factors. Woodhall et al. previously reported that OECs are capable to produce nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF) and glial-derived 
neurotrophic factor (GDNF) [12]. The higher metabolic activity and proliferation rate 
presented by the stem cells may be consequence of the action of these factors. 
Moreover, these results are also in accordance with a previously work where we 
demonstrated that the OEC secretome is able to promote the proliferation of neural stem 
cells either in 2D and 3D culture [23]. 
The stem cells herein used are also able to secrete several factors. For instance, Rehman 
et al. previously reported that ASCSs produce basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-
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β) [24]. Additionally, previous studies also demonstrated that bmMSCs and HUCPVCs 
are capable to secrete factors such as BDNF, GDNF, VEGF and granulocyte-colony 
stimulating factor (G-CSF) [25, 26]. These factors secreted by the stem cells may 
explain why the OECs in co-culture presented a higher number of p75 positive cells. 
Furthermore, it was previously demonstrated that the presence of growth factors such as 
bFGF allow for primary cell cultures with higher percentage of OECs in relation to 
fibroblast [27]. This phenomena may explain our results, since the purity of OECs 
increased when cells where under the influence of the factors secreted by the stem cells.  
Nevertheless, even with a higher percentage of OECs in the co-culture group than in the 
controls, we only obtained ~50% of OECs in culture. This percentage is similar to what 
can be found in literature when OECs were used. For instance, Keyvan-Fouladi et al. 
demonstrated that a yielded cell cultures having around 50% OECs and 50% 
fibronectin
+
 olfactory nerve fibroblasts are able to promote functional repair of the 
corticospinal tract [28]. Moreover, Jani et al. proposed that the olfactory nerve 
fibroblasts may not be contaminants that needs to be removed but rather essential 
components of the cell suspension, that play a crucial role in the OECs growth and 
promoting its ability to graft [29]. 
It was only possible to find a single report using a similar strategy to the one that we 
used in this work. Wang et al., co-culture OECs and ASCs and found out that in this 
conditions ASCs were able to differentiate in OECs-like cells [30]. These results 
contrast with the ones presented here, where no differentiation was detected for all the 
stem cells used, including the ASCs. The possible explanations for this difference may 
reside on the substrate where the ASCs were growing. In Wang’s work, the authors 
seeded the ASCs on a collagen scaffold since they believe that the 3D culture is an 
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important factor in the ASCs differentiation. We believe that not only the 3D culture, 
but also the collagen scaffold may have influence on the ASCs differentiation. 
Amemori et al. previously demonstrated that the co-transplantation of OECs and 
bmMSCs does not have synergistic effects after SCI in the rat compression model [31]. 
Interestingly, the only negative effect here observed was between the OECs and 
bmMSCs, namely the secretome of the bone marrow derived stem cells negatively 
affected the metabolic activity of the OECs. This may be one of the reasons for the 
absence of synergistic effects. 
In Summary, the results herein described add new and important knowledge in the cell 
therapy field about the secretome effects between OECs and mesenchymal stem cells 
from adipose, bone marrow and umbilical cord origins. Further work will focus on the 
seeding of ASCSs and OECs in the hybrid scaffold followed by implantation in SCI 
animal models. 
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Chapter VIII. 
 
General Conclusions and Final Remarks 
 
Repair of the injured spinal cord is probably the “holy grail” of regenerative medicine. 
The development of strategies to protect and repair the injured spinal cord has been 
facilitated by the identification of key mechanisms of secondary injury. Due to the 
nature of the injury, it is of general consensus that successful functional recovery will 
not simply rely on a single therapeutic approach. Future clinical regenerative 
approaches will most likely include a combination of multiple strategies. In this sense, 
the work developed in the scope of this thesis was based in the concepts of tissue 
engineering. This new field of science merges the knowledge from physics, materials 
science, engineering, chemistry, biology, and medicine in an integrated manner with the 
ultimate goal to restore, maintain, or improve tissue function. Based on these concepts, 
the generation of a novel potential tool to help in the solution of spinal cord injuries was 
pursued. 
 
Firstly, a novel hybrid biodegradable 3D scaffold was developed and characterized. 
This biphasic scaffold was comprised of two natural polysaccharide-based biomaterials: 
starch/poly-ε-caprolactone (SPCL) blend and gellan gum. The choice for natural-based 
materials relies in the advantages they may ultimately confer to the performance of the 
tissue engineered construct. Therefore, natural materials frequently exhibit better 
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integration, less cytotoxicity, and most are present or display structural affinity with the 
native tissue. 
SPCL has been originally proposed by Reis and colleagues for a wide range of 
applications, retrieving promising results, particularly, in bone tissue engineering. In our 
concept, the SPCL tubular structure assures mechanical stability to the entire construct, 
namely by establishing a connection to the adjacent vertebral bone. In this sense, the 
SPCL phase is aimed at mimicking the bone functions. Alternatively, gellan gum 
hydrogel is aimed as a cell encapsulation system to support axonal regeneration in the 
injured spinal cord. Gellan gum was originally proposed by our group for cartilage 
tissue engineering. It is a FDA approved material that can be prepared and mixed with 
cells/drugs using very simple techniques and using as reagents only water and PBS. 
Gellan gum can be injected in a minimally-invasive way to form a gel in situ, thereby 
not being harmful to cells and the surrounding tissues. Moreover, it possesses a 
carboxylic group in the glucuronic residue that may be modified to confer improved 
functions. 
The SPCL 3D structure was developed by rapid prototyping. This processing technique 
was quite versatile allowing for the development of tubular scaffolds with configurable 
outer layer thickness, fiber/filament orientation and pore geometry. The SPCL scaffolds 
also possessed configurable mechanical properties and high interconnectivity. Then, we 
demonstrated that SPCL/gellan gum hybrid structures were non-cytotoxic and disclosed 
an apparent biocompatible response in vivo. It was also possible to observe that these 
structures allowed the in vitro culturing of oligodendrocytes for periods up to one week. 
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After the development, the physical and biological characterization, the biocompatible 
tests of the hybrid structures, and the in vivo proof of concept of the methodology herein 
proposed was performed. The hemisection model was used due to its feasibility for 
strategies that aim at axonal regeneration. Moreover, since the integrity and function of 
one side of the cord is preserved, the bladder and bowel function are maintained, 
resulting in less post-operative care and less animal death. The results showed that 
SPCL scaffolds are suitable structures to promote spine stabilization. Moreover, SPCL 
also provided support for bone ingrowth. However, the most important achievement of 
this work was the disclosure, for the first time, of a correlation between spine 
stabilization and motor recovery in SCI rats. The motor evaluation was assessed by 
three different tests, reinforcing in this way the conclusions obtained. These results 
suggests that researchers currently testing treatments for SCI repair might have to take 
into account the use of spine stabilization in combination with their approaches. 
 
In the in vivo proof of concept experiment, it was also employed the gellan gum 
hydrogel. However, this material failed to demonstrate any beneficial outcome in the 
motor behavior of SCI rats (data not shown). In order to answer this drawback, two 
different experimental methodologies were designed. In the first one, we studied the 
ability of SPCL scaffolds to support the 3D culture of OECs and SCs. It was previously 
demonstrated that OECs and SCs are able to secrete neurotrophic factors such as nerve 
growth factor, brain-derived neurotrophic factor and glia cell line-derived neurotrophic 
factor. Moreover, it is known that these factors have a positive effect on axonal growth.  
In this sense, combining the secretome effects of OECs and SCs with the previously 
observed beneficial effects of spine stabilization provided by the SPCL scaffolds 
implantation may lead to further locomotor recovery. The results demonstrated that 
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starch-based scaffolds were able to support the growth and migration of OECs and SCs. 
Additionally we demonstrated the importance of studying the long-term in vitro 
incubation periods on the number of cells that could be transplanted within the scaffold. 
 
The second experimental work designed to improve the poor performance of gellan gum 
in the in vivo test was the chemical modification of the gel. In order to better mimic the 
properties of the ECM, gellan gum was chemically conjugated with the fibronectin-
derived peptide sequence GRGDS via Diels-Alder click chemistry. Then, the impact of 
GRGDS-modified gellan gum (GRGDS-GG) on cell fate was studied. Amino acid 
analysis demonstrated the gellan gum was successfully conjugated with GRGDS. 
Futhermore, the GRGDS-gellan gum had a profound effect on neural stem/progenitor 
cell (NSPC) morphology and proliferation, distinct from the one observed in regular 
gellan gum, demonstrating the importance of GRGDS for cell-gellan gum interaction. 
The simplicity and broad applicability of the Diels-Alder click chemistry can be easily 
extended to other biomolecules to further promote cell differentiation and proliferation, 
for a better integration in the host tissue. In this work, we also demonstrated NSCs 
interacted extensively with OECs and showed significant survival and proliferation in 
relation to monocultures of NSCs alone. This combination strategy could be powerful, 
with OECs and gellan gum providing a cellular pathway on which NSCs could 
differentiate, thereby replacing the damaged tissue and achieving greater functional 
repair. 
 
In the last work developed on the scope of this thesis, we studied the effects of OECs 
secretome on the metabolic activity and proliferation of ASCs, bmMSCs and 
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HUCPVCs. The stem cells’ secretome effects on metabolic activity and proliferation of 
the OECs were also considered. The rationalite beyond this study lies in the fact that 
mesenchymal stromal cells and OECs will be used in our hybrid concept. Adult stem 
cells will be seeded in the SPCL scaffolds, in order to improve bone repair, and OECs 
will be encapsulated in the gellan gum, in order to foster axonal regeneration. In this 
sense, our therapeutic approach puts in close contact both the mesenchymal stem cells 
and the OECs, allowing the secreted factors by these cells to diffuse and interact with 
each other. Results revealed that the secretome of OECs have a positive effect on the 
metabolic activity and proliferation of mesenchymal stem cells from different origins, 
being the ASCs the most positively affected. Moreover, the stem cells’ secretome also 
have a beneficial effect on the metabolic activity and proliferation/survival of OECs. 
Moreover, the results obtained in this work add new and important knowledge in the 
cell therapy field about the secretome effects between OECs and mesenchymal stem 
cells from adipose, bone marrow and umbilical cord origins. 
 
As final remarks, it can be stated that the work performed and included in this thesis 
provided interesting studies on the potential use of our concept in the SCI field. More 
research studies should be performed by other research units to strengthen and validate 
this data. Importantly, the knowledge about the consequences of spine stabilization of 
SCI animal models was originally demonstrated in this thesis and may have an 
enormous impact in the field. Moreover, the synthesis of a gellan gum chemically 
conjugated with furfurylamine was also first reported in this thesis. This modification 
allows now researchers to conjugate the gellan gum with a wide range of factors/drugs 
via Diels-Alder click chemistry. Finally, important understanding was herein created 
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about biological/molecular interactions between OECs and adult stem cells obtained 
from adipose, bone marrow, umbilical cord, and nervous tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
